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The research presented within this thesis is concerned with the design and synthesis 
of redox-active derivatives for the use as labels for DNA probes to be used in a 
commercial DNA detection assay. 
Chapter 1: Introduces the area of electrochemical DNA sensing, the methods used 
and the transducer derivatives used. Also included within this chapter is the 
discussion on the use of ferrocene and its derivatives as redox-active transducer 
moieties and their use in a DNA sensing capacity. 
Chapter 2: Introduces the sponsoring company, Atlas genetics, and the DNA 
detection assay they are developing for use in a point of care device (POC). The 
chapter also details the design, synthesis and electrochemical analysis via differential 
pulse voltammetry of mono-ferrocenyl derivatives for the use as redox-active labels 
for DNA sensing. The chapter outlines the development of labels containing a 
variety of functionality as well as possessing a range of oxidation potentials from 95 
to 610 mV (vs Ag/AgCl).  
Chapter 3: Introduces and details the sensitivity issues between mono-ferrocenyl and 
di-ferrocenyl labels and the effect this could have on the commercial DNA detection 
assay. Within this chapter there are the details of the design, synthesis and 
electrochemical analysis via differential pulse voltammetry of the di-ferrocenyl 
labels. The chapter shows the synthesis of di-ferrocenyl labels containing a wide 
range of functionality on both the ferrocene core as well as the linker unit, with the 
labels processing a range of oxidation potentials from 242 to 500 mV (vs. Ag/AgCl). 
Chapter 4: Discusses the use of the labels designed and synthesised in chapters 2 and 
3 in the commercial DNA detection assay developed by Atlas genetics. The 
development of the labels used as DNA probes in the DNA detection assay and their 
ability to be used in multiplex DNA detection assays are also described. 
Demonstrated within this chapter is the use of the labels synthesised in this thesis 
that give both a duplex between two different probes and also the development of a 
triplex assay using three different labels to detect for two different target DNAs as 
well as provide an internal control.  
vii 
 
Chapter 5: Introduces the synthetic methods towards the synthesis of 2-oxazolines 
and discusses their use within ring-opening reactions. This chapter details the 
optimisation of the ring-opening reaction of phenyl-2-oxazoline with a range of 
carboxylic acid derivatives. The synthesis of a range of 2-oxazolines with various 
functionality aimed towards the analytical detection of carboxylic acids through the 
direct conjugation with 2-oxazolines. The ring-opening reaction was found to 
tolerate a wide range of carboxylic acid derivatives as well as a variety of 
functionality on the 2-oxazolines such as ferrocene-2-oxazolines and also 3,5 – 
bis(trifluoromethyl)phenyl-2-oxazoline. The use of ferrocene-2-oxazoline allowed 
for the electrochemical detection of carboxylic acids and the 3,5 – 
bis(trifluoromethyl)phenyl-2-oxazoline allows for thedetection of carboxylic acids 
through its ring-opened form via 
19
F NMR. These two functionalised 2-oxazolines 
were used to further analyse the reactions viability as a possible analytical tool for 
the detection of carboxylic acids by carring out the ring-opening reaction conditions 











AQMS anthrquinone monosulfonic acid 
ATP adenosine triphosphate 
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CuBr copper bromide 
d Doublet 




DNA deoxyribonucleic acid 
DMF N,N-dimethylformamide 
DMSO Dimethyl sulfoxide 
DMT dimethoxytrityl 
EDCI/EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
FAD flavin adenine dinucleotide 
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HPLC high-performance liquid chromatography 
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J Coupling constant in Hz 
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NHS N-hydroxy succinimide 
NMR nuclear magnetic resonace 
NP nanoparticle 
PCR polymerase chain reaction 
PHPB pyridinium hypobromide 
PNA peptide nucleic acid 
q Quartet 
r.t. Room temperature 
s Singlet 
SAM self-assembled monolayer 
ssDNA single-stranded DNA 
T thymidine 
t Triplet 
TBAF tetrabutylammonium fluoride  
TEA triethyl amine 






1 Introduction : Electrochemical DNA Sensors 
 
The development of novel biosensors is a field of great interest, due to the wide 
range of applications that have a use for biosensors such as; the food industry,
1
 




 biological and 
pharmacological research and  medical diagnostics.
4
 A biosensor can be described as 
a compact analytical device that contains a biologically derived sensor component 
that is closely linked with a physicochemical transducer (Figure 1.1), the 










Figure 1.1: Schematic of a biosensor 
 
The common aim that all biosensors share is to produce a digital signal that is 
quantative and is directly related to a single analyte or related family of analytes.
10
 




 or nucleic acid
13
 and in 






The ability to detect specific sequences of DNA is at the heart of the diagnosis of 
both genetic diseases and infectious disease causing pathogens. Fluorescent and 
colormetric detection methods are the most established transducer approaches.
15-16
 
The use of optical detection methods such as fluorescence has a number of 
disadvantages for the development of biosensors. The main disadvantage is that 
optical detection methods require expensive, often large and sophisticated equipment 
that usually requires a trained operator to run and maintain the system.
 
Fluorescent 
detection methods are also susceptible to photobleaching of the reporter moiety, 
which is the inactivation of the reporter moiety. This has an effect on the sensitivity 
of the technique and also on the life-time of the reporter moieties. 
 
However using 
electrochemical detection methods holds a number of advantages over these 
detection methods. Advantages such as the simplicity at which the systems can be 
minaturised and the fact that a direct electrical response is received, therefore no 
further analysis of the signaling response is required. 
 
1.1 DNA Structure and Function 
 
Deoxyribonucleic acid (DNA) consists of two chains of deoxyribonucleotides that 
are joined together via a phosphodiester bonds from the 5 carbon of one nucleotide 
and the 3 carbon of another nucleotide. The individual strands are labelled at each 
end as either 5’ or 3’ depending on which end groups terminates the ends of the 




Figure 1.2: Structure of DNA 
Deoxyribonucleotides are made up of deoxyribose sugars with a nitrogeneous base 
substituents. DNA contains four different nitrogeneous bases: adenine (A), Cytosine 
(C), Guanine (G) and Thymine (T). These four bases are further divided into two 
subgroups purines (A and G) and pyrimidines (C and T), this is due to the difference 
in the structures of the nucleoside bases. Purines are made up of bis-heterocycle 
rings whereas pyrimidines are made up of only one heterocycle ring. Within double 
stranded DNA the nucleotide bases interact through hydrogen bonding and pair up 
into specific base pair units adenine and thymine and the other pair of cytosine and 
guanine (Figure 1.3). 
 
 




1.2 DNA hybridisation and Detection Assays 
 
In a DNA assay the hybridisation  between a target DNA and a DNA probe is 
followed by a detection event. Single-stranded DNA (ssDNA) is used as a probe due 
to the specificity of DNA hybridisation, which can also be controlled by stringency. 
Stringency has an effect on the selectivity of the hybridiation, if the DNA 
hybridisation conditions are carried out under high stringency such as high 
temperature and low salt concentration in the buffer solution this leads to only highly 
complementary DNA strands hybridising. Whereas with lower stringency strands 
that are not fully complementary are able to hybridise, leading to base-pair 
mismatches. The hybridisation can be detected by a wide range of techniques. The 
DNA probe is usually a shorter DNA strand which is complementary to a specific 
region on the target DNA.
 
These DNA probes are typically synthetic 
oligonucleotides, which are usually synthesised with the desired sequence and 
normally the probes are labelled with the reporter moiety. Probe oligonucleotides are 
normally shorter strands of synthetically made DNA which are usually between 20-
40 nucleotides in length, the use of longer oligonucleotides does form duplexes with 
higher stability however their hybridisation with the target DNA takes longer than 
shorter oligonucleotide probes. Oligonucleotides are typically synthesised using an 
automated solid supported oligonucleotide synthesiser, this enables the 
oligonucleotides to be synthesised with the desired sequence. The oligonucleotides 
are built up from the 3’ end of the strand which is loaded on the solid support. The 
oligonucleotides are build up one nucleotide at a time, with each nucleotide addition 
going through a synthetic cycle (Scheme 1.1). The synthetic cycle goes through four 
main steps; Detritylation, coupling, capping and oxidation. The detritylation step can 
also be known as de-blocking, it is the deprotection of the DMT protecting group. 
The deprotection is carried out under acidic conditions in an inert organic solvent. 
The coupling is then carried out between the now deprotected hydroxyl group at the 
5’terminal of the strand and the 3’-terminal phosphoramidite of the next nucleoside. 
The coupling is typically carried out in acetonitrile (MeCN) in the presence of an 
acidic azole catalyst such as 1H-tetrazole. Post the coupling step in the synthetic 
cycle there is a capping step, in which the solid supported strand is treated with 
acetic anhydride and usually 1-methylimidazole as the catalyst. The capping step 
5 
 
serves to permanently block off any un-reacted 5’-hydroxyl groups, to guarantee that 
only the successfully coupled products are able to continue in the synthesis of the 
oligonucleotide.  The capping is done by the acetylation of the un-reacted hydroxyl 
groups. The formed tricoordinated phosphite triester linkage is then oxidised through 
the treatment with iodine, water and a weak base such as 2,6-lutidine. This treatment 
oxidises the phosphite triester to the phosphate triester, which is a protected 
precursor to the natural phosphate diester found in the backbone of DNA strands.  
 
Scheme 1.1: Oligonucleotide synthetic cycle 
 
There are two main procedures used in DNA hybridisation assays; surface 
hybridisation and solution based assays. Surface probe hybridisation involves a 
capture probe being immobilised on a surface such as an electrode. Surface 
immobilisation of DNA probes led to the development of DNA chip sensors. There 
are a range of methods utilised for the immobilisation of the probe DNA, such as 
direct adsorption, covalent attachment to the electrode surface, affinity binding, and 
chemisorption. Direct adsorption methods rely on the electrostatic interaction 
between the electrode surface and the DNA probe.
17-18
 Covalent attachment of DNA 
probes to an electrode surface require the functionalisation of the electrode surface, 
6 
 
different methods for covalently attaching the DNA probe to the electrode surface 
are used depending on what electrode is being used in the assay (Figure 1.4). 
 
 
Figure 1.4: Example of surface immoblisation of oligonucleotide 
 
DNA hybridisation detection methods are usually classified by the detection method 
utilised and also the target they are designed to detect. The detection methods used 
often require different labels. There are three main methods used to label probes with 
reporter derivatives: covalent labelling, non-covalent labelling and direct detection 
techniques. A DNA sensor should be both sensitive and specific, therefore allowing 
the assay to detect a low concentration of the target DNA and only detect that 
specific target DNA. 
 
1.3 Polymerase chain reaction  
 
Polymerase chain reaction (PCR) is a biological technique that is routinely used to 
increase the number of copies of target DNA present in DNA detection assays. PCR 
was first developed in 1983 by Mullis,
19





An important aspect of any DNA detection assay is having a sufficient quantity of 
target DNA present in the assay system. PCR is an enzyme based reaction which 
utilises the function of polymerase enzymes. Polymerase enzymes copy genetic 
materials and synthesise new single-strands of the specific region of the DNA. For 
the PCR reaction to function it requires two things, the target DNA strand and also 
the two primers. Two primers are required a forward primer and a reverse primer. 
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These two primers bind to opposite ends of the two strands of DNA. PCR primers 
are made up of short nucleotide sequences of usually four bases in length. The 
primers are chosen so that they are able to bind either side of the sequence of 
interest, this guarantees that only this region of the strand between the two primers 
will be replicated and amplified.  
 
There are three main steps involved in the PCR mechanism. First of all the DNA is 
denatured which causes separation of the two strands of DNA. This is usually carried 
out between 90-96˚C. This stage is known as melting. The next step is the annealing 
of the primers that bind to their complementary base sequences on the single-
stranded DNA. The DNA polymerase enzyme works on single-stranded DNA, 
however it requires a short region of double-stranded DNA to initiate the replication 
hence why the primers are required. The final stage is the synthesis of new DNA by 










1.4 DNA Hybridisation Sensors via Electrochemical transducer 
methods 
 
Electrochemical DNA sensing is a vast field, the sections following will highlight 
and discuss the recent advances made in the approaches for the electrochemical 
detection of DNA.  
 
1.4.1 Direct hybridisation analysis 
 
DNA can be detected electrochemically in solution
21
 as well as on the electrode 
surface.
22
 DNA itself is redox-active through the purine bases; adenine and guanine 
(Figure 1.5).
23
 Guanosine is the most readily oxidised nucleoside. 
 
 




 published work into the redox processes associated 
with the oxidation of a immobilised probe on a graphite electrode. It was shown that 
it was possible to directly measure the oxidation of adenine bases of ssDNA 
immobilised on the electrode surface. When the immobilised DNA strand was 
hybridised with a complementary target strand there was a reduction in the oxidation 





Scheme 1.3: Direct DNA detection at the electrode surface 
 
Due to the higher volume of DNA present at the electrode surface post hybridisation 
there is a higher background current observed, this leads to issues with the sensitivity 
of this assay method. Wang et al,
25
 also showed that it was possible to directly 
measure the oxidation of guanine bases present in the immobilised DNA. However 
this method also suffered from the higher background current due to the increased 
volume of DNA present at the electrode surface. Wang et al,
26
 further published 
work into the electrochemical analysis of guanosine on the immobilised DNA probe 
strand and into the guanosine in the strand being replaced by inosine which is 
identical to guanosine just without the amine group (Figure 1.6). 
 
Figure 1.6: Guanine and inosine 
 
The use of inosine increased the sensitivity as the oxidation potential for inosine can 
be distinguished from that of guanosine, therefore reducing the effect of the post 






 reported the use of ruthenium complexes as a mediator for guanine 





(Figure 1.7). The two different ruthenium 
complexes carry out selective oxidisations. Out of the two complexes used in this 
assay Ru(dmb)3
2+
, selectively oxidises the guanine derivative and Ru(bpy)3
2+
 is able 
to carry out the oxidation of both guanine and adenine. The use of the ruthenium 
mediators improves the sensitivity of the direct detection method. 
 
 




 developed a sensitive label-free DNA sensor using a polymer 
coated electrode. The use of an electrochemically conductive polymer has a number 
of benefits, the polymer coating aids the transfer of electrons to the electrode surface 
and also improves the surface conjugation of the capture probe to the electrode 
surface. The assay uses the ferro/ferricyanide redox-couple as a mediator (Figure 
1.8), which is used for the detection of the hybridisation of the capture probe with 
the target DNA. 
 
 





1.4.2 Non Covalent Label Detection Approaches 
 
The most common form of label used in non-covalent label based DNA assays are 
modified DNA intercalators. Electrochemical intercalators are small 
electrochemically active compounds which have a high binding affinity to DNA. 
DNA intercalators bind in the grooves in the double-stranded DNA (dsDNA) and 
between the nucleotide bases. DNA intercalators must have a very high affinity for 
dsDNA and a much lower binding affinity for ssDNA to be suitable for use as a label 
in the detection of target DNA (Figure 1.9). Electrochemical DNA intercalators also 
require both the oxidised and the reduced form of the compound to be stable. 
 
 




 reported the first electrochemically active DNA intercalators for 
the use in DNA detection assays. The colbalt complex Co(bpy)3
3+
 was shown to have 









 synthesised a bifuntional redox-active intercalator probe (Figure 




Figure 1.11: Lorenzo's DNA intercalator 
 
The conjugated phenyl ring portion of the compound is able to act as a DNA 
intercalator with the ruthenium complex region acting as a redox-active label. The 
ruthenium complex can be analysed via differential pulse voltammetry to distinguish 





Scheme 1.4: DNA intercalation and switch on of electrochemical signal 
 
Acridine – DNA interactions are well understood,31 they have been used as a tool in 
the modelling of dsDNA.
32
 Acridine’s themselves are not redox-active (Figure 1.12). 
 
 




 reported work into the modification and use of acridine derivatives as 
redox-active intercalator labels for the use in DNA detection assays. 9-Acridone 9 




Scheme 1.5: Nitro functionalisation of 9-acridone 
 
The addition of the nitro functionality transformed 9 into a redox active compound 
10 which was found to have an oxidation potential of approximately -116 mV. This 
14 
 
simple intercalator was able to electrochemically distinguish between ssDNA, 
complementary dsDNA and mismatched oligomer targets (Scheme 1.6). 
 
 
Scheme 1.6: Increase in electrochemical signal from intercalator between ssDNA and dsDNA 
 
10 was found to form a 2 : 1 complex with dsDNA and had a binding constant of 
3.19 x 10
5
 L/mol. Upon analysis via cyclic voltammetry there was shown to be an 




 designed and synthesised a ruthenium modified threaded DNA 
intercalator for an electrochemical DNA biosensor. The backbone of the intercalator 
N,N’-bis[(3-propyl)-imidazole]-1,4,5,8-naphthalene diimide 13 (PIND), which was 
synthesised from 1,4,5,8-naphthalenetetracarboxylic dianhydride 11  and N-(3-





Scheme 1.7: Synthetic route to intercalator 14 
 
The imidazole rings present in 13 are then complexed with Ru(bpy)2Cl. A PNA 
capture probe was immobilised onto an indium tin oxide electrode surface, which 
forms the bio-recognition event of the biosensor with the target DNA. The target 
DNA is then hybridised with the immobilised capture probe. The PIND-Ru 
intercalator 14 is then added to the assay mixture, 14 is selective only for dsDNA. 
the intercalated dsDNA was found to be a highly stable complex with reversible 
electrochemical oxidation/reduction processes. The peak currents exhibited from the 
intercalator can be directly related to the target DNA concentration in the assay 
matrix. The high affinity PIND-Ru has for dsDNA has a high significance in the 
design of a sensitive DNA biosensor. This was demonstrated when Tansil et al, 
carried out the assay in an amine-containing buffer solution, in which the 
electrocatalytic activity of the [Ru(bpy)2Cl] moieties on the intercalator. This 
electrocatalytical activity and the current observed from the interaction between the 
Ru complex and the amine compounds in the buffer solution increased the sensitivity 





 described the development of an electrochemical DNA intercalator 
for the detection of DNA hybridisation in real time via the method of monitoring the 
16 
 
charge transfer through dsDNA. The utilisation of anthraquinone monosulfonic acid 
(AQMS) 15 as the DNA intercalator (Figure 1.13). 
 
 
Figure 1.13: anthraquinone monosulfonic acid 
 
15 has been propsed to intercalate into dsDNA at the top of the duplex. 15 was found 
to have an oxidation potential of -540 mV and upon intercalation to dsDNA the 
oxidation potential of 15 undergoes a positive redox potential shift. The oxidation 




 reported the synthesis and use of a bis-intercalative electrochemical 
probe 16 (Figure 1.14). 
 
 
Figure 1.14: DNA intercalator synthesised by Buttry et al 
16 was used to distinguish between ssDNA and dsDNA in a DNA detection assay. 
16 was found to have a strong binding affinity for dsDNA, due to a very low 
17 
 
dissociation rate from dsDNA. 16 was synthesised from a 4-4’-bipyridine linked 
backbone with 1H-benzo[de]isoquioline-1,3(2H)-dione at each end of the 
intercalator molecule 16 (Scheme 1.8). 
 
 
Scheme 1.8: Synthetic route to 16 
 
The high binding affinity for dsDNA of 16 allows for the detection at the electrode 
surface, even when the electrode has been moved to a non saline solution. As some 
intercalators show a strong interactions with ssDNA,
37-38
 which would lead to a false 
positive in a sensing capacity. However the higher binding affinity of 16 with 





The use of electrochemical DNA intercalators have the main advantage of the probe 
not having to be covalently attached to the probe strand in the assay, as this requires 
some sensitive reagents and specific reaction conditions. However due to the 
difficulties sometimes exhibited in distinguishing between ssDNA and dsDNA, this 
leads to the assays not being of a high enough sensitivity level to be used in a 
sensing capacity.  
 
1.4.3 Covalently Labelled Probes 
 
This approach requires the covalent labelling of a redox-active reporter moiety to 
one of the oligonucleotides used in the detection assay. It is usually the probe or the 
captive probe that are labelled rather than the target strand itself. The labelling of the 
oligonucleotide with a reporter moiety enables an electrochemical signal to be 
produced post hybridisation. There are two main groups of reporter derivatives that 





 Ferrocene and its derivatives are the most 
commonly used reporter derivatives in the covalently labelling of DNA, which will 
be covered later in this chapter. After ferrocene the next most common family of 
redox-active labels to be used as transducer moieties are ruthenium complexes are 
ruthenium complexes.
44
 These ruthenium complexes also undergo a reversible one-




 published the synthesis of transition metal labelled PNA 
strands for the use in DNA detection assays. The PNA strands were synthesised 
through the standard solid supported peptide synthesis methods.
46-47
 The PNA 





Figure 1.15: Ru complex labelled to PNA conjugate 
 
The stability of the ruthenium labelled PNA conjugate and its binding to a 
complementary strand of DNA, which was found to be slightly less than the un-
labelled PNA strand. This therefore allows for the metal labelled PNA strand to act 




 reported the design and synthesis of nucleobase labelled with 
Ru(bpy)3
2+
 complex and then incorporated into an oligonucleotide (Figure 1.16).  
 
 
Figure 1.16: Nucleobase labelled with Ru(bpy3)
2+ 
 
The ruthenium complex Ru(bpy)3
2+
 was conjugated to the nucleotide on the 





Scheme 1.9: Synthesis of Ru labelled thymine nucleotide 
 
The labelling of the thymine nucleotide on the sugar back bone of the base post 
hybridisation was shown not to have any effect on the dsDNA duplex structure or 
stability. It was also shown that the ruthenium complex post labelling does not lose 




 developed a highly selective biosensor for the detection of target 
DNA, utilising a hairpin DNA probe as the recognition section which was labelled 
with the ruthenium complex Ru(bpy)2(dcbpy)NHS (Figure 1.17). 
 




The hairpin probe is immobilised onto a gold electrode, when there is no target DNA 
present the ruthenium labelled probe is in the folded conformation. Therefore the 
ruthenium complex is held in close proximity to the electrode surface leading to a 
high signal intensity. Whereas when there is target DNA present the stem-loop probe 
is converted to linear dsDNA, therefore the ruthenium complex is no longer in close 
proximity to the electrode surface causing a decrease in the signal intensity generated 
by the ruthenium complex (Scheme 1.10). With a high enough concentration of 




Scheme 1.10: Switching off electrochemical signal post target hybridisation 
 










the development of the facile and automated procedure for the synthesis of 
oligonucleotides which have been labelled at the 5’ end of the oligonucleotide in a 
high yield. The oligonucleotides were labelled with organo-reporter moieties 9-
fluorene-4-carboxylic acid 28, 2-anthraquinone carboxylic acid 29 and phenothiazine 





Figure 1.18: organo-reporter derivatives 28, 29, 30 
 
The redox-active derivatives were labelled onto the oligonucleotides via the 
synthesis of their corresponding phosphoramidite derivatives. The phosphoramidites 
of 28 and 29 were synthesised through an amide coupling with aminoethanol to 
instill the required hydroxyl group, which in turn is conjugated to the 
phosphoramidite (Scheme 1.11). 
 
 
Scheme 1.11: Functionalisation and phosphoramidite synthestic route used for 28 and 29 
 
The phosphoramidite of 30 was synthesised by reacting the amine group with tert-
butylbromoacetate which was reduced to yield the necessary hydroxyl group 





Scheme 1.12: Functionalisation and phosphoramidite synthesis of 30 
 
The duplexes formed with the 5’ labelled oligonucleotides and a target strand were 
shown to be as stable or have increased stability in comparison to the duplex formed 
between the un-labelled oligonucleotide and the target DNA. These labelled 





 reported the development of a surface immobilised methylene blue 
labelled capture probe for the detection of target DNA (Figure 1.19) 
 
 
Figure 1.19: Methylene blue 
 
The sensor was designed around the immobilisation of a 27-base probe sequence 
onto an electrode surface. The probe was labelled at the 5’-terminal with the 
24 
 
methylene blue reporter moiety. The flexibility of ssDNA allows for the methylene 
blue to reach the electrode surface, the methylene blue probe was found to have an 
oxidation potential of ~-260 mV and an intensity of 6.9 µA. However when the 
complementary target DNA strand was present in the assay mixture and 
hybridisation occurred a significant drop in the signal from the methylene blue was 
observed, this change in the signal at the electrode is due to the more rigid structure 
of dsDNA leading to less of the methylene blue probe being able to reach the 
electrode surface (Scheme 1.13). 
 
 
Scheme 1.13: DNA detection assay using methylene blue labelled probe 
 
Plaxco et al, showed that the same drop in signal intensity could be exhibited in a 
blood serum solution which had been spiked with the target DNA, this proves that 
the assay could be used as a functioning biosensor. However there is a drop in the 




 reported the synthesis of a 2’-deoxyuridine nucleoside labelled 
derivative. The nucleosides were labelled with an anthraquinone moiety. The 
synthesis was started from 2-bromoanthraquinone 38, which was converted to the 






Scheme 1.14: Synthesis of boronic ester derivative 39 
 
However the Suzuki coupling reaction of 39 with 2’-deoxy-5-iodouridine 42 did not 
yield any product and caused decomposition of the nucleoside. A protected form of 
38 was then synthesised (Scheme 1.15), to afford the dimethyl protected 
anthraquinone pinacol boronic ester species 41. 
 
 
Scheme 1.15: Synthesis of protected boronic ester derivative 41 
 
41 did yield the desired product 43 in the Suzuki coupling reaction, however after 
the Suzuki reaction a demethylation step followed by an oxidation is required to 





Scheme 1.16: Suzuki coupling of 41 and deprotection of labelled nucleoside 
 
Grothelf el al, showed that the labelled uridine nucleosides could be incorporated in 
stable oligonucleotides. The inclusion of the anthraquinone derivative directly onto 
the nucleoside base did not have an effect on the stability of the duplexes formed. 
The anthraquinone labelled nucleoside base was found to have an oxidation potential 
of -422 mV and when 44 was included into an oligonucleotide which was loaded 
onto a gold electrodes surface an oxidation potential of -414 mV was observed, 
therefore showing that the inclusion into the oligonucleotide did not have a large 




 reported the development of an electrochemically active solution based 
molecular beacon assay for the detection of target DNA, using a molecular beacon 
probe that is labelled at both the 5’ and the 3’ ends of the strand with a carminic acid 





Figure 1.20: Carminic acid derivative 45 
 
 
When the molecular beacon is in the closed form the electrochemical signal from the 
two carminic acid derivatives is switched off, this is due to the two compounds being 
in close enough proximity to form a dimer. When complementary target DNA was 
present in the assay solution there was a change in the conformation of the molecular 
beacon form the closed hairpin conformation to the open linear form of the dsDNA, 
post hybridisation with the target DNA. The change in the conformation leads to the 
two redox-active derivatives being separated at either end of the duplex formed 
which in turn causes the switching on of the electrochemical signal (Scheme 1.17). 
 
 
Scheme 1.17: Molecular beacon assay using 45 as redox-reporter 
 
 
1.4.4 Nanoparticle Based DNA Detection  
 
Metal nanoparticles (NPs) have been used in a wide-range of applications due to 
their large surface area and the nanoparticles size inherant optical properties.
58
 NPs 
have been regularly used in the field of biosensors in the role of signal 
amplification,
59-60
 or as solid supports which increase the surface area of the sensor. 
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There are a wide range of different NPs used in the field of sensing. The most 
common of which are gold nanoparticles,
61-62
 however silver, zinc, palladium and 
cadmium NPs have all been used in the field of biosensing.  
Wang et al,
63
 developed a nucleic acid hybridisation assay using three different NP 
labelled probes. The three NP reporter moieties are based around three inorganic 
sulfide complexes that make up the NPs; zinc sulfide, lead sulfide and cadmium 
sulfide. Capture probes are immobilised onto a mercury-coated glassy-carbon 
electrode, three different capture probes are used in the assay. The capture probes all 
have sequences that are unique to a specific region on different strands of target 
DNA. The NP labelled probes are then added to the assay mixture to hybridise with 
the trapped target DNA. The three different NP labelled probes are each labelled 
with a different metallic nanoparticle each probe has a different sequence that is 
complementary to a specific region of its complementary target DNA (Scheme 1.18). 
 
 
Scheme 1.18: Multi-target detection using NP labelled probes 
    
The hybridisation of the NP labelled probes with the target DNA is detected using 
stripping voltammetry with the different metal containing NPs were found to have 
unique oxidation potentials of -1.12 V for the zinc NP, -680 mV for the cadmium NP 
and -530 mV for the lead NP. This method can be used for the simultaneous 
detection of three different DNA targets. Wang et al, used this assay for the 
simultaneous detection of the genes related to BCRA1 breast-cancer genes in a 






 reported the development of a highly sensitive DNA sensing mechanism 
for the detection of low volumes of target DNA. The assay is based around a 
sandwich assay. A capture probe is immobilised onto a gold electrode surface, to 
which the target DNA is added to this assay mixture and hybridised. The 
hybridisation of the target DNA with the capture probe allows for the hybridisation 




Scheme 1.19: Bard's DNA detection assay using platinum labelled probe in sandwich assay 
 
The hybridisation of the labelled probe to the bound target strand allows for the 
platinum NP to get to the electrode surface and carry out the oxidation of hydrazine. 
 
 
1.4.5 Enzymatic Based DNA Detection 
 
Oligonucleotides can also be labelled with an enzyme, such as horse radish 
peroxidase (HRP). The probe bound enzymes can function in two different 
methods.
65
 The enzyme can either directly detect the hybridisation of the probe and 
the target DNA or they can be used indirectly, where the enzyme reacts with a 






Tuñόn-blanco et al,67 developed a hairpin based biosensor for the enzymatic 
electrochemical detection of target DNA. A capture probe was immobilised onto the 
electrode surface, the capture probe was designed and synthesised to be 
complementary to a region on the target DNA. A secondary probe which was 




Scheme 1.20: Sandwich assay with alkaline phosphatase labelled probe 
 
Once the secondary probe had been hybridised to the target DNA, to the assay 
mixture a streptavidin bead which was labelled with alkaline phosphatase was added. 
Due to the very high binding affinity of biotin and streptavidin the duplex is now 
labelled with the alkaline phosphatase. The progress of the assay was analysed by the 
enzymatic conversion of 1-naphthyl phosphate to 1-naphthol (Scheme 1.21). The 1-










 developed an array biosensor, also utilising the action of avidin-alkaline 
phosphatase to convert 1-naphtyl phosphate into a readox-active species. The DNA 
capture probes for the biosensor were immobilised on a photolithographically gold 
array electrode via standard chemical conjugation techniques. The assay developed 
by Xu works along a very similar principle as the assay developed by Tuñόn-Blanco 
as both the assays are sandwich based assays involving the trapping the target DNA 
between two probes.   
 
1.5 Nanopore Electrochemical DNA Detection 
 
A nanopore is a very small hole in a thin membrane. Nanopores are usually formed 
by pore-forming proteins such as α-hemolysin and MspA porin.69 The proteins form 
the pores in lipid bilayers (Figure 1.21). More recently nanopores have been made in 
thin synthetic membranes, produced from silicon and graphene.
70-71
 Silicon nitride is 
one of the most common silicon compounds in which nanopores are produced in. 
Nanopores in synthetic membranes can be produced by several techniques such as 







Figure 1.21: Example of nanopore in lipid bilayer 
 
Nanopores can be used to detect and identify analytes directly or electronically. The 
detection of analytes is possible by the formation of a nanopore in an 
electrochemically resistant membrane, the membrane is suspended in a physiological 
solution. The membrane then has a voltage applied across it, this results in an ionic 
current to be passed through the nanopore. This ionic current is disrupted when the 
analyte of interest passes through the pore (Figure 1.22).  
 
 
Figure 1.22: SsDNA passing through a nanopore 
 
The use of nanopores in sensing was first proposed in the mid 90s. They have been 
studied for the possible sensing applications for a wide range of analytes; small 
molecules,
73-74
 the identification of biomarkers,
75-76
 the studing of ion channels
77
 and 
for DNA sequencing and sensing. Nanopore sequencing and sensing of DNA is of 
interest due to no analytical reporter label being required, it does not require an 
amplification method such as PCR and the fact that the single molecule methods can 
be scaled up for high-thoughput DNA analysis. The use of nanopores to sequence 
DNA was first proposed by Church et al.
78
 The concept for the sequencing of 
ssDNA as it passes through the nanopore, works on the principle that each nucleotide 
base has a different structure and will interact with the nanopore in a different way. 
Therefore there would be a different shift in the residual ionic current depending on 
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which nucleotide is in the nanopore at that moment (Figure 1.23). Deamer et al,
79
 
carried out proof of principle experiments using two naturally produced nanpores by 
the enzymes α-haemolysin and Mycobacterium smegmatis porin, which showed that 
there was a difference in the residual ionic current when a nucleotide base was 
present is the pore. Also it was shown that there was a unique shift in the residual 
current for each of the four nucleotide bases that make up DNA.      
 
 




 described the development of a nanopore based resistive-pulse sensing 
of ssDNA up to 7250 bases in length and also to a lesser level the sensing of dsDNA. 
the development of conically shaped nanopores in a polycarbonate membrane was 
carried out using anisotropic chemical eteching. The conical had an opening 
diameter at the tip of 40 nm and an opening diameter of 1.5 µm at the base of the 
nanopore. The polycarbonate films were placed in an U-tube cell, an etch solution of 
KOH (9M) was added to one half of the U-tube cell and a stop solution of formic 
acid was added to the other half of the cell. The eteching process continued until the 
etching solution broke through the membrane into the stop solution. The break 
through was detected via an increase in current from the Pt wires that were in each 
half of the cell and the potential difference of 15 V was applied to the cell during the 
34 
 
etching process. The cell was set up so that the anode was in the side of the U-tube 
cell with the etch solution.  
 
During the DNA sensing application of these conical nanopores, ssDNA was driven 
electrophoretically through one of the nanopores. This translocation event results in 
the transient current-blocking events as the pore is filled with the strand of ssDNA. 
The frequency of which these current-blocking events is linearly related to the 
concentration of ssDNA. The current-blocking effects of dsDNA was also 
investigated, however due to dsDNAs larger size and its poor flexibility of the 
dsDNA can not enter the tip opening of the nanopore or translocate through the 
nanopore. Therefore the shorter duration of the current-blocking event and the lower 
levels of current shift observed were believed to be due to the dsDNA bumping 
against the tip opening of the conical nanopore.  
 
The use of graphene membranes for the fabrication of nanopores is of interest due to 
the mechanical, electrical and thermal properties of the graphene membranes.
81
 
Another benefit to the use of graphene membranes is that the thickness of a single 
layer of graphene membrane is the same thinkness as the spacing between the 
nucleotides in DNA. Drndic et al,
82
 were the first to produce nanopores and 
nanopore arrays in suspended graphene films and study the nanopore formation 




 reported the use of atomically thin graphene conducting 
membranes containing single nanopores for the use in DNA sensing and sequencing. 
The graphene membranes used in this study were as thin as one or two atomic layers 
thick, even at this thickness the graphene membranes were found to be very efficient 
ionic insulators. Electrical analysis of these graphene membranes with a single 
nanopore, showed that the effective insultating thickness of these membranes was 
less than a nano meter. The fact that the effective insultating thickness of the 
graphene membrane is so small makes them ideal membranes for the high resolution 
nanopore-based single molecule detectors. Govovchenko et al, studied the effect of 
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electrophoretically driving negatively charged DNA through the nanopores. As each 
nucleotide base passes through the nanopore it transiently reduce or block the ionic 
current in a way that eludes to the size of the DNA strand and also the conformation 




 reported research into the translocation of DNA through nanopores 
created in graphene membranes of a thickness between 1-5 nm. Using electron-
beaming techniques nanopores of between 5-10 nm in diameter were etched into the 
graphene membrane. With the thinness of the graphene membranes used in this 
study, larger blocked ionic currents were observed in comparison to traditional solid-
state nanopores. However, at this thinness of membrane the ionic current background 
noise levels are larger than for silicon nitride based nanopores. The background 
noise levels of the device were shown to be reduced by the atomic layer deposition 
of a 5 nm layer of titanium dioxide over the whole device. Unlike nanopores in 
silicon nitride based membranes, nanopores in graphene membranes opens up the 
possibility of a new style of device in which the electronic sensing and control can 
be carried out directly at the nanopore.   
 
1.6 Introduction of Ferrocene in DNA sensing 
 
Ferrocene was first discovered and characterised in the 1950’s, thereafter there has 
been a large interest in the chemical characteristics and chemistry of the transition 
metal sandwich complexes. Ferrocene itself is used in a wide range of chemistry 
from chiral ligands for catalysis
85-86





The redox couple between ferrocene (Fc) and the oxidised ferrocenium ion (Fc
+
) is 





Scheme 1.22: Ferrocene redox couple 
 
The reduced form of ferrocene and its derivatives is the most stable form, therefore a 
lot of the work is carried out into the oxidation of ferrocene to the ferrocenium ion. 
This oxidation provides the oxidation potential of the ferrocene derivative. The 
oxidation potential of ferrocene can be altered by affecting the overall electronics of 
the metallocene itself, this is carried out via the substitution of the cyclopentadienyl 
rings (Cp). Ferrocene can be affected by inductive and mesomeric affects via the Cp 





Figure 1.24:Showing the effects of EWG and EDG on Cp ring 
 
The inductive and mesomeric effects can be electron donating or electron 
withdrawing, substitution on to the Cp with an electron donating group (EDG) can 
stabilise the formation of the ferrocenium ion. Conversely, substitution using an 
electron withdrawing group (EWG) does not favour the formation of the oxidised 
ferrocenium ion. This is due to the electron withdrawing group pulling electron 
density from the metallocene core, therefore a higher oxidation potential is required 
to remove the electron and oxidise the ferrocene derivative. Ferrocene and its 
derivatives are used in a wide array of roles in sensing assays. Ferrocene can be used 
as a mediator or an electron shuttle. In the field of medical diagnostics, the key 
example of ferrocene being used as a mediator in a biosensor is in the glucose 
biosensor. The glucose biosensor was developed for the personal monitoring of 
blood glucose levels in diabetics. The biosensor utilises the biological response of 
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the oxidation of β-D-glucose to δ-D-glucolactone by the enzyme glucose oxidase 
(GOD). The oxidation of glucose is a two electron process, the oxidation is carried 
out by the redox-active centre of GOD along with a cofactor. Flavin adenine 
dinucleotide (FAD) is the cofactor, within the oxidation process FAD is converted to 
FADH2 (Scheme 1.23). FAD is then regenerated by dioxygen to produce hydrogen 




Scheme 1.23: Oxidation of glucose by GOD 
 
In converting this biological process into a biosensor the inclusion of a 
physicochemical transducer is required, in this case and electrochemical transducer 
utilising ferrocene. The ferrocene is utilised as a mediator between the biological 
response and the electrode. GOD was directly labelled using a ferrocene carboxylic 
acid derivative via and EDC coupling reaction. The ferrocene derivatives replace the 
requirement for dioxygen leading to no side products being produced (Scheme 1.24). 
The ferrocene derivative allows for the electron transfer from FADH2 to the 
electrode to regenerate the FAD. This is possible as the ferrocene moiety would 
become oxidised to the ferrocenium ion by the electrode, making it receptive to 
electrons from the cofactor. Work into developing the biosensor was carried out in 








Ferrocene derivatives have also been used as redox-active reporter moieties for 







 reported the synthesis and characterisation of four ferrocenyl 
nucleobases, the ferrocenyl nucleobases contained a linker group that was either 
unsaturated or saturated connecting the ferrocene moiety and either adenine or 
thymine (Figure 1.25). 
 
 
Figure 1.25: Examples of the synthesised nucleobase derivatives 
 
The starting material for all four of the desired products was ferrocene-1,1’-
dicarboxaldehyde 50. 50 was reacted with the benzoyl protected phosphonates of 
either adenine or thymine via a Horner-Wadsworth-Emmons reaction (Scheme 1.25), 





Scheme 1.25: Synthetic route to 49 and 53 
 
For the saturated linker containing derivatives the alkene bonds were reduced via 
hydrogenation with Pd(OH)2/C and hydrogen gas (1 atm) (Scheme 1.26).  
 
 
Scheme 1.26: Hydrogenation reaction to afford 54 and 55 
 
Tucker et al, studied the four derivatives via electrochemical analysis and to further 
the understanding of their behaviour during solid-state aggregation studies. The four 
derivatives were analysed via cyclic voltammetry and there was found to be a large 
difference in the redox potentials between the saturated derivatives: 54 (525 mV) and 









 reported the synthesis of a ferrocene modified 
naphthalene diimide intercalator (Figure 1.26). The intercalator is a threading 
intercalator, these intercalators contain a region of planar functionality that 




Figure 1.26: Takenaka DNA intercalator 
 
The intercalator 56 was found to have an oxidation potential of ~250 mV. Takenaka 
et al,
94
 later published improvements of their original intercalator 56. the intercalator 








60a and 60b were then labelled with a range of ferrocene derivatives to produce a 
range of redox-active DNA intercalators (Scheme 1.28). 
 
 
Scheme 1.28: Functionalisation of Intercalator with ferrocene moiety 
 
The ferrocene derivatives used to label naphthalene diimide linker 
ferrocenecarboylic acid, ferrocene acetic acid and ferrocenepropionic acid. The 
labelled intercalators were found to have a range of oxidation potentials from 180 
mV – 440 mV depending on which ferrocene derivative was used.  
 
Oligonucleotides can be tagged with ferrocene labels in two main ways: post-
labelling and nucleobase incorporation. The post-labelling approach involves the 
synthesis of the complete oligonucleotide strand, to which the ferrocene containing 
label is conjugated to complete the DNA probe. The conjugation of the transducer 
label to the oligonucleotide normally is carried out on the 5’ end of the 





Figure 1.27: Representation of post-labelling approach 
 
Synthetic post-labelling is one of the most common methods used in post-labelling 
of probes This involves the synthesis of an oligonucleotide probe which has been 
labelled with a linker and once purified the oligonucleotide is then further reacted 
with an activated form of the desired ferrocene derivative such as an N-
hydroxysuccinimide ester (NHS). This method was first reported in the literature 
using the NHS ester of ferrocenecarboxylic acid, which was reacted with an 
oligonucleotide that had been labelled with a carbon chain with a terminal amine 
group (Scheme 1.29). 
 
 
Scheme 1.29: Conjugation to oligonucleotide via NHS ester 
 
The labelled probe was used for a DNA hybridisation based assay as a sensor, the 
ferrocene probe was added to a solution that contains a complementary target strand 
of DNA. The hybridised DNA is injected into an HPLC column that allows dsDNA 
to pass through the column to the electrochemical detector. The assay is calibrated 
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using certain concentration of the ferrocene probe, this allows for quantitive analysis 






 functionalised the free phosphate groups on the oligonucleotide by 
reacting it with imidazole, then ethylene diamine and finally, via an EDCI coupling 




Scheme 1.30: Example of covalently labelling an oligonucleotide probe 
 
The assay developed works via target DNA being adsorbed onto the surface of a 
carbon electrode, to which the DNA probe was added and hybridisation occurs and a 





 developed a biosensor for the detection of target DNA using an 
electrode immobilised capture probe that was labelled with a ferrocene moiety at the 
3’-terminal of the oligonucleotide. When the target DNA is present and hybridisation 
with the labelled capture probe has taken place there is an 87% decrease in the 





Scheme 1.31: Schematic of White's DNA detection assay 
 
Ferrocenecarboxylic acid is used as the redox-active moiety. The 
ferrocenecarboxylic acid was converted to the activated NHS ester which was 
coupled to the amine labelled 3’-terminal of the oligonucleotide (Scheme 1.32). 
 
 




 reported the development of a target responsive electrochemical switch 
assay to be used in the development of a biosensor. In this assay an oligonucleotide 
was labelled at the 5’-terminal with a reporter moiety, in the case of this assay a 
ferrocene derivative was used. The 3’-terminal of the oligonucleotide was thiolated 
for the immobilisation of the probe to the surface of a gold electrode (Scheme 1.33). 
The immobilised capture probe is able to hybridise with the target DNA, which 
causes a reduction in the signal at the electrode from the reporter moiety.  
 
 




Adenosine triphosphate (ATP) is used in the assay to separate the complementary 
strand from the immobilised capture strand which switched on the electrochemical 
signal at the electrode (Scheme 1.4. 
 
 
Scheme 1.34: Switching on of electrochemical signal by dehybridisation via ATP 
 
The assay developed by Fan et al, has a number of advantages, like most DNA 
detection assays it is largely resistant to non-complementary DNA strands and was 




 produced a system for electrochemical detection of nucleic acids via 
micro arrays, also providing a selective detection method for molecular diagnostics. 
Gold elctrodes were printed on circuit boards and coated with a self-assembled 
monolayer (SAM) containing DNA capture probes. Target nucleic acids are 
immobilised on the surface of the electrode via SAM using the capture DNA 
oligonucleotide. Another oligonucleotide containing ferrocene-modified nucleotide 
complementary to another section of the target DNA is introduced. The ferrocene 






Figure 1.28: Example of Farkas SAM assay 
 
The SAM layer allows for the electron transfer to the electrode and also has the 
benefit of blocking the electrode from other redox active species in the solution – 
including the unbound probe (Scheme 1.35).  
 
 
Scheme 1.35: Reaction at the electrode surface 
 
Through the use of PCR and oligonucleotides this method shows high sensitivity for 
the target DNA. Also high sensitivity towards a positive sample due to only the 




carried out work using a ferrocene derivative as an electron mediator 
in the detection of DNA hybridization in the study and characterisation of 
oligonucleotides. Gothelf et al present work showing the trapping of a ferrocene 
derivative between a single strand of DNA and an electrode, either a gold or glassy 
carbon electrode. DNA that has been fixed to an electrode has been shown to have 
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interesting hybridisation properties that can be seen through the reversible redox 
potential shift of a mediator, in this case a ferrocene based derivative. This redox 
shift is detected during the hybridisation and denaturation process. The ferrocene 
derivative Gothelf studies was synthesised from ferrocene carboxylic acid. It was 
modified with a triazene moiety on one of the cyclopentadienyl rings, this group is 
used in the fixation of the ferrocene mediator to the electrode. The carboxylic acid 
derivative is converted to an active ester which is then conjugated to an aminated 
DNA strand (Scheme 1.36). 
 
Scheme 1.36: Synthesis of ferrocene linker unit 73 
 
Using a target strand of DNA that had been labeled with methylene blue, the 
hybridisation between the mediator immobilised DNA and the methylene blue 




 reported the development of electrochemical probes for nucleic acid 
detection, uising a ferrocene phosphoramidite derivative 74. 74 was incorporated 
into a stem-loop structure. Stem-loop structures are often used in fluorescent 
detection methods of DNA.
102-103
 Oligonucleotides used in the synthesis of these 
stem –loop structures are often functionalised at either the 5’ end or the 3’ end with 
the transducer reporter moiety. Chaix et al, developed a functionalised stem-loop 
with the ferrocene derivative 74 being incorporated into the stem-loop structure 
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itself, between the stem region and the loop moiety. The assay works on the 
detection of a shift in the redox properties of 74, between the closed stem-loop 
structure and the opening of the stem-loop during the hybridisation with target DNA. 
The ferrocene derivative used as the label in this assay was ferrocene-1,1’-
bispropanol (Scheme 1.37). 
 
 




 further reported the development of a ferrocene modified stem-loop 
probe for the detection of target DNA and even a single-base mismatch. Ferrocene 
bis propanol 75 was used as the ferrocene derivative in this assay, in which four 
ferrocenes were labelled onto the 5’ end of the stem-loop with the 3’ end being 
trapped onto the surface of a gold electrode. The use of the four ferrocenes in a row 
allowed for the detection of target DNA in concentrations as low as in the 1 pM. The 
ferrocene bis propanol was activated for the use in an automated oligonucleotide 
synthesiser with both a trityl protecting group and a phosphoramidite (Scheme 1.38).  
 
 




When there was no target DNA present the hairpin remained intact and therefore 
allowed the ferrocenes to reach the electrode and a signal was observed, however 
when the target DNA was present there was a decrease in the signal observed or the 
signal was completely shut off (Scheme 1.39).   
 
 




 reported the development of electroactive self-assembled monolayers 
as platform for biosensors. Specifically ferrocenyl molecules with functional groups 
suitable for bioconjugation and immobilisation with SAMs. This paper describes the 
synthesis of novel redox active biofunctional crosslinkers from unsymmetrical 1,1’-
disubstitued  ferrocenes (Figure 1.29). 
 
 
Figure 1.29: Ferrocene derivative for incorporation into SAM layer 
 
The derivatives were analysed via cyclic voltammetry, the derivatives were first 
tested as N-boc protected derivatives. Both of the derivatives exhibited reversible 
one electron redox reaction. 78 was found to have an oxidation potential at 338 mV 





Figure 1.30: Boc-protected versions of 76 and 77 
 
The deprotected derivatives were found at 76 392 mV and 77 297 mV (Figure 1.29). 
The difference in oxidation potential exhibited between the protected and 
deprotected derivatives can be explained by the electron withdrawing effects of the 
amine TFA salts in the deprotected compounds and the effect this has over the 
electrochemistry of ferrocene. The preparation of novel metal containing peptide 
nucleic acids (PNA) is an area of great interest in the field of sensing. PNA’s are 
unnatural nucleic acids with a back bone made of N-(2-aminoethyl)glycine units. 
They are bound together via methylene carbonyl to the nucleobases. The sequence of 
PNA have to hold up to the values of the Watson-crick base pairing rules. The 
modification of PNA’s with the incorporation of metal containing groups has been 
carried out for a number of different reasons such as biosensors, development of 




 reported the development of a duplex PNA based biosensor for 
the detection of two different sequences of target DNA. The synthesis of two 
differently sequenced oligonucleotides was carried out using solid supported 
methodology with the 3’ end being built of a PNA linker, which is present to tether 
the oligonucleotide to the surface of an electrode. The 5’ end of the oligonucleotide 
was labelled with an acetyl azide derivative.  Two electrochemically unique 
ferrocene alkyne derivatives were used (Figure 1.31), in the post oligonucleotide 





Figure 1.31: Ferrocene derivatives usied by Metler-Nolte 
 
The ferrocene derivatives 80 and 81 were conjugated to the oligonucleotides via 
click chemistry with the terminal azide group on the oligonucleotides (Scheme 1.40). 
 
 
Scheme 1.40: Post-synthesis labelling via click chemistry 
 
The two labelled oligonucleotides 83 and 84 both produce a signal at the electrode 
when neither of the target DNA strands are present, this is thought to be due to the 
flexibility of the oligonucleotides. Both the ferrocene derivatives have different 
oxidation potentials with 83 having an oxidation potential of approximately 350 mV 
and 84 having an oxidation potential of approximately 500 mV. However when the 
target DNA was added there was an approximate 60% decrease in intensity of the 
signal from the ferrocene labelled oligonucleotide. The drop in intensity was caused 
by the hybridised DNA being less flexible than the single-stranded oligonucleotide, 




 described the development of an electrochemical DNA biosensor based 
around the proximity-dependent surface assay. The biosensor assay involved the 
immobilisation of a capture probe onto the surface of a gold electrode, through a 3’-
thiol group. The sequence of the capture probe is complementary to both half the 
strand of the target DNA and the labelled end of the ferrocene labelled probe. The 
ferrocene probe was labelled at the 5’-end through an EDC coupling reaction 
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between ferrocenecarboxylic acid and the 5’-terminal amine on the oligonucleotide. 
The ferrocene labelled probe is also complementary to the other half of the target 
DNA, this leads the to 5’-labelled ferrocene being trapped close to the gold electrode 
surface (Scheme 1.41) 
 
 
Scheme 1.41: Li biosensor assay 
 
Li et al, showed that they could detect target DNA in as lower concentration as 1 Fm 
as well as the assay being able to distinguish between complementary DNA 
compared to mismatch hybridisation. This would allow for the assay to be used as an 
electrochemical DNA biosensor, for the detection of a specific target DNA in a 




 reported the development of an electrochemical DNA sensor which 
involves two different redox-active labels, methylene blue and ferrocene are the two 
redox-active moieties used. The assay functions as both a signal-off and a signal-on 
probe based assay. The assay involves the immobilisation of the capture probe onto 
the gold electrode surface. The capture probe is immobilised onto the gold electrode 
surface via a 5’-alkanethiol group. The capture probe was also labelled at the 3’-end 
with the redox-active label methylene blue, when no target DNA was present in the 
assay mixture the methylene blue moiety was able to reach the electrode surface and 
a signal was observed. Lai et al, found the methylene blue moiety to have an 





Scheme 1.42: Methylene blue labelled capture porbe on gold electrode surface 
 
When the target DNA is present in the assay medium there is a drop in intensity of 
the signal exhibited from the methylene blue labelled capture probe. A ferrocene 
labelled probe is also used in the assay, which is partially complementary to the 
target DNA as well as the methylene blue labelled capture probe. The ferrocene 
labelled probe becomes captured with the ferrocene label moiety being in close 




Scheme 1.43: 'Switch off' - 'switch on' assay developed by Lai et al 
 
Lai et al, showed that not only could the assay protocol be used as a DNA sensor for 
a specific target DNA but the assay could also be used to determine specific 
mismatches between the capture probe and the target, through the comparison of the 
signal intensities observed for the two redox-active labels used in the assay.   
 
Nucleobase incorporation uses ferrocene modified nucleobases in the synthesis of 
the oligonucleotide probe, this allows the label to be positioned in the probe at a 





Figure 1.32: Representation of nucleobase incorporation approach 
 
The most common method for nucleobase incorporated probes is via a solid 
supported synthesiser. This method is widely used in the preparation of DNA chips 
for surface modification. Labelling nucleobases with ferrocene has the advantage of 
being able to incorporate the ferrocene labelled nucleobase anywhere in the 
sequence.  
 
Meade et al, developed a ferrocene modified nucleobase for the use in nucleobase 









The electrochemical moiety is synthesised from ferrocene via a Friedel-Crafts 
acylation followed by a Clemmensen reduction (Scheme 1.44), which was then 
coupled to adenosine.  
 
Scheme 1.44: Synthetic route to ferrocene labelled adenosine 85 
 
The ferrocene modified adenosine was incorporated into an oligonucleotide at 
various locations along the strand. The incorporation of the ferrocenyl modified 
nucleotide into the oligonucleotide was found to have little destabilisation of the 
oligonucleotide or the duplex.  
 
Electrochemical analysis of the labelled oligonucleotides containing ferrocene 
showed that the oligonucleotides can be used as a signalling probe for the 
electrochemical detection of nucleic acids. This was carried out via the incorporation 
of the ferrocene modified oligonucleotides into a CMS-DNA chip, to detect single 
base mismatches using a second labelled oligonucleotide with a previously 






 reported the synthesis of oligonucleotides with ferrocene 
derivatives at specific sites within the oligonucleotides. The oligonucleotides were 
synthesised containing halogenated bases within the oligonucleotide, which were 
labelled with a ferrocene derivative via a sonagashira  cross-coupling reaction 
(Scheme 1.45). The structure and stability of hybridised DNA is not altered by the 
addition of ferrocene derivatives.  
 




The field of DNA sensing is large area of research that covers a range of different 
transducer methods. The most common transducer method used in DNA sensors are 
optical detection methods, however since the 1990 there has been a large amount of 
interest in the use of electrochemical reporter moieties for the use in DNA detection.  
A range of these methods have been outlined in this chapter, from the more 
established methods such as; redox-active DNA intercalators and the labelling of 
DNA probes with a redox-active reporter moiety to the relatively newer methods 
such as the use of nanopores for DNA sensing and sequencing. Ferrocene and its 
derivatives are the most common redox-active moieties used in a wide range of 
applications in the field of DNA sensing, ferrocene derivatives have been used as 




2 Chapter 2: The Synthesis of Mono-ferrocenyl Labels for the use 
as DNA Probes 
 
Summary of Chapter 2 
 
This chapter details the synthesis of a range of monoferrocenyl derivatives for the 
use as redox-active labels and application in a DNA detection assay. The 
monoferrocenyl derivatives were analysed via differential pulse voltammetry to 
provide the oxidation potentials for the range of labels synthesised.  
 
2.1 Atlas Genetics, T7 exonuclease assay 
 
Atlas genetics are a UK-based diagnostics company producing an in vitro point-of-
care device for the use in doctors surgeries and hospital wards. Atlas genetics are 
particularly focused on sexually transmitted diseases where quick diagnosis is 
required for treatment and control of the disease. Point-of-care devices have to be 
rapid in detection of the target compared to the standard laboratory testing methods, 
which in some cases can take up to a week to get the results back to the patient. They 
are also required to be extremely selective and sensitive. Atlas aim to cut the waiting 
time down to 30 minutes from sample extraction to being able to give the patient the 
results. The point-of-care device being developed by Atlas is based around one-use 
disposable cartridges, in which the whole assay is carried out. The clinical sample is 





Figure 2.1: Atlas Genetics Point-of-care device 
 
Once the cartridge is loaded into the instrument there is no further operator 
interaction required until the end of the testing process. The cartridges contain all the 
necessary reagents required to carry out the assay. The sample and the assay are 
processed through the card via pneumatically controlled fluidic movements. The 
assay cartridges contain multiple channels for the assay to be processed through with 
each channel leading to an electrode (Figure 2.2), the use of multiple channels sets 
the cartridge up for the multiplex detection of different pathogenic targets in the 
same cartridge.   
 
 




Atlas have developed a highly selective assay for the detection of pathogenic 
bacterial DNA. The Atlas assay can be broken down into four main sections: 1) 
extraction of the clinical sample, 2) amplification of target DNA and hybridisation, 


























Scheme 2.1: Schematic of the Atlas assay 
 
The amplification step of the Atlas assay is carried out via PCR, this allows for the 
accurate detection of target DNA from a clinical sample in which there could be as 
few as five copies of the target DNA. The PCR method that Atlas are using amplifies 
a specific region of sequence in the target DNA, this region is unique to the 
particular bacterial pathogen of interest. The PCR amplification is able to be 
selective for a specific region in the target DNA due to the forward and reverse 
phase primers that are being used in the amplification step. Through the use of PCR 
the sensitivity of the assay is increased due to the higher volume of target DNA 
being present in the assay mixture post amplification.  
 
Atlas are pairing the PCR amplification of a specific region of target DNA with the 
use of labelled oligonucleotide probes that are synthesised to have a complementary 
sequence to the target DNA. The oligonucleotide probes are labelled at the 5’ end of 
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the strand with an electrochemically active molecule (Figure 2.3), in the case of the 
Atlas assay a ferrocene label is used.  
 
 
Figure 2.3: Structure of the labelled oligonucleotide probes 
 
After PCR amplification the ferrocene labelled probe is hybridised with the taget 
DNA. The dsDNA is then exposed to T7 exonuclease. T7 exonuclease is an enzyme 
that cleaves the phosphodieseter bonds between  nucleotides in nucleic acids. T7 is 




Figure 2.4: Action of T7 leaving single labelled nucleotide digest product 
 
The digest product from the T7 exonuclease reaction is a single nucleotide with the 
ferrocene label attached. It is this digest product which is analysed on the electrode 
via differential pulse voltammetry. However if the sample is a negative and there is 
no target DNA present for the labelled probe to hybridise with, the T7 enzyme does 






2.2 Aims and Previous work 
 
Previous work in the group focused on the synthesis of ferrocene containing DNA 
probes for the detection of gene sequences using an exonuclease enzyme based 




 synthesised a ferrrocene label 96 that could be readily coupled to an 
oligonucleotide post synthesis via a coupling reaction using a 5’ amine-labelled 








developed a ferrocene containing label for the detection of target 
DNA. The previous label 96 by Hillier et al was synthesised to be covalently 
labelled post oligonucleotide synthesis, whereas 97 was designed to to be conjugated 
to the oligonucleotide via the phosphoramidite derivative. Ferrocenecarboxylic acid 
was used as the starting material for the synthesis of label 97. Ferrocenecarboxylic 
acid was taken through an amide coupling via the in situ generation of the acid 
chloride, which was reacted with 6-aminohexan-1-ol to afford 97, which was found 




Scheme 2.3: Amide label 97 synthesised by Hillier et al 
 
There is a large difference in the oxidation potentials of the two compounds 
synthesised, this is due to the urea functionalities in 96 being able to stabilise the 
ferrocenium ion, therefore leading to a lower oxidation potential compared to amide 
97. Flower et al, designed and synthesised a label containing two identical ferrocene 
moieties (Figure 2.5). 98 was found to have an oxidation potential of 250 mV vs. 
Ag/AgCl and is the current label being used in the assay developed by Atlas 
Genetics. 98 has an increased sensitivity in the assay in comparison to 96 and 97, 
due to 98 containing two ferrocene moieties.   
 
 
Figure 2.5: Label developed by Flower et al 
 
The primary aim of the work presented within the thesis is to design and synthesise a 
range of redox-active compounds for the use as labels in a multiplex Atlas DNA 
detection assay via the conjugation of the labels to an oligonucleotide probe. The aim 
was to synthesise redox-active compounds based around ferrocene with unique 
oxidation potentials in comparison to each other and the current label 98 being used 
by Atlas. The main aim of the project is to utilise the range of labels synthesised in 
duplex or multiplex assays with 98 for the detection of more than one pathogen. The 
detection of more than one pathogen in the same assay is required due to the fact that 
a number of infectious diseases co-infect (such as Chlamydia and Gonorrhea) or that 
63 
 
there can be a number of different strains of the bacterial pathogen like 
Staphylococcus aureus (such as in hospital acquired infections).   
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2.3 Results and Discussion 
 
The development of new labelled oligonucleotide probes for the use in the multiplex 
DNA detection assay can be separated into three areas; 1) the design and synthesis of 
the redox-active label component of the overall probe, 2) the synthesis of the 
oligonucleotides and the conjugation of the activated label to the oligonucleotide 








For the Atlas assay these three areas are carried out at three different locations. The 
area that concerns the work carried out in Chapter two and three, is the design and 
synthesis of the redox-active labels and their functionalisation for conjugation to the 
oligonucleotide. When designing a new redox-active label for the use in the 
synthesis of probe oligonucleotides there are three main sections to consider; the 
redox-active moiety, the linker structure and functionality and the conjugation 
technique going to be used. The redox-active moiety of the labels to be designed and 
synthesised in this thesis are based around ferrocene. Ferrocene was chosen due to 
the ferrocene/ferrocenium ion redox couple being well understood as well as the 
ability to alter the oxidation potential of ferrocene via the functionalization of the Cp 
rings of the ferrocene.
114-115
 The ability to synthesis ferrocene based redox-active 
labels with different oxidation potentials is of importance in the development of a 
multiplex detection assay. As the linker portion of the label will be directly 
substituted onto the ferrocene, the functionality on the linker that is in close 
proximity to the ferrocene moiety will also have an effect on the oxidation potential 
of the ferrocene moiety. Therefore a range of linkers were targeted that contain a 
variety of functionalities such as; amine, amide, triazole and ether groups. A range of 
target labels were identified involving various levels of substitution on the ferrocene, 
as well as the utilisation of the linker moieties mentioned previously (Figure 2.7).  
 
 







The first of the target labels to be synthesised was 99, the proposed synthetic route to 




Figure 2.8: 3-Ferrocenyl-N-(6-hydroxyhexyl)propanamide 
 
The label was synthesised starting from ferrocenecarboxaldehyde. First, a Horner-
Wadsworth-Emmons reaction was carried out (Scheme 2.4) to afford the enone 101 
in a good yield. The enone 101 was then reduced to the corresponding saturated ester 
under standard hydrogenation conditions using palladium on carbon to afford 102 in 
a high yield. 
 
 
Scheme 2.4: Synthetic route to 102 
 
The final steps of the synthesis of 99 was a saponification of ester 102 to yield 
carboxylic acid 103, followed by an amide coupling with 6-aminohexanol. The 
carboxylic acid 103 was subsequently used for the synthesis of another label via a 





Scheme 2.5: Synthetic route to 3-ferrocenyl-N-(6-hydroxyhexyl)propanamide 
 
3-Ferrocenyl-N-(6-hydroxyhexyl)propanamide 99 was easily synthesised on a 
relatively large scale and in a good yield over 4 steps. 99 was then analysed via 
differential pulse voltammetry under the standard conditions, showing it to have an 
oxidation potential of 85 mV vs. Ag/AgCl. The oxidation potential for 99 was found 
to be in a unique region of the electrochemical range, with comparison to 98. 
Therefore the corresponding phosphoramidite was synthesised (Scheme 2.6). 104 
was analysed via DPV and was found to have an oxidation potential of 85 mV vs. 
Ag/AgCl. However the label was not taken any further at this stage as the linker was 
believed to be too short for efficient coupling to oligonucleotide, being only a three 
carbon distance between the ferrocene and the hydroxyl group.  
 
 






 during their study of the structure of ferrocene, demonstrated that 
the reactivity of ferrocene was analogous to the reactivity of benzene rings. The 
cyclopentadienyl rings of the sandwich complex are electronically the same as a 
benzene ring. Therefore ferrocene can readily undergo aromatic electrophilic 
substitution reactions such as the Friedel – Crafts acylation reaction. One of the most 
common examples of ferrocene undergoing a Friedel – Crafts acylation reaction is in 





Scheme 2.7: Synthesis of acetylferrocene via Friedel-Crafts acylation 
 
When the reactivity of ferrocene was compared to that of anisole in the Friedel – 
Crafts acylation reaction it was shown that ferrocene reacted at a much higher rate 
than the anisole. The reason for the higher rate of reaction for ferrocene is due to the 
electron density of ferrocene. The Cp ring has a higher electron density than that of a 
corresponding benzene ring. Salmain et al, published work on the use of biotin as an 
acylating agent in the Friedel – Crafts reactions with aromatic compounds, they 
showed an example using ferrocene as the aromatic derivative (Scheme 2.8).
118
 It 
was decided to utilise the reaction developed by Salmain et al, in the design and 
synthesis of a range of redox-active labels.  
 
 




Using a modified version of Salmain’s conditions the reaction was repeated, using 
trimethylsilyl trifluoromethanesulfonate (TMS triflate) instead of triflic acid. The 
reaction proceeds by the formation of the acyltrifluoroacetate of biotin which then 
undergoes the Friedel – Crafts reaction in the presence of TMS triflate and ferrocene. 
It was discovered that through the use of TMS triflate there was an increase in yield 
to 95 %, compared to the 55% yield of product 110 when triflic acid is used. The 
scope of this reaction was explored using a range of ferrocene derivatives (Scheme 
2.9, Table 2.1). 
Scheme 2.9: Synthetic route to Friedel - Crafts products 110-113 
Table 2.1: Yields from Friedel – Crafts reaction with a range of ferrocene derivatives 




















As shown in Table 2.1 the reaction works in good yield for the various substituted 
ferrocene derivatives. The majority of the products from the reaction substitution on 
the substituted Cp ring giving a 1,3-disubstituted ferrocene, however with the 
bromoferrocene derivative substitution was observed on the unsubstituted 
cyclopentadienyl ring giving a 1,1’-disubstituted ferrocene. The result was proven by 
the proton NMR spectra, in which there are four individual peaks for the protons on 
the Cp rings compared to the free Cp ring which all the protons come as a 5H singlet. 
The positive results from this reaction lead to the use of this methodology in the 
design and synthesis of a range of ferrocenyl derivatives to be used as labels for 
DNA probes. The carboxylic acid used in place of biotin had to have a functionality 
in the molecule that could be further functionalised either pre or post the Friedel – 
Crafts reaction to instill the free hydroxyl group needed for the conjugation of the 
label to the oligonucleotide probe, the compound chosen for such a task was 3-
bromopropionic acid. 3-Bromopropionic acid was then utilised as the starting 
material for the synthesis of compound 118. The route to 118 was to go through two 
synthetic steps, firstly a Friedel – Crafts reaction to give the desired ketone 115 
followed by an etherification to give the target compound 118 (Scheme 2.10). 
 
 
Scheme 2.10: Proposed synthetic route to labels using Friedel - Crafts methodology 
 
The Friedel – Crafts reaction gave similar yields to the previous reactions carried out 





Scheme 2.11: General synthetic route to products 115-117 
Table 2.2: Friedel – Crafts reaction with 3-bromopropionic acid 











However when the Friedel – Crafts reaction was carried out on a larger than 1 mmol 
scale, a significant side product was observed from the reaction. This second product 
was isolated and found to be the acrylate of the ferrocene species 118 (Scheme 2.12).  
 
 
Scheme 2.12: Etherification reaction and acrylate by-product 
 
Upon discovery of this result it was necessary to redesign the synthetic route towards 
these labels in an attempt to limit the formation of the acrylate. The first proposed 
strategy was carried out by synthesising the linker unit prior to the Friedel – Crafts 





Scheme 2.13: Synthesis of linker unit prior to Friedel - Crafts reaction 
 
The synthesis of the linker was successful without the presence of any acrylate being 
formed, the linker was then exposed to the Friedel – Crafts conditions and this 




Scheme 2.14: Friedel - Crafts reaction between linker 120 and a range of ferrocene derivatives 
Table 2.3: Friedel - Crafts reaction with linker 120 











 This group of labels were analysed via differential pulse voltammetry to calculate 
their oxidation potential. The labels exhibited a range of oxidation potentials from 
150 mV to 610 mV vs. Ag/AgCl, with 118 having an oxidation potential of 433 mV 
vs. Ag/AgCl which is due to the electron – withdrawing effects of the linker group 
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itself. The electron-withdrawing effects of the linker can be seen from the shift that 
has been exhibited on the oxidation potential of the ferrocene, which is usually at 
160 mV and shifted to 433 mV (Figure 2.9). 
 











Figure 2.9: Voltammogram of the DPV scan of 118 
 
The further electron – withdrawing effects of the bromide in compound 121 can be 
seen by its oxidation potential being 610 mV vs. Ag/AgCl, therefore the formation of 
the ferrocenium ion of this derivative is more difficult and requires a considerably 
higher voltage to oxidise the ferrocene (Figure 2.10). 
 









Figure 2.10: Voltammogram of the DPV scan of 121 
 
The electron-donating ethyl group of 122 counteracts the electron-withdrawing 
nature of the linker group and an oxidation potential of 150 mV vs. Ag/AgCl is 















Figure 2.11: Voltammogram of the DPV scan of 122 
 
 
All the oxidation potentials of these compounds come in unique regions compared to 
compound 98, therefore they are all viable for a multiplex assay for the detection of 
target DNA. 118 was used for a duplex assay at the free hydroxyl stage, to assess the 
viability of using these monoferrocenyl labels in an assay with 98 (Figure 2.12, 
Table 2.4). It can be seen from the positions of the peaks 98 at 275 mV vs. Ag/AgCl 
and 118 at 433 mV vs. Ag/AgCl, there is definite separation between the two signal 
peaks.  
 
















Table 2.4: Showing comparison of 98 and 119 via DVP 
Label Peak position (mV) Peak height (µA) 
98 275 7.5 
118 433 3.2 
 
However as can be seen from the Figure 2.12 the signal produced for 118 is 
considerably lower in intensity than that for 98. While it would be expected for 98 to 
produce a signal of higher intensity as it is a label containing two ferrocene moieties 
whereas 118 only contains one ferrocene moiety (Figure 2.13). 
 
 
Figure 2.13: Labels 118 and 98 used in duplex 
 
It would be expected that a label with half the number of redox-active components to 
produce a signal with half the intensity of a label containing double the number of 
redox-active components such as 98. What is actually being observed in this case is 
that 118 is giving a signal with a third of the intensity compared to the signal 
received for 98. With 98 giving a peak height of around 7.5 µA and 118 giving a 
peak height of 3.2 µA (Table 2.4).  
 
The labels are then converted to the phosphoramidite via the free hydroxyl group for 
the conjugation to an oligonucleotide. First of all however all the labels are subjected 
to the conditions for the oligonucleotide cleavage from the solid support, these are to 
expose the compounds to 5 M NH4OH solution at both room temperature and at 
50˚C. All of the compounds survived under these conditions overnight, therefore 
they were taken forward to the corresponding phosphoramidite, the synthesis of the 
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Scheme 2.15: General synthetic route to phosphoramidite 123-124 
Table 2.5: Yields and phosphorous peaks for 123-125 
No. 
31
P NMR Yield 
123 147.16 78% 
124 147.24 20% 
125 147.27 74% 
 
Once the phosphoramidites had been synthesised and prior to the conjugation to an 
oligonucleotide the compounds were subjected to a range of stability tests as the 
oligonucleotide synthesis is both expensive and was undertaken offsite so survival of 
the compound during transportation is necessary. The stability of the 
phosphoramidites was followed by 
31
P NMR analysis, if the phosphoramidite began 
to decompose the growth of a second peak in the phosphorus NMR can be seen. The 








The stability tests were carried out at room temperature, with an aliquot being kept at 
room temperature neat and another aliquot being dissolved in deuterated acetonitrile. 
Acetonitrile was used as it is the most common solvent used to load 
phosphoramidites into the oligonucleotide synthesiser. 
31
P NMRs were then taken of 
the aliquots after 12 hrs, 24 hrs, 48 hrs and one week. If the labels passed the 
stability tests over 48 hrs they were then sent off to be conjugated to an 




Figure 2.15: 31P NMR of the stability test of 123 run over 1 week in CD3CN 
 
Stability testing of 123 showed that the phosphoramidite was stable at room 
temperature in MeCN over 24 hours (Figure 2.15). The phosphoramidite did start to 
decompose to the phosphine oxide after 48 hours at room temperature, the level of 
decomposition was found to be 13% and after a week 24%. From the effect of the 
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linker on the oxidation potential of ferrocene exhibited in 118 it was decided to 
reduce the ketone to the alkane using borane dimethylsulfide (BMS) (Scheme 2.16).  
 
 
Scheme 2.16: BMS reduction of 118 
 
The reduced compound 127 exhibited a difference in oxidation potential compared 
to the parent compound 118, the elicited change is due to the reduced form of the 
being less electron – withdrawing due to the reduction of the ketone moiety. The 
oxidation potential of 127 was found to be 114 mV vs. Ag/AgCl (Figure 2.16).  
 










Figure 2.16: Voltammogram of the DPV scan of 127 
 
This compound was then taken through to the phosphoramidite in a 79% yield 
(Scheme 2.17), 128 was found to be stable under the conditions of the stability test 





Scheme 2.17: Synthesis of phosphoramidite 128 
 
Electron rich ferrocene derivatives have lower oxidation potentials due to an 
increased electron density, therefore a lower voltage is required to oxidise the 
ferrocene moiety. Therefore the synthesis of a highly electron rich label is a logical 
progression in the design of labels for the use in multiplex detection assays. Using 
decamethylferrocene as an electron rich ferrocene starting material was likely to give 
a label in a unique region of the electrochemical spectrum. Nonamethyl 
ferrocenecarboxaldehyde 130 was prepared by a selective oxidation of a single 
methyl group on decamethylferrocene using barium manganate via the procedure 





Scheme 2.18: Selective oxidation of methyl group to aldehyde 130 
 
The aldehyde 130 provides a useful functional handle for the synthesis of labels 
containing an electron rich ferrocene moiety. The aldehyde could be taken through a 
functional group transformation such as the reduction of the aldehyde to the 
corresponding alcohol or reacted as the aldehyde itself via a reductive amination 





Scheme 2.19: Synthetic route to 132 
 
132 was analysed via DPV to ascertain its oxidation potential. Analysis showed it to 
have a low oxidation potential of -105 mV vs. Ag/AgCl. The negative oxidation 
potential is due to the ferrocene being electron rich, this is due to the nine methyl 
groups on the cyclopentadienyl rings which have an inductive electron donating 
(Figure 2.17). 
 









Figure 2.17: Voltammogram of the DPV scan of 132 
 
Figure 2.17 shows that the peak observed for this derivative is very broad, this could 
be an issue when it comes to using this as a label in a multiplex assay. This led to the 
design of the synthesis of another label starting from the 
nonamethylferrocenecarboxaldehyde derivative. The first step of the synthesis is the 






Scheme 2.20: Sodium borohydride reduction of 133 
 
The next step of the synthesis was a nucleophilic substitution reaction with 3-
bromopropionic acid, in which the bromide is displaced by the nonamethylferrocene 
methanol 133 to form the ether 135 (Scheme 2.21). The next step is then to 
incorporate the free hydroxyl group into the compound, this was carried out through 
the reduction of the carboxylic acid to afford 135.  
 
 
Scheme 2.21: Synthetic route to 135 
 
Analysis was carried out to ascertain the oxidation potential of 135, which was found 
to be -85 mV vs. Ag/AgCl (Figure 2.18). Figure 2.18 shows that the peak observed 
for 135 is a lot sharper than the peak observed for 132. 
 













The phosphoramidite 136 was then synthesised and stability tests were carried out 
(Scheme 2.22). 136 was found to be stable upon testing under the standard stability 
conditions both for the solid support cleavage conditions and also the 
phosphoramidite transport conditions. 
 
 
Scheme 2.22: Synthesis of phosphoramidite 136 
 
From the development of the two nonamethylferrocenyl labels 132 and 135 which 
are electron rich species and where found to have negative oxidation potentials, it 
was decided to synthesise the standard ferrocene derivative versions of the labels to 
compare the oxidation potentials with the electron-rich labels. The non-substituted 
ferrocene labels were also synthesised for the investigation of the possibility of the 
duplex between the different label species. Both 137 and 140 were synthesised 
through the same respective synthetic routes either starting from 
ferrocenecarboxaldehyde or ferrocene methanol (Scheme 2.23). 
 
 




137 and 140 have oxidation potentials of 250 mV and 179 mV vs. Ag/AgCl 
respectively (Table 2.6). 
 
Table 2.6: Comparison of oxidation potentials of electron rich ferrocene derivatives and standard 
ferrocene derivatives 
No Oxidation potential 






The same observation can be made between the voltammograms of 137 and 140, 



















0 100 200 300 400 500 600
 
Figure 2.19: Voltammogram of the DPV scan of 137 and 140 
 
The fact that the electron-rich ferrocene labels 132 and 135 come in a unique 
location compared to their standard ferrocene derivatives and therefore they are an 
ideal pair to be used in a duplex assay. A duplex was run of 132 and 137 (Figure 
2.20) and it can be seen from the figure 2.20 that the signal peaks for both the labels 
are clearly distinguishable from each other and also of the same intensity at equal 











Figure 2.20: Voltammogram of the duplex of 132 and 137 
 
Having clear separation is important in a duplex assay as when using two different 
labels to detect different targets in the same solution it is vital to have clear 
separation as not to get a false negative or positive from one of the labels. However 
with this duplex the signal from 132 does not make it back down to the base line and 
the signal from 137 starts to grow in at the same time, this leads to a broadening of 
the signal peaks of these two labels. When 135 was duplexed with 140 at equal 
molar concentration in the duplex solution there can be seen a greater separation 
between the two peaks than exhibited between 132 and 137 (Figure 2.21), which 
follows on from the observation that both 135 and 140 have sharper signal peaks 
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Figure 2.21 shows that there is not only good separation between the two peaks 
exhibited from 135 and 140 but there is also no overlap observed between the two 
peak signals as the tail of the signal for 135 returns to the baseline level before there 
is the growth in of the peak exhibited for 140. Therefore the duplex between 135 and 
140 possesses more desirable characteristics than that of the duplex between 132 and 
137, these being sharper signals for the two labels in the duplex and also a higher 
level of separation between the two peaks.   
 
As mentioned previously a range of functionalities on the linker have been targeted, 
one specific linker functionality that was outlined as a target was a triazole 
containing linker which can be achieved via click chemistry. Click chemistry 
reactions have been used for the post-labelling of functionalised oligonucleotides.
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It was proposed to utilise click chemistry in the synthesis of redox-active labels. This 
could be carried out either by having the azide moiety situated on the ferrocene 
derivative or the alkyne moiety situated on the ferrocene derivative (Figure 2.22) 
 
 
Figure 2.22: Ferrocene derivatives for the click reactions 
 
The click reaction will be used to tie together the redox-active ferrocene moiety and 
the free hydroxyl containing moiety in the synthesis of triazole containing linkers. 
(1-(Ferrocenylmethyl)-1H-1,2,3-triazol-4-yl)methanol 142 (Figure 2.23), was the 





Figure 2.23: label 142 
 
Starting from ferrocenemethyl azide 141, which was synthesised from ferrocene 
methanol 138 using 1,8-diazabicycloundec-7-ene (DBU) and diphenylphosphoryl 
azide (DPPA) (Scheme 2.23). 
 
 
Scheme 2.23: Synthetic route to 142 via click reaction 
 
142 was used without isolation or purification, the in situ generated azide was then 
reacted with propargyl alcohol in the presence of copper acetate and sodium 
ascorbate solution to afford 142. The triazole product was found to have an oxidation 
potential of 250 mV vs. Ag/AgCl (Figure 2.24). This shows that the triazole ring in 
the linker is having an electron withdrawing effect on the ferrocene core, shifting the 
ferrocenes’ oxidation potential by approximately 90 mV.  
 















As the oxidation potential of 142 is in the same region as previously synthesised 
labels it would not be viable for a duplex label. Therefore the utilisation of the click 
reaction was then investigated with ferrocene ethylene as the starting material for the 
synthesis of another label. This would put the ferrocene moiety at the four position 
on the triazole, rather than the one position as it is in 142 (Figure 2.25). 
 
 
Figure 2.25: Ferrocene at the 4-position of the triazole 143 
 
The azide derivative for this label was prepared from bromohexan-1-ol via treatment 
with sodium azide in a 1:1 butanol:water mixture, to give the desired azide 145 
which was used without isolation or purification. To the reaction mixture was added 
ferrocene ethylene 80 along with copper acetate solution and sodium ascorbate 
solution to afford compound 143 (Scheme 2.24). 
 
 
Scheme 2.24: Synthesis of 143 
 
6-(4-Ferrocenyl-1H-1,2,3-triazol-1-yl)hexan-1-ol 143 was analysed via differential 
pulse voltammetry and found to have an oxidation potential of 450 mV vs. Ag/AgCl 












Figure 2.26: Volammogram of the DPV scan of 143 
 
The comparison of the oxidation potentials of 142 (250 mV vs. Ag/AgCl) and 143 
(450 mV vs. Ag/AgCl) shows that there is a stronger electron withdrawing effect on 
the ferrocene moiety at the four position due to the ferrocene being directly bound to 
the conjugated triazole ring, whereas in the one position there is a carbon between 
the ferrocene and the triazole ring therefore the electron withdrawing effect on the 
ferrocene is lower.   
 
From the previous work done in the group by Hillier et al, on the synthesis of 97 
(Figure 2.27). 97 was found to have an oxidation potential of 400 mV vs. Ag/AgCl. 
 
 
Figure 2.27: 97 synthesised by Hillier et al 
 
Along with the synthesis of 99 which was found to have an oxidation potential of 85 
mV vs. Ag/AgCl (Figure 2.28), it was decided to study the effect of the number of 
carbon atoms between the ferrocene moiety and the amide group has on the 





Figure 2.28: Compound 99 
 
There is an approximate shift of approximately 300 mV in the oxidation potential 
between 97 with the amide being directly situated on the amide and 99 in which 
there is a two carbon linker between the ferrocene and the amide group. 2-
Ferrocenyl-N-(6-hydroxyhexyl)acetamide 147 was therefore proposed to be 
synthesised, the starting material was ferrocene acetic acid. The synthesis of the label 
147 was carried out via the in situ generation of the acid chloride, which was reacted 
with 6-aminohexanol (Scheme 2.25). 
 
 
Scheme 2.25: Synthetic route to 147 
 
147 was found to have an oxidation potential of 269 mV vs. Ag/AgCl, which is just 
over halfway between the other two labels (Figure 2.29). This shows that there is a 
decrease of approximately 150 mV for every carbon added between the ferrocene 
















This chapter has shown the synthesis of a range of mono-ferrocenyl derivatives for 
the use as redox-active labels in the synthesis of DNA probes, to be used in a DNA 
biosensor. The compounds synthesised were analysed via differential pulse 
voltammetry, which showed a range of oxidation potentials have been achieved 
(Graph 2.1). However, the sensitivity of the mono-ferrocenyl labels was shown to be 
lower than that of di-ferrocenyl label currently being used in the biosensor assay. 
Labels with unique oxidation potentials were activated for bioconjugation via the 
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3 Chapter 3: The synthesis of Di-ferrocenyl labels for the use as 
DNA Probes 
 
Summary of Chapter 
 
This chapter details the design and synthesis of redox-active labels containing more 
than one redox-active moiety present in the label. All the redox-active components 
are symmetrical, so that there is only one oxidation potential for the label and not 
separate peaks for the individual redox-active components. The ferrocene containing 
redox active labels described in this chapter are to be used in the Atlas DNA 




From the work presented in chapter 2 on the synthesis of mono-ferrocenyl labels it 
became apparent that the mono-ferrocenyl derivatives have a lower sensitivity in 
comparison to 98 which is currently the main redox-active label used as a probe in 
the Atlas assay. This lower level of sensitivity at the electrode can be seen in graph 



























E / mV vs. Ag/AgCl
 
Graph 3.1: Graph depicting the difference between the di-label 98 and the mono-labels synthesised 
 
The difference in the sensitivity was highlighted in the duplex assay between 98 and 
118 (Figure 3.1), the signal intensity of 118 was found to be lower in comparison to 
the intensity of the signal for 98 when each of the labels were in equimolar 
concentration within the duplex assay mixture.  
 
 
Figure 3.1: Redox-active labels used in the duplex assay 
 
A lower intensity of signal between the two compounds would be expected due to 
118 containing one ferrocene moiety compared to two ferrocene moieties in 98, from 
this information the intensity at the electrode for 118 would be expected to be 
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approximately half the intensity of 98. However in practise the signal intensity for 
118 was found to be approximately a third of the signal intensity of 98. The result 
was reproducible as seen in Table 3.1, where 118 was found to have an average 
signal intensity of 2.6 µA and 98 having an average intensity of 6.9 µA, over the 
three runs carried out on the duplex assay (Table 3.1)  
 
Table 3.1: Duplex at equal concentration of 98 and 118 
Run Label 




1 98 272 7.47 
118 440 2.70 
2 98 275 6.49 
118 440 2.43 
3 98 274 7.45 
118 441 2.53 
 
The difference between the two labels can be clearly seen from the overlays of the 
three duplex runs on Figure 3.2 (Figure 3.2). 
 















A further experiment was under taken, the concentration of 118 was doubled in the 
duplex solution with the concentration of 98 being kept constant, therefore 
effectively equalising the number of redox-active moieties with regards to the two 
labels. When the duplex solution was analysed via differential pulse voltammetry it 
was shown that there was an increase in the intensity of the signal for 118, the signal 
intensity was increased from a third of the intensity to a signal intensity of two thirds 
of the intensity in comparison to the signal for 98 (Figure 3.3). 









Figure 3.3: Voltammogram of the duplex run between 98 and 118 with 118 at double the concentration 
With the redox-active moieties for the two labels in the duplex being equal it would 
have been theoretically perceived that the signal intensity for both labels 98 and 118 
would be equal. However in practise this is not the case, the signal intensity for 118 
was shown to be two thirds of the intensity of 98 (Table 3.2). 
 
Table 3.2: Duplex of 118 and 98 at a 2:1 ratio 
Run  Label Peak Position (mV 
vs. Ag/AgCl) 
Peak Height (µA) 
1 98 288 5.77 
118 446 4.31 
2 98 282 6.17 
118 446 3.80 
3 98 275 7.17 




At double the concentration label 118 has the average peak height of 3.9 µA whereas 
label 98 has the average peak height of 6.4 µA. The results of the duplex at this 
concentration mix in the duplex are repeatable (Figure 3.4). 
 










Figure 3.4: Overlay of the voltammograms of the duplex run between 98 and 118 with 118 at double the 
concentration 
 
A final experiment was conducted, the concentration of 118 was triple in comparison 
to 98 (Figure 3.5). At this ratio it was found that the intensities of the peaks for 98 
and 118 were found to be equal. 
 















As can be seen from Figure 3.5 the intensity of the signal produced by 118 is now 
equal in intensity to the signal produced by 98, for which the concentration of the 
label has stayed the same in all of the duplex assay systems (Table 3.3). 
 
Table 3.3: Duplex of 118 and 98 at a 3:1 ratio 
Run Label Peak Position (mV vs. 
Ag/AgCl) 
Peak Height (µA) 
1 98 285 5.75 
118 455 5.53 
2 98 272 7.66 
118 455 7.39 
3 98 288 5.88 
118 455 5.31 
 
 
As shown in the Table 3.3 the results for this duplex were found to be constant 
across all of the three runs of the duplex system (Figure 3.6).  
 

















3.2 Results and Discussion 
 
From the synthesis and electrochemical analysis via DPV of the monoferrocenyl 
labels presented in chapter 2, it was shown that the mono labels were less sensitive 
than 98. Therefore the design and synthesis of a range of redox-active labels 
containing more than one redox-active moiety present in the label structure was 
proposed. The first targeted range of labels are derivatives of the label developed by 
Flower et al 98, which is the current label used in the Atlas DNA detection assay. 
The labels targeted were either derivatives of 98 which were either further 
substituted on the Cp rings or with the alteration of the functionality of the linker 
unit (Figure 3.7). 
 
 
Figure 3.7: Structures of labels targeted based around 98 
 
The first label designed for synthesis containing more than one ferrocene moiety was 
a direct derivative of 98 using an ether containing linker moiety, with the aim of 
improving the labels solubility in aqueous media. The solubility of the labels 
synthesised is important due to the DNA detection assay being carried out in an 
aqueous buffer medium. Solutbility however becomes less of an issue when the 
labels are conjugated to the oligonucleotide. 149 was synthesised using a reductive 
amination procedure, starting from ferrocenecarboxaldehyde and 





Scheme 3.1: Synthesis of 149 
 
Upon electrochemical analysis it was found that 149 had an oxidation potential of 
242 mV vs. Ag/AgCl (Figure 3.8). The oxidation potential of 149 was found to be 
very similar to the oxidation potential of 98 which is the current label used in the 
DNA detection assay, which has an oxidation potential of 275 mV vs. Ag/AgCl. 149 
was synthesised to investigate the effect of the ether group in the linker unit has on 
the behaviour and oxidation potential of the label in the DNA detection assay. 
 












Figure 3.8: Voltammogram of the DPV scan of 149 
 
The phosphoramidite of 149 was then synthesised (Scheme 3.2), which proved to be 





Scheme 3.2: Synthesis of phosphoramidite 150 
 
The first substituted derivative of 98 proposed for synthesis was 6-(bis((2-
methylferrocenyl)methyl)amino)hexan-1-ol 151 which has a methyl group 
substituted onto one of the Cp rings. The starting material for this label is methyl 
ferrocene 152 which was synthesised from ferrocene via the deprotonation of 
ferrocene with n-butyl lithium giving the lithioferrocene derivative, the reactive 
lithioferrocene derivative was reacted with methyl iodide to instil the desired methyl 
group in a good yield (Scheme 3.3).   
 
 
Scheme 3.3: Synthesis of methylferrocene 
 
The next step of the synthesis was to instil the aldehyde functionality onto the 
ferrocene Cp ring, this was also carried out via the generation of the lithioferrocene 
species, which was reacted with DMF to afford the methylferrocenecarboxaldehyde 
153 in a 73% yield (Scheme 3.4) 
 
 




The final step in the synthetic route to 151 was a reductive amination reaction with 
6-aminohexan-1-ol, to instil the desired nitrogen containing bridge head unit and the 
linker moiety (Scheme 3.5).  
 
 
Scheme 3.5: Synthesis of 151 via reductive amination 
 
Upon running the differential pulse voltammetry of 151 it was found that it processes 
an oxidation potential of 330 mV vs. Ag/AgCl (Figure 3.9). This shows the effect of 
the linker nitrogen bridge unit between the two ferrocene moieties on the oxidation 
potential. With regards to 151 it can been seen clearly the effect the linker has on the 
oxidation potential of the ferrocene itself. The incorporation of an ortho-methyl 
group on the ferrocene results in an increase in the oxidation potential, this could 
possibly be due to steric effects. An interesting observation to make from 151 is that 
the substitution of a methyl group on to the cyclopentadienyl ring as well as the 
linker moiety the oxidation potential is 330 mV, with the electron donating effect of 
the methyl group it could be argued that the oxidation potential should be closer to 












Figure 3.9: Voltammogram of the DPV scan of 151 
 
The next label targeted was a label that incorporated amine functionality onto the 
ferrocene as well as the nitrogen containing linker moiety. The amine functionality 
was targeted as the amine functionality of the linker in label 98 was shown to shift 
the oxidation potential of the ferrocene by approximately 135 mV, therefore it was 
theorised that the inclusion of another amine group onto the ferrocene core would 
have a similar effect on the oxidation potential of the label compound. The label 
targeted was bis((dimethylamino)methylferrocenyl)-6-aminohexan-1-ol 154, the 
starting material for the synthesis of 154 was (dimethylamino)methyl ferrocene 155 
(Figure 3.10).  
 
 
Figure 3.10: (dimethylamino)Methyl ferrocene 155 
 
The dimethylamine group on 155 has the ability to stabilise the lithioferrocene 
species generated via the lone pair on the nitrogen, therefore keeping the 
lithioferrocene species around for longer in the reaction mixture.
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 The 
lithioferrocene intermediate was then in situ reacted with DMF to instil the aldehyde 





Scheme 3.6: Synthesis of aldehyde 156 
 
The aldehyde generated was afforded in a higher yield of 88% rather than that of the 
aldehyde 153 which was afforded in a 68% yield. This is due to the lithioferrocene 
species generated in the synthesis of 153 being less stable than the lithioferrocene 
species generated in the synthesis of 156, which is stabilised by the presence of the 
amine functionality. Aldehyde 156 was used in a reductive amination with 6-
aminohexanol to afford the desired label 154 in 75% yield (Scheme 3.7). 
 
 
Scheme 3.7: Synthesis of 154 
 
154 was then analysed via DPV and was found to have an oxidation potential of 380 
mV vs. Ag/AgCl (Figure 3.11). As can be seen from Figure3.11 the peak exhibited 
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Figure 3.11: Voltammogram of the DPV scan of 154 
 
It has been shown by previous work in the group and work presented in chapter 2 
that amides have an effect on the oxidation of the ferrocene derivative, the effect has 
been shown to vary depending on the distance between the ferrocene moiety and the 
amide moiety. Hiller et al, showed that having the amide situated directly on the Cp 
ring shifted the oxidation potential of the ferrocene moiety to 400 mV vs. Ag/AgCl. 
Therefore the next label targeted would be substituted with an amide group on the 
Cp ring. 2,2-(6-Hydroxyhexylazanedyl)bis(methylene)bis(N,N’-
diisopropylferrocenecarboxamide) 157 was the amide containing label designed, the 
proposed synthetic route to 157 started from ferrocenecarboxylic acid 62. The first 
step of the synthetic route to 157 was the in situ generation of an acid chloride by 
reacting ferrocenecarboxylic acid with oxalyl chloride. The generated acid chloride 
was then reacted with diisoproyl amine (DIPA) to incorporate the amide 
functionality onto the Cp ring to afford the desired amide derivative (Scheme 3.8). 
 
 




86 was then reacted with n-butyl lithium to generate a lithioferrocene species, which 
was quenched with DMF to afford the desired aldehyde functionality 158 into the 
compound that is required for the final step of the synthesis of 157 (Scheme 3.9). 
 
 
Scheme 3.9: Synthesis of aldehyde 158 
 
With aldehyde 158 in hand, the final step of the synthetic route to 157 was a 
reductive amination reaction of 158 with 6-aminohexan-1-ol (Scheme 3.10). This 
gave the desired compound  157 in a good yield. 
 
 
Scheme 3.10: Synthesis of 157 
 
157 was analysed via DPV and was found to have an oxidation potential of 350 mV 
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Figure 3.12: Voltammogram of the DPV scan of 157 
 
As labels 151, 154 and 157 all have oxidation potentials that are in close proximity 
to 98 they were not taken any further at this stage. It has become apparent from the 
synthesis of 151, 154 and 157 that the linker moiety of the derivatives has an effect 
on the oxidation potential of the labels as well as any substitution on the Cp rings.  
 
Therefore it was decided to analyse the effect of further functionality within the 
linker moiety has on the oxidation potential of the labels. The nitrogen containing 
bridging unit between the two ferrocene moieties was kept the same and the 
functionality was installed into the compound between the bridged ferrocene 
moieties and the free hydroxyl group. The functionality targeted within the linker 
unit was an amide functional group. Therefore a label was designed around the linker 
unit being in two halves to instil the desired functionality into the linker unit. The 
ferrocene end of the label was designed to still contain the same nitrogen containing 
bridging unit between the two ferrocene derivatives as in 98. The use of glycine as 
the first half of the linker was proposed, this would lead to an amide functional group 
in the linker. Starting from ferrocenecarboxaldehyde and glycine, which were taken 
through a reductive amination reaction to afford the di-ferrocenyl head group 160 in 





Scheme 3.11: Synthesis of 160 from glycine 
 
160 was then reacted with oxalyl chloride to generate the acid chloride in situ which 
was then further reacted with 6-aminohexan-1-ol (Scheme 3.12), to afford 2-
(bis(ferrocenylmethyl)amino)-N-(6-hydroxyhexyl)acetamide 161.  
 
 
Scheme 3.12: Amide coupling to afford 161 
 
161 was analysed via DPV and was found to have an oxidation potential of 500 mV 
vs. Ag/AgCl (Figure 3.13). The inclusion of the amide moiety in the linker increases 
the electron-withdrawing effect of the linker on the ferrocenes themselves, therefore 
a higher oxidation potential is required to oxidise the ferrocenes to their ferrocenium 
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The oxidation potential of 161 was found to be considerably different to that of 98, 
therefore the phophoramidite 162 was then synthesised for the use as a duplex label 
with 98 (Scheme 3.13). However upon stability analysis on 162 as well as attempted 
conjugation to oligonucleotide there were some issues with the labels stability. A 
possible reason for this unstability the amide in the linker still has a free proton, 
which could lead to deprotonation and possible decomposition of the label due to the 
5M ammonium hydroxide that is used in the final step of the oligonucleotide 
synthesis.   
 
 
Scheme 3.13: Synthesis of phosphoramidite 162 
 
Therefore it was decided to change the primary amine used to a secondary amine to 
analyse the effect the removal of the amide proton has on the stability of the label. 
The secondary amine chosen was 4-piperidine methanol to be used as the amino 
alcohol moiety.  
 
The synthetic route to 2-(bis(ferrocenylmethyl)amino)acetic acid 160 was altered to 
increase the yield of the desired compound. The first step was still a reductive 
amination starting from ferrocenecarboxaldehyde 100, however instead of glycine 
the ethyl ester protected derivative of glycine 159 was used as the amine source for 
the reaction. The use of the ethyl ester increased the yield of the reductive amination 
from 64% to 97%. The next step of the synthesis was a saponification under basic 





Scheme 3.14: Synthesis of 160 through altered route 
 
The final step of the synthetic route to 165 was an amide coupling reaction carried 
out via the in situ generation of the acid chloride of 160 which was further reacted 




Scheme 3.15: Synthesis of amide 165 
 
165 was analysed via DPV and was found to have an oxidation potential of 410 mV 
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The oxidation potential of 165 is in a unique region of the scan width compared to 
98 which is the current redox-active label being used in the Atlas DNA detection 
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Figure 3.16: Voltammogram of the duplex run between 98 and 165 
 
The duplex assay was run with equal molar concentration of the two labels 98 and 
165. As Figure 3.16 shows there is separation between the two signals for the two 
labels. However there is not complete separation between the two signals from the 
labels, this can be seen as the tail of the peak for 98 does not reach the baseline 
before the signal for 165 grows in. This could become an issue if the labels were 
used in a DNA detection duplex assay as it could lead to a false negative result if one 
of the targets associated to one of the labels was in lower concentration to the other. 
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It was decided following the result of this duplex to analyse the capability of these 
two labels being combined with a third label in a multiplex assay. The third label 
chosen for this was 135 which has an oxidation potential of -80 mV vs. Ag/AgCl, 
this label was chosen for the multiplex assay as the region from zero down to -300 
was smooth and the label would have clear separation from the other two labels 
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Figure 3.17: Voltammogram of the triplex run between 98, 135 and 165 
 
As Figure 3.17 shows that labels 135, 98 and 165 are able to be used in a multiplex 
assay and the fact that all three of the labels can be individually identified. There is 
clear separation between the peaks of 135 and 98 with there being no overlap 
between the two signals observed for these two labels. However there is some 
overlap observed between the signals for 98 and 165, this could lead to a sensitivity 
issue in the assay.  
 
From the work presented in chapter 2 it has been shown that labels developed with 
an ether group in the linker moiety are stable, therefore it was decided to design and 
synthesise a di-ferrocenyl label containing an ether linkage, 1,1,1-
tris(hydroxymethyl)ethane 166 was targeted as the linker moiety for the synthesis of 





Figure 3.18: Triol 166 to be used as linker moiety 
 
The label 3-ferrocenylmethyl-2-(ferrocenylmethyl)-2-methyl propan-1-ol 167 was 
designed to be synthesised utilising the linker 166 along with ferrocene methanol 
139 as the redox-active moiety of the label (Figure 3.19). 
 
 
Figure 3.19: 3-ferrocenylmethyl-2-(ferrocenylmethyl)-2-methylpropan-1-ol 167 
 
The initial proposed synthetic route to 167 was three steps with ferrocene methanol 
being the starting material, the primary synthetic step was the halogenation of the 
hydroxyl group to afford (bromomethyl)ferrocene 168 via the use of phosphorous 
tribromide (Scheme 3.16). 
 
 
Scheme 3.16: Synthesis of 168 
 
The next step was the in situ generation of the di-sodium salt of 166 using sodium 
hydride, the generated sodium salt was then reacted with two equivalents of 168 to 





Scheme 3.17: Synthesis of 167 
 
The yield for this reaction was poor for the desired product, however a higher 
yielding biproduct was observed. The biproduct was found to be the mono-
substituted triol 169, following this discovery the mono-substituted triol was re-
exposed to the reaction conditions to attempt to reach 167 (Scheme 3.18). 
 
 
Scheme 3.18: Synthesis of 167 via re-exposure of 169 to reaction conditions 
 
However as the synthesis of 167 was still found to be low yielding after exposing 
169 to the reaction conditions for a second time a new synthetic route to 167 was 
designed. In the new proposed synthetic route the starting material was 
(dimethylamino)methyl ferrocene 155, which was converted to the 









The formation of salt 170 makes the ferrocene derivative more electrophilic at the 
benzylic carbon. Therefore this makes the ferrocene derivative more susceptible to 




Scheme 3.20: Synthesis of 167 via trimethylaminium iodide salt 
 
The re-deisgn of the synthetic route to 167 proved to be successful as the only 
product observed from this reaction was the desired product 167. 167 was analysed 








0 100 200 300 400 500 600 700
 
Figure 3.20: Voltammogram of the DPV scan of 167 
 
The oxidation potential of 167 is close to the oxidation potential of 98 which is the 
current label being used in the DNA detection assay, therefore a duplex of 98 and 
167 was run to analyse the capability of using 167 as a redox-active label for the use 
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in a DNA detection assay. The duplex was run with 98 and 167 at equal 
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Figure 3.21: Voltammogram of the duplex run between 98 and 167 
 
As Figure 3.21 shows the two compounds oxidation potentials are too close together 
to be used as a successful duplex detection assay, as there is no clear separation 
between the oxidation potentials of the two compounds 98 and 167. Therefore these 
two labels would not be suitable for the use in a duplex DNA detection assay, as one 
of the most important requirements for a successful duplex assay is clear separation 
between the two labels oxidation potentials so that if the targets are in different 
concentrations in the assay mixture therefore both labels would be able to be picked 
up. However with labels 98 and 167 this would not be possible as if either of the 
labels were at a lower concentration to the other there signal peak would be lost 
underneath the other labels peak. This would lead to just one peak being exhibited as 
a broad signal and therefore could lead to a false negative in respect to the assay. 
3.3 Conclusion 
 
This chapter has shown the synthesis of a range of di-ferrocenyl derivatives for use 
as redox-active labels in the synthesis of DNA probes, for use in a DNA biosensor. 
The compounds synthesised were analysed via DPV to ascertain their oxidation 
potentials and show that a range of oxidation potentials has been achieved (Graph 
3.2). Graph 3.2 shows that the di-ferrocenyl derivatives synthesised have similar 
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signal intensities to that of the current label being used in the biosensor developed by 
Atlas. It has also been shown that there is the capability through the use of the labels 
synthesised in this chapter along with chapter 2 for the development of duplex and 
multiplex assays.  
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4 Chapter 4: The Analysis of Unique Redox-Active DNA probes in 
the Atlas DNA Detection Assay 
 
Summary of Chapter  
This chapter details the use of the labels synthesised in chapters 2 and 3 in the 




The development of redox-active labels presented in this thesis in chapters two and 
three were designed and synthesised to be used in the DNA detection assay 
developed by Atlas Genetics, with the aim for the redox-active labels to be used in a 
multiplex detection assay. Once the labels designed have been synthesised and 
functionalised for conjugation they are sent to ATDBio who carry out the synthesis 
of the oligonucleotides for use in the assay as well as the labelling of the 
oligonucleotides with the specific redox-active label. The labelled oligonucleotide 
probes are then sent to Atlas for testing in the DNA detection assay. The primary 
testing carried out on a new label is usually the synthetic target assay. A synthetic 
target assay involves not only the labelled probe being a synthetic strand of DNA but 
also the target strand is a synthetic oligonucleotide strand. The synthetic target assay 
is used for the primary analysis of new redox-active probes as the assay contains a 
higher level of operator control, as the target DNA concentration in the reaction can 






Scheme 4.1: Synthetic target assay schematic 
 
Once a probe has been tested through the synthetic target assay the probe is then 
analysed in the commercial DNA detection assay developed by Atlas. In the current 
commercial DNA detection assay the probe 172 is used in the assay as the 
Chlamydia probe, with the aim to use the labels developed in this thesis as an 
internal control probe and another labelled probe for the detection of a secondary 
target in this case a Gonorrhoea probe. 
 
4.2 Results and Discussion 
 
The major aim of the work presented in this thesis has been the design and synthesis 
of redox-active labels for the use as DNA probes in the Atlas T7 DNA detection 
assay. More specifically the synthesis of labels for the development of a multiplex 
DNA detection assay, with the probe that is currently being used in the DNA 




Scheme 4.2: Schematic of targeted multiplex DNA detection assay 
 
The phosphoramidite 150 was conjugated to an oligonucleotide probe, even though 
149 was found to have a similar oxidation potential to that of 98 which is the current 
label being used in the DNA detection assay (Figure 4.1, Table 4.1). As the 
oxidation potential of 149 is in close proximity to the oxidation potential of 98, 
therefore a duplex assay between these two labels would not be possible. 150 was 
conjugated to an oligonucleotide probe to investigate the effect the ether linker in 
149 had on the oxidation potential of the DNA digest product and also the effect on 





Figure 4.1: Labels 149 and 98 
 
Table 4.1: Oxidation potential and intensity of 98 and 149 vs. Ag/AgCl 
Label Peak Position (mV vs. 
Ag/AgCl) 






From the electrochemical analysis of 149 via DPV it was observed that at the free 
alcohol label stage the signal for 149 was found to be sharper than the signal for 98 
(Figure 4.2). This observation can be seen on Figure 4.2, which is an overlay of the 
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As can be seen from the peaks on Figure 4.2 both the peaks are symmetrical in shape 
as well as both peaks starting to grow in at the same point at approximately 180 mV. 
Both peaks start to grow in at the same voltage however the peak for 149 (ii) has a 
steeper gradient than the peak of 98 (i). This leads to a broader peak being exhibited 
for 98, this can be seen from the Figure 4.2 as the peak for 98 (i) starts at the same 
point as 149, however it does not return to the baseline until approximately 400 mV. 
When designing a duplex or multiplex assay the use of a label that possess a sharp 
signal via DPV analysis has a number of benefits, primarily being the fact that the 
pairing of the label with another is made easier by the fact that there is more of the 
range free. Also the use of a label with a sharp signal also lowers the chance of any 
overlap between the two peaks, which can affect the sensitivity of the assays being 
run.  
 
The phosphoramidite label 150 was conjugated to an oligonucleotide, the probe 
synthesis was carried out with high coupling efficiency (Scheme 4.3).  
 
 
Scheme 4.3: The synthesis of probe 175 
 
150 was conjugated to the synthetic target probe, this is an oligonucleotide probe that 
was synthesised to be complementary in sequence to that of another synthetic target 
strand. The volumes of reagents needed for one assay volume were calculated, the 
assays are always repeated in triplicate this is to confirm the results is accurate and 
also to discount for any false positives or negatives (Table 4.2). When the volumes 
for the triplicates are calculated they are calculated for both positive and negative 
assay runs. The triplicate volumes are calculated for four assay runs as the extra 
assay volume guarantees that there will be the same volume in each assay run and 
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also that each assay run will contain the correct volumes of all the reagents necessary 
for an effective assay. 
 
Table 4.2: Reaction volumes for the synthetic target assay 
Reagent 1 x rxn 
(µL) 
Positive 4 x rxn (µL) Negative 4 x rxn 
(µL) 
175   0.6 2.4 2.4 
Synth target 
DNA 
1 4 / 
MgCl2 4 16 16 
10x Atlas PCR 
buffer 
2 8 8 
T7 0.2 0.8 0.8 
H2O 12.2 46.4 52 
 
The assay was then run and following the incubation with T7, the reaction volumes 
were read on the electrodes (Table 4.3, Figure 4.3).  
 
Table 4.3: DPV analysis of 176 in the assay solution 












1 175 3.57 / / 
2 178 3.20 / / 
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Figure 4.3: Voltammogram of the DPV scan of the digest product 176 
 
One observation that can be made from Figure 4.3 is that the oxidation potential of 
149 has shifted from 242 mV vs. Ag/AgCl as the free alcohol to 175 mV vs. 
Ag/AgCl for the digest product 176 (Figure 4.4).  
 
 
Figure 4.4: Oxidation potentials of label 149 and 176 digest product 
 
First of all the development of a duplex between the current probe 172 that is 
conjugated to a Chlamydia oligonucleotide probe and a secondary label with an 
oxidation potential that is different to that of 98 and with a high degree of separation 
between the two labels oxidation potentials. The second label being added to the 
assay is initially going to be the internal control probe. The first label targeted for use 




Figure 4.5: Chosen label 99 for duplex 
 
99 was chosen as it was found to have an oxidation potential of 85 mV vs. Ag/AgCl 
which has a difference in oxidation potential of 190 mV compared to that of 98 
which has an oxidation potential of 275 mV vs. Ag/AgCl.    
 
 
Scheme 4.4: Synthesis of probe 177 
 
The phosphoramidite 105 went through the conjugation to an oligonucleotide probe, 
however the efficiency of the coupling reaction was low (Scheme 4. 4). First of all 
the probe 177 was used in the synthetic target assay to analyse the probes behaviour 
in the assay and the T7 exonuclease reaction (Assay reaction volumes Table 1. 
Appendix). The assay was run and following the incubation with T7 exonucelase the 
assay runs were read on the electrode to detect for the probe digest product 178 
(Scheme 4.5, Table 4.4, Figure 4.6). 
 
 




Table 4.5: Electrochemical results of digest product 178 












1 65 4.28 / / 
2 83 4.86 / / 
3 68 3.34 / / 











Figure 4.6: Voltammogram of the DPV scan of digest product 178 
 
After the completion of the assay it was shown from the DPV analysis that 177 
functions in the DNA detection assay. The fact that 177 functions well in the 
synthetic target assay, lead to 177 being used as the second probe in a duplex DNA 
detection assay along with 172. The volumes of the reagents required for the duplex 







Table 4.5: Reagents for duplex assay between probes 172 and 177 
Reagent Positive 4 x rxn (µL) Negative 4 x rxn (µL) 
172  2.4 2.4 
177  2.4 2.4 
Synth target DNA 4 / 
MgCl2 16 16 
10x Atlas PCR buffer 8 8 
T7 0.8 0.8 
H2O 46.4 52 
 
Once the DNA detection assay had been carried out, the assay runs were read on the 
electrodes for the detection of the probe digest products via the use of probe 177 as 
the second redox-active probe in the duplex assay was successful, however the signal 
from probe digest product 178 was found to be less intense that that of the signal for 
probe digest product 174 (Table 4.6, Figure 4.7). 
 
Table 4.7: Results of the duplex assay between 174 and 178 at the electrode 
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Figure 4.7: DPV scan of the duplex between 174 and 178 
 
Figure 4.7 shows that the peak for digest product 178 does not make it back down to 
the baseline before the peak for probe digest product 174 starts to grow in, therefore 
considerable overlap between the two signals for the digest products was observed in 
the duplex assay. The fact that there is not clear separation between the signals 
received for the probe digest products of the duplex and the lower intensity of the 
signal for probe digest product 178 could affect the sensitivity of the duplex assay 
between these two labels. The use of probe 177 as a second label for a duplex assay 
with probe 172 as the lower intensity and overlap between the two peaks could lead 
to possible false negative results of the assay for probe 177. 
 
From the result of the duplex between probes 177 and 172, it was shown that a 
duplex assay between a mono-ferrocenyl labelled probe and a di-ferrocenyl labelled 
probe was possible and successfully carried out. Therefore a triplex DNA detection 
assay was targeted between two of the mono-ferrocenyl labels presented in Chapter 2 
and the di-ferrocenyl label 98. Labels 118 and 127 were chosen as possible labels to 
be used in the synthesis of redox-active probes in a multiplex DNA detection assay. 
Labels 127 and 118 were targeted as their oxidation potentials of 114 mV vs. 
Ag/AgCl and 433 mV vs. Ag/AgCl respectively were found to be either side of the 
oxidation potential of 98 which was found to have an oxidation potential of 275 mV 





Figure 4.8: Labels and their oxidation potentials (vs. Ag/AgCl) 
 
In the multiplex DNA detection assay the three phosphoramidite labels 171, 123 and 
128 were conjugated to three different probe strands. The aim was to conjugate the 
mono-labels to an internal control strand and the other to a second target strand in 
this case a Gonorrhoea probe. However upon conjugation 123 was found to have 
poor coupling efficiency to the oligonucleotide probe, were as 128 was found to have 
a high coupling efficiency to the oligonucleotide probe (Scheme 4.6). Therefore it 
was found that a triplex assay between 98, 118 and 127 was not possible due to the 
poor coupling efficiency of 123 to the oligonucleotide. This lead to a duplex assay 
being run between probe 172 and probe 179, with the mono-ferrocenyl probe being 
the internal control probe. 
 
 




Probe 179 was first analysed in the DNA detection assay to investigate how it 
interacts within the DNA detection assay. The DNA detection assay run was the 
synthetic target assay (Assay volumes in appendix Table 2). 
 
The reaction mixtures are made up to the desired volume without the addition of T7 
in a master mix, the three positive and negative reaction mixes are then aliquoted 
into individual PCR tubes. The reaction mixture are then incubated using a PCR 
heating block to aid the hybridisation of the probe with the synthetic target DNA. 
The T7 is then added to each of the reaction tubes and the reaction mixtures are then 
incubated at 37
˚
C which is the ideal temperature for the enzyme for 20 minutes to 
allow the T7 exonuclease reaction to take place and for the double-stranded DNA to 
be cleaved one base pair at a time from the 5’end of the DNA and the digest products 
were read on the electrode (Table 4.7). 
 
Table 4.7: DPV results from the synthetic target assay detecting for probe digest product 181 
























Probe 179 was found to function well in the synthetic target DNA detection assay. 
The digest product 181 when analysed via DPV it was found to have an oxidation 
potential of 75 mV vs. Ag/AgCl. The oxidation potential of 181 was found to be 
approximately 40 mV lower than that of label 128 which has an oxidation potential 
of 114 mV vs. Ag/AgCl (Figure 4.9). The shift in oxidation potential from the digest 
product 181 and the label 128 exhibited from this assay fits with the shifts in 
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oxidation potentials exhibited by other labels under the assay conditions such as 
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Figure 4.9: Voltammogram of the DPV scan of probe digest product 181 
The shift in the oxidation potential from 128 to the digest product 181 is thought to 
be due to the nucleotide base that is still coupled to the label post T7 cleavage, which 
is having an effect on the overall oxidation potential of the digest product. From the 
results showing that the probe has a good efficiency of hybridisation and also that the 
T7 exonuclease reaction works well on the hybridised product of this DNA probe 
shown in table 4.9, a duplex was carried out been the 179 probe and the current 
probe 172 used in the assay (Table of assay volumes in appendix Table 3). After the 
incubation with T7, the reactions were run on individual electrodes. It was found that 









Table 4.8: DPV reults of duplex assay probe digest products 174 and 181 
Run  Probe Peak position 
(mV)  
Peak Height (µA) 





























Figure 4.10: Voltammogram of the DPV scan of the product digest products 174 and 181 
 
Figure 4.10 shows that the duplex between probe 181 and 174 is a viable duplex 
reaction with a greater level of separation between the two peaks than exhibited from 
the duplex between probe 177 and probe 172. However as can be seen from figure 
4.10 there is a large difference in the intensities observed for the two peaks. With the 
signal from 181 being less intense than that of the signal received from probe 174, 
this was expected as previously mono-ferrocenyl labels have been shown to be less 
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intense than di-ferrocenyl labels. Therefore probe 179 would not be suitable for the 
detection of a second target DNA as the signal intensity is so much lower than the 
signal from probe 172, this could lead to at lower concentrations of target DNA the 
loss of the signal from 181 under the start of the signal for 174. As the signal for 181 
is at a different oxidation potential to that of 174 and the signals exhibited by both 
digest products 181 and 174 are clearly separable it would be a suitable probe to be 
used as an internal control for the assay, therefore the concentration of the internal 
control target DNA would be at a constant concentration across all the assays.  
 
With the duplex between probe 179 and probe 172 being found to be successful with 
179 being used as the internal control probe in the assay and 172 being used as the 
Chlamydia probe. Therefore there was the need for a third label to be used as the 
label for the probe of another target. In the case of the multiplex DNA detection 
assay the third redox-active labelled probe is the probe for the detection of 
Gonorrhoea. 135 was chosen as the label to be used as the redox-active component 
of the Gonorrhoea probe (Figure 4.11), 135 was chosen as it has an oxidation 
potential of -80 mV vs. Ag/AgCl which is different to the oxidation potentials of 
both the other two redox-active probes going to be used in the multiplex DNA 
detection assay. 135 is another mono-ferrocenyl label, however as its oxidation 
potential is in such a unique region compared to the other two labels being used in 
the assay therefore there should not be any issue of overlap between the signal 
received for the probe labelled with 135 with the other two probes being used. 135 
has been shown to be a viable label to be used in both duplex and triplex assays at 
the free alcohol stage. 
 
 




The phosphoramidite 136 went through the conjugation to the oligonucleotide 
successfully to give probe 182 (Scheme 4.7).  
 
 
Scheme 4.7: Synthesis of probe 182 
 
Probe 182 was then taken through a triplex assay with probes 172 and 179. The 
assay volume for one reaction is then calculated followed by the scale up to four 
reactions (Table 4.9). The assay mixture is then incubated to allow the probes to 
hybridise with their target DNA present in the assay mixture.  
Table 4.9: Reagent volumes required for triplex assay between probes 172, 179 and 182 
Reagent Positive 4 x rxn (µL) Negative 4 x rxn (µL) 
172  4.5 4.5 
179  4.5 4.5 
182  4.5 4.5 
Synth target DNA 7.45 / 
MgCl2 16 16 
10x Atlas PCR buffer 8 8 
T7 0.8 0.8 
H2O 41.9 47.5 
 
The T7 was then added to the reaction mediums which are incubated at 37˚C for 20 




Figure 4.12: Digest products 174, 181 and 183 from the triplex assay 
Table 4.10: DPV results of the triplex assay digest products 174, 181 and 183 
Run Peak Position (mV vs. 
Ag/AgCl) 

























As shown from the data in table 4.10 all three of the peaks for the three probes used 
in the multiplex assay are distinguishable from each other, therefore showing that a 
commercial triplex DNA detection assay between these three probes is possible and 
can be carried out successfully. From table 4.14 it can be seen that the oxidation 
potentials from the three probe digest products have all shifted from the oxidation 
potential that the free labels were found to have. However as can be seen from figure 
4.13 there is a large difference in the sensitivities between the two mono-ferrocenyl 
probes and the di-ferrocenyl probes (Figure 4.13). The signal for 174 was expected 
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Figure 4.13: DPV scan of triplex assay of probe digest products 174, 181 and 183 at equimolar 
concentraion 
 
From the results in table 4.10 and from figure 4.13 it has been shown that the use of 
these three labels are able to be used in the detection of multiple DNA targets in a 
single commercial DNA detection assay. However the signal from the digest product 
174 was found to have a significantly higher intensity than that of the two mono-
ferrocenyl labelled probes digest products 181 and 183, when the probes were in 
equimolar concentration in the assay medium. This result was found to support the 
findings on label sensitivities presented in chapters 2 and 3. The multiplex DNA 
detection assay was therefore carried out with probe 172 being at a third of the 
concentration in comparison to that of the two mono-ferrocenyl labelled probes 
which are in equimolar concentration with respect to each other (Assay volumes in 
appendix Table 4).  
The T7 is then added to the reaction mixtures and they are incubated at 37˚C for 20 








Table 4.11: DPV results of the triplex assay of probe digest products 174, 181 and 183 with a lower 
concentration of probe 172 
Run Peak Position (mV vs. 
Ag/AgCl) 

























As can be seen from the data in table 4.16 the signals received for the digest products 
of the probes are still all distinguishable from one another, however the signal 
received for the digest product 174 was still found to be more intense than the 
signals for the other two mono-labels (Figure 4.14). The greater intensity of the 
signal for the digest product 174 could not only be due to the label containing two 
redox-active moieties but also the possibility of the digest product 174 depositing on 
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Figure 4.14: Voltammogram of the triplex assay digest products 174, 181 and 183 with probe 172 being at 
a third of the original concentration 
 
The assay was then run with the 172 being at a ninth of the concentration compared 
to the probes 179 and 182 (Assay volumes in appendix Table 5). The assay is then 
run with the T7 being added post primary incubation and the assay reaction mixtures 
were then incubated for a further 20 minutes at 37˚C, the samples are then run on the 
electrodes (Table 4.12). 
 
Table 4.12: Electrochemical results of triplex assay 

























As can be seen from the data on table 4.12 the intensities of the signals from the 
three probe digest products are almost all equal in intensity to one another, with the 
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Figure 4.15: Voltammogram of the triplex assay digest products 174, 181 and 183 with probe 172 being at 
a ninth of the original concentration 
 
Figure 4.15 shows that with probe 172 at a lower concentration there is clear 
separation between all the peaks from the probe digest products as well as all the 
peak intensities for the three probes being found to be similar in intensity to each 
other. Therefore this shows that a successful multiplex DNA detection assay has 
been carried out for the detection of two separate pathogenic DNA targets in the case 





This chapter has shown the use of the labels synthesised in chapters 2 and 3 as labels 
for redox-active probes and their use in the Atlas DNA detection assay. It has been 
shown that through the labels synthesised a successful duplex DNA detection assay 















Scheme 4.8: Schematic of the duplex DNA detection assay between probes 172 and 179 
 
As well as the DNA duplex between probes 172 and 179, it has been shown that a 
triplex DNA detection assay has been produced for the detection of two pathogens as 
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Scheme 4.9: Schematic of the multiplex DNA detection assay between probes 172, 179 and 182 
 
The multiplex detection assay developed between probes 172, 179 and 182 is now 
being utilised in the full commercial assay on the cartridges developed by Atlas 
Genetics (Figure 4.16). 
 
 






5 Chapter 5: The synthesis of 2-Oxazolines and The Ring-Opening 
Reaction for the use as an Analytical Tool for Carboxylic Acids 
 
Summary of Chapter 
 
This chapter details the synthesis of a range of functionalised oxazoline derivatives 
and their ring-opening reactions with a range of carboxylic acid derivatives. The 
direct conjugation of oxazolines and carboxylic acids has the potential application in 
the analytical detection of carboxylic acids which has been exhibited in this chapter 






Oxazolines are a class of heterocycle, they are 5-membered rings that contain two 
different heteroatoms, a nitrogen and an oxygen. Oxazolines also contain a double 
bond and there are three possible positions the double bond can be in, leading to 




Figure 5.1: The three structural isomers of oxazolines 
 
 
2-Oxazolines are of interest and importance in the area of organic chemistry due to 





as ligands in catalytic reactions,
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There are a number of synthetic routes towards the synthesis of 2-substituted 2-
oxazolines, starting from a range of simple and commercially available compounds, 







 Recently there have been a number of publications reporting the synthesis of 2-
oxazolines from aldehydes and alcohols using pyridinium hypobromide (PHPB) or 






Scheme 5.1: Conditions for the synthesis of oxazolines using PHPB-H2O 
 
The scope of the reaction tolerated a range of substituted benzaldehyde derivatives 
with ten examples, with yields ranging from 72-90%. Togo et al, published findings 
into the synthesis of 2-oxazolines starting from aldehydes as well as from 






Scheme 5.2: Togo's conditions for the synthesis of oxazolines 
 
The molecular iodine is in the reaction medium as an oxidising agent, in the case of 
the 2-oxazoline synthesis from the benzylalcohol derivatives the molecular iodine is 
thought to be involved in the generation of an aldehyde species in situ. Starting from 
benzaldehyde derivatives, with a range of functionality off the aldehyde such as 
substituted aryl rings, bicyclic derivatives and heteroaromatic derivatives are all 
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tolerated in the reaction. Eleven examples of 2-substituted 2-oxazolines were 
synthesised with yields up to 83%. The reaction system starting from the 
benzylalcohol derivatives also proved to be able to tolerate a range of functionality 
with eleven examples with yields up to 88%.  
 
The synthesis of 2-oxazolines from nitrile compounds was first reported by Witte 
and Seeliger in 1974.
135
 The reaction was carried out between the nitrile derivatives 
with an amino alcohol via the utilisation of a Lewis-acid catalyst (Scheme 5.3). The 
number of commercially available nitrile compounds makes this route for the 
synthesis of a range of 2-oxazolines via this method ideal for the synthesis of a range 
of 2-oxazoline derivatives. 
 
 




 utilised the wide range of work into the synthesis of 2-substituted-
2-oxazolines from nitriles using an automated parallel synthesiser to analyse the 
scope of the reaction. Using zinc acetate as a catalyst in chlorobenzene for the 
reaction between a range of nitrile derivatives and 2-aminoethanol, a total of 
eighteen 2-substituted-2-oxazolines were synthesised. A wide range of functionality 
from allyl to aromatic derivatives with yields for the synthesis of 2-oxazolines from 
3-100% (Scheme 5.4). 
 
 





5.2 Ring-opening reactions of 2-oxazolines 
 
The ring-opening of 2-oxazolines has been well documented and found to have a 
wide range of functions. For example, they have been used in polymerisation 
reactions as well as in the synthesis of novel amino acid derivatives. Tishler et al,
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utilised this reaction of oxazolines to synthesise DL-threonine from 2-phenyl-5-
methyl-4-carbomethoxy-2-oxazoline 184 (Scheme 5.5). This hydrolysis reaction 
afforded the amino acid 185 in a 70% yield.  
 
 
Scheme 5.5: Synthesis of DL-threonine from ring-opening reaction 
 
When 2-phenyl-5-methyl-4-carbomethoxy-2-oxazoline underwent alkaline 
hydrolysis the DL-threonine was only afforded in a 20% yield. The position where a 
2-substituted-2-oxazoline ring opens depends on which reagent is used and under 
what conditions the reactions are carried out. When 2-phenyl-2-oxazoline 186 is 
reacted with p-nitrobenzoyl chloride 187 it yields the compound N-(2-chloroethyl)-
N-p-nitrobenzoyl benzamide 188 (Scheme 5.6).  
 
 
Scheme 5.6: 2-phenyl-2-oxazoline 186 ring-opening with p-nitrobenzoyl chloride 187 
 
However when 2-phenyl-2-oxazoline 186 is reacted with p-nitrobenzoic acid 189 at 







Scheme 5.7: 2-phenyl-2-oxazoline 186 ring-opening with p-nitrobenzoic acid 189 
 
One of the main applications of 2-oxazoline ring-opening reactions is in the 
formation of polymers or as a functional handle on the side chain of polymers. When 
a bis-oxazoline ring containing compound, that are joined together at the 2-position 
by allyl, aromatic or hetrocyclic groups reacts with a dicarboxylic acid it is known to 






Scheme 5.8: Example of bis-oxazoline ring-opening polymerisation 
 
Oxazolines with an unsubstituted backbone can undergo polymerisation in the 
presence of a cationic catalyst. Seeliger et al, showed that 2-propyl-2-oxazoline 
heated to 120-130˚C for 15 hours in the presence of p-nitrobenzene-diazonium 
fluoroborate, yields a hard thermoplastic.
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CROP that uses cationic catalyst or 
initiators for the ring-opening polymerisation of 2-oxazolines give poly(N-










The mechanism of CROP is shown in scheme 5.10. An oxazoline is first of all 
activated using a cationic initiator to form the oxazolinium ion which then reacts 
with a second oxazoline through a nucleophilic addition from the nitrogen of the 
second oxazoline (Scheme 5.10). 
 
 
Scheme 5.10: Mechanistic route for CROP polymerisation of 2-oxazolines 
 
Schubert et al, reported the synthesis of polymers with large unsaturated fatty acid 
side chain, via CROP polymerisation of 2-oxazoline synthesised from soy bean fatty 
acid (Figure 5.2). 
 
 
Figure 5.2: 2-Oxazoline monomer for CROP polymerisation, synthesised from soy bean carboxylic acid 
 
The CROP polymerisation was initiated by methyl tosylate under micro-wave 
assisted conditions. The polymers with fatty acid side chains are sort after for the use 
in the synthesis of a wide range of applications, such as in the synthesis of rubbers 




 reported the ring-opening of oxazoline side chains on an oxazoline-
methyl methacrylate copolymers. The copolymers were synthesised from 2-
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isopropenyl-2-oxazoline 191 with methyl methacrylate 192 in acetonitrile via a 




Scheme 5.11: Block co-polymerisation of 2-isopropenyl-2-oxazoline and methyl methacrylate 
 
This led to the synthesis of copolymer 193 with alternating oxazoline and ester side 
chains. The polymer was then reacted with 194 under relatively harsh conditions, in 
DMF at 160˚C the oxazoline is ring opened to yield a side chain containing an amide 
and ester linking moieties (Scheme 5.12).  
 
 
Scheme 5.12: Functionalisation of oxazoline side-chain via carboxylic acid ring-opening 
 
 
The ring-opened polymer products were found to have a decreased thermal stability 
compared to the oxazoline containing copolymer. The azobenzene containing 
polymers were analysed by fluorescence spectroscopy. Another application for the 
ring-opening reaction of 2-oxazolines is in the synthesis of novel amino acids and 
amide compounds. Vargas et al, published work into the synthesis of selenium or 
sulphur containing chiral β-chalcogen amides from the indium catalysed ring-
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opening reaction of 2-oxazolines (Scheme 5.13).
147
Selenium and organoselenium 
derivatives are of interest as they have been found to possess anti-tumor, antioxidant 
and antiviral properties. 
 
 
Scheme 5.13: General scheme for indium catalysed synthesis of chiral β-chalcogen amide 
 
A reaction optimisation was carried out to analyse the effect of the catalyst loading, 
temperature, solvent and loading of organoyl halide moiety on the ring-opening 
reaction. It was found that when the indium source was used in less than one 
equivalent of the catalyst the reaction either dropped in yield or the product was not 
obtained at all. With the optimised conditions in hand the scope of the reaction was 
investigated with a range of 2-oxazolines and organoselenium derivatives. The 
reaction conditions were found to tolerate a wide range of both derivatives with ten 
examples, with the yields ranging from 44-98%. 
 
Yoon et al, described the synthesis of all four diastereomers of 3-mercaptoaspartic 
acid via both the hydrolytic ring-opening reaction as well as the nucleophilic ring-
opening reaction of oxazoline-4,5-dicarboxylate. In the case of the nucleophilic ring-
opening thioacetic acid was used as the nucleophile.
148
 β-substituted aspartates are of 
synthetic interest due to numerous derivatives being incorporated in natural and 
synthetic biologically active compounds. By using both the hydrolytic ring-opening 
and the nucleophilic ring-opening reactions of oxazolines means that more control 
on the stereochemistry of the products can be included. When the oxazoline is ring-
opened via the hydrolytic method using an aqueous acid source there is no change in 
the configuration at the C-5 position of the oxazoline.
149
 However when the 
nucleophilic ring-opening is carried out there is inversion seen at the C-5 carbon in 







Figure 5.3: Products from the two different ring-opening reactions 
 
Starting from L-aspartic acid 196 they get through to the key intermediate for the 
synthesis of the four diastereomers trans-(4S, 5S)-oxazoline-4,5-dicarboxylate 197 
as the only product. The oxazoline then undergoes either a nucleophilic ring-opening 
reaction to afford the first diastereomer L-erythro-(2R, 3R)-3-mercaptoaspartic acid 
199 in a 68% yield. 197 can also undergo the hydrolytic ring-opening reaction with a 
mild acid, the product is then converted to the cis-(4S, 5R)-oxazoline-4,5-
dicarboxylate 200. 200 undergoes nucleophilic ring-opening to afford the second 




Scheme 5.14: Synthetic route to the two L-diastereoisomers of 3-mercaptoaspartic acid derivatives 
 
It was shown that the D-configuration could be synthesised via the same method as 
for the preparation of the two L-diastereomers by starting from D-aspartic acid, 
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however the remaining two diastereomers could also be synthesised via further 
manipulation of 197 via a base-induced epimerization of the C-4 position on the 
oxazoline which yielded the more stable trans derivative 202. 202 could then 
undergo the same two pathways as the first key intermediate 197 and allow the 
synthesis of the two D-diastereomers 204 and 205 (Scheme 5.15). 
 
 
Scheme 5.15: Synthetic route to the D-diastereoisomers of 3-mercaptoaspartic acid derivtatives 
 
Juge et al, reported a new method for the preparation of N,(N)-protected β-halogeno 
α-aminoesters via an electrophilic ring-opening of oxazolines using a chloroformate 





Scheme 5.16: General reaction conditions for 2-oxazoline ring-opening 
 
The oxazolines were synthesised by a previously published condensation method 
between amino esters and an iminoether hydrochloride (Scheme 5.17).
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 The scope 
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of the reaction with chloroformates proved to tolerate a range of different 
functionality on the chloroformate affording the ring opening product in 48-89% 
yields over nine examples. With four examples of the electrophilic ring-opening 




Scheme 5.17: Synthesis of 2-oxazolines from iminoether hydrochloride 
 
 
5.3 Aims and Objectives 
 
As presented in previous chapters an interest in bioconjugation has been exhibited 
through the synthesis of redox-active phosphoramidite derivatives and their 
conjugation to oligonucleotides. The aim of the research presented in this chapter is 
to utilise the direct conjugation of 2-oxazolines with carboxylic acids in the 
analytical detection carboxylic acids of interest, such as amino acids and drug 
compounds. The aim is to synthesise a range of oxazolines that have been derivatised 
with analytical reporter moieties for the analytical detection of carboxylic acids, such 
as: electrochemical, fluorescent and fluorine markers.                                                             
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5.4 Results and Discussion 
 
Phenyloxazoline was chosen as a simple starting material to investigate the scope of 
the ring opening reaction with N-boc amino acids being chosen as the carboxylic 
acid derivatives. The reactions were carried out in acetonitrile at 80ᵒC and with no 
further additives (Table 5.1).  
 
 
Scheme 5.18: General synthetic route to ring-opened products 
Table 5.1: Yields from the ring-opening reactions of 2-phenyl-2-oxazoline 
Product  Amino acid Yield 
206 Boc-Phe-OH 72 
207 Boc-Ala-OH 89 
208 Boc-Val-OH 65 
209 Boc-Pro-OH 69 
 
As shown in Scheme 5.18 the product formed via this ring opening reaction is the 
ester amide derivative. This is supported by the presence of an additional NH signal 
in the 
1
H NMR spectrum. The yields exhibited for this reaction are good (Table 5.1). 
The reaction between Boc-valine and phenyloxazoline was used to explore the effect 
of various reaction parameters. First of all, the amount of Boc-valine was increased 
to two and three equivalents, to analyse the effect of the amount of carboxylic acid 












The results presented in Table 5.2 show that there is an increase in the yield as the 
equivalents of carboxylic acid moiety are increased within the reaction. When the 
reaction is carried out with three equivalents of Boc-valine the reaction goes to 
completion. This is a promising result, however if this reaction is going to be 
suitable for use in a bioconjugation capability the limiting reagent in the reaction 
would be the target, in this reaction that would be the presence of the carboxylic acid 
derivative. Therefore the reaction was tested with the number of equivalents of 
oxazoline present in the reaction mixture being varied while the equivalents of the 
carboxylic acid derivative, Boc-valine being kept constant. It was found that with 
increasing the equivalents of the oxazoline moiety had the same effect on the yield of 
the reaction and at three equivalents the reaction had gone to completion (Table 5.3).  
 








Taking the two equivalents of oxazoline as the conditions for further optimisation, 
the next aspect of the reaction to be studied was the effect temperature has on the 
reaction. As the reaction is currently being carried out at 80˚C, close to the boiling 
point of MeCN. This temperature is also an unfavourable temperature for use in 
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bioconjugation. Therefore the conversion of the reaction at lower temperatures was 
investigated (Table 5.4). 
 
Table 5.4: Yields of 208 at different temperature 
Temperature (˚C) Yield (%) 




As can be seen from the results posted in Table 5.4 the reaction does take place at 
room temperature, an ideal temperature for conjugation is between room temperature 
and 40˚C as this is the optimum temperature range for the biological component. 
However the reaction progressed at a slow rate, with only 20% conversion after 96 
hours. The conversion of the reaction at 50˚C was moderate so optimisation was 
continued. The effects of solvent on the reaction was next investigated using the 
conditions of two equivalents of phenyloxazoline at 50˚C. These conditions were 
chosen as the conversion at this temperature in MeCN is at 40% and therefore any 
effect on the reaction from solvents will be easy to monitor. A range of non-polar 
and polar solvents, both protic and aprotic solvents were chosen (Table 5.5). 
 
Table 5.5: Results from the solvent screen 




Iso-butyl alcohol 39 
Propionitrile 39 






a=reaction carried out at 80˚C 
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As can be seen from the results in the Table 5.5 polar aprotic solvents were shown to 
give the best results, however with MeCN still giving the highest yield at 40%. From 
this result it was decided that MeCN would still be used as the solvent of choice for 
the examination of the effect of additives in the reaction medium. A range of Lewis 
acid and nucleophilic catalysts, at a 5 mol% loading were tested in the reaction to see 
if the addition of a catalyst would increase the yield of the reaction (Table 5.6). 
 
Table 5.6: Yields from 5 mol% loading 
Additive (5 mol%) Yield (%) 
Phenylboronic acid 45 




The addition of a Lewis acid or nucleophilic catalyst failed to give an increase in 
yield compared to the reaction carried out with no additive at a 5 mol% loading, the 
reactions were repeated at a 20 mol% loading to check it was not the loading being 
too low to have an effect in this case (Table 5.7). 
 
Table 5.7: Yields from 20 mol% loading 
Additive (20 mol%) Yield (%) 





With the loading being at 20 mol% there is still only a minimal effect on the overall 
yield of the reaction, which could be in the range of experimental error. Therefore it 
was decided to take through the conditions of the oxazoline being at two equivalents 
and at 80˚C in MeCN without the use of any additives.  
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The scope of the reaction was then tested under the optimised conditions with a 
range of carboxylic acid derivatives (Scheme 5.19, Table 5.8). The ring-opening 
reaction of phenyl-oxazoline was found to tolerate a wide range of functionalised 
carboxylic acid derivatives in good yield. 
 
 
Scheme 5.19:Synthetic route to ring-open products 206-211 
Table 5.8: Scope of the ring-opening reaction with 2-phenyl-2-oxazoline 
No. Carboxylic acid  Yield (%) 
206 Boc-phenylalanine  92 
207 Boc-alanine  93 
208 Boc-valine 89 
209 Boc-proline 74 
210 Sarcosine 95 
211 3-bromopropionic acid 92 
 
Next, a range of oxazolines were synthesised with different transducer elements such 
as fluorescent or electrochemical groups. Ferrocene-2-oxazoline 212 was the first 
target, which could be achieved by reacting ferrocenecarboxylic acid with ethanol 
amine via the in situ generation of the acid chloride with oxalyl chloride to yield the 
amide 213 (Scheme 5.20). 
  
 




The free hydroxyl group is then mesylated and under basic conditions the ring 




Scheme 5.21: Synthesis of ferrocene-2-oxazoline 
 









Figure 5.4: Voltammogram of the DPV scan of 212 
 
212 was analysed via differential pulse voltammetry under the standard conditions 
shown in the experimental section, to analyse its oxidation potential. 212 was found 
to have an oxidation potential of 360 mV vs. Ag/AgCl (Figure 5.4, under the same 
conditions as used in the DNA label work). The scope of the reaction using 
ferroceneoxazoline was examined under the standard conditions with a range of 










Scheme 5.22: Synthetic route to ring-open products 214-219 
Table 5.9: Scope of ferrocene-2-oxazoline ring-opening reaction 
No. Carboxylic acid Yield (%) 
214 Boc-valine 76 
215 Boc-phenylalanine 79 
216 Boc-alanine 76 
217 3,5-bis(trifluoromethyl)benzoic acid 88 
218 Sarcosine 82 
219 3-bromopropionic acid 93 
 
It was found that the oxazoline ring opening reaction worked to a good to high yield 
with a range of carboxylic acids including amino acids, aromatic and simple alkyl 
carboxylic acids. To analyse the viability of the use of 212 in this reaction as a 
possible electrochemical analytical reporter for the use in the detection of carboxylic 
acids the oxidation potential of the boc-valine derivative was analysed to calculate 
the oxidation potential of compound 214, which was found to be 430 mV vs. 















Figure 5.5: Voltammogram of the DPV scan of 214 
 
 For this system to be viable for the use in analytical detection of carboxylic acid 
derivatives there must be a distinguishable difference between the 
ferroceneoxazoline 212 and the ring opened product 214. As can be seen from Table 
5.11 there is an approximate shift of 70 mV between the ring opened product and the 
parent oxazoline derivative. 
 
Table 5.11: Oxidation potential of ferrocene-2-oxazoline and the ring-opened product 
No. Oxidation potential 





Work carried out by Togo et al,
139
 into the synthesis of 2-oxazoline derivatives 
starting from aldehydes and aminoethanol, was utilised to synthesise a range of 
oxazolines starting from the parent aldehydes. Anthracenecarboxaldehyde and 
naphthalenecarboxaldehyde were used to prepare two fluorescent oxazolines for the 
use as potential fluorescent detection method. p-Bromophenyl-2-oxazoline was also 




Scheme 2.23: Synthesis of 2-oxazolines from aldehydes 
Table 5.12: 2-oxazolines synthesised from aromatic aldehydes 





These oxazoline derivatives went through the ring opening reaction under the 




Scheme 5.24: Route to ring-opened products 
Table 5.13: Yields from ring-opening reactions 
R R’ Product Yield (%) 
 
Boc-valine 223 79 
 
Boc-valine 224 73 
 
Boc-phenylalanine 225 78 
 
Boc-valine 226 70 
 
The p-bromophenyloxazoline can be used in further reactions to install functionality 
onto the aromatic ring, such as transition metal catalyst cross coupling reactions. One 
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method for functionalising the oxazoline is via a Suzuki cross-coupling reaction with 
a boronic acid. The p-bromophenyloxazoline was taken through a Suzuki cross-
coupling with a boronic acid with the functionality for the use as an analytical 
reporter moiety, in this case 3,5-bis(trifluoromethyl)phenylboronic acid was chosen 
for the use of the 
19
F NMR as the analytical detection technique (Scheme 5.25). 
 
 
Scheme 5.25: Functionalisation of p-bromophenyl oxazoline via suzuki cross-coupling reaction 
3,5-Bis(trifluoromethyl)benzoic acid was chosen as a possible starting material for 
the synthesis of an oxazoline derivative with the fluorine functionality in closer 
proximity to the oxazoline ring. Starting from 3,5-bis(trifluoromethyl)benzoic acid 
the amide derivative was synthesised using ethanolamine, via the generation of the 
acid chloride in situ using oxalyl chloride (Scheme 5.26). 
 
 
Scheme 5.26: Synthesis of N-(2-hydroxyethyl)-3,5-bis(trifluoromethyl)benzamide 
 
231 was then converted to the oxazoline via the generation of the mesylate of the 
free hydroxyl group using methane sulfonyl chloride, which was then cyclised under 






Scheme 5.27: Synthesis of 2-(3,5-bis(trifluoromethyl)phenyl)-2-oxazoline 
 
 
232 was then taken through the optimised ring-opening reaction (Scheme 5.28), it 
afforded the 234 in a good yields. In comparison to 232, 228 was also taken through 
the ring-opening reaction and afforded 233 in a good yield.  
 
 
Scheme 5.28: Ring-opening of 228 and 232 
 
These two functionalised oxazolines were compared to assess which one would be 
suitable for use as an analytical reporter moiety for the analytical detection of 
carboxylic acids, for them to be suitable there would have to be a shift exhibited in 






Table 5.14: Fluorine NMR signals for oxazoline and their ring-opened counterpart  
Oxazoline Ring-opened Δ 19F 
228 233 0.1 
-62.71 -62.80 
232 234 1.3 
-61.94 -63.24 
 
Table 5.14 shows that there is not a shift in the fluorine NMR for the ring-opening of 
228, however there is a shift of approximately 1.3 ppm between 232 and 234. 
Therefore 232 would be a valid analytical reporter for the detection of carboxylic 
acids. 
The 3,5-bis(trifluoromethyl)phenyl oxazoline was taken through the ring opening 
reaction with a range of carboxylic acid derivatives (Scheme 5.29, Table 5.15), 
carboxylic acid derivatives ranging from amino acids, alkyl derivatives and aromatic 
carboxylic acids.  
 
 
Scheme 5.29: Ring-opening of 232 
Table 5.15: Scope of 2-(3,5-bis(trifluoromethyl)phenyl)-2-oxazoline ring-opening reaction 
No. R Yield (%) 
235 Boc-valine 88 
236 Boc-phenylalanine 91 
237 Sarcosine 89 
238 3-bromopropionic acid 79 
239 p-bromobenzoic acid 83 





As the table shows the ring opening reaction with the oxazoline derivative proceeded 
in very good yields across the scope of carboxylic acid derivatives used.  
 
A number of drugs contain carboxylic acid functionality, the carboxylic acid groups 
in drugs are involved in specific charge-charge interaction and are often critical for 
the binding to the targets. Using the optimised conditions for the ring-opening 
reaction of oxazoline derivatives, the capability of the reaction to work under slightly 
more challenging conditions to detect the presence of the carboxylic acid derivative 
was investigated. Ibuprofen was chosen as the target due to its wide spread use and 
availability as an over the counter pain-relief medication (Figure 5.6). 
  
 
Figure 5.6: Ibuprofen 
 
The reaction was carried out using ibuprofen tablets purchased over the counter from 
a supermarket. The tablets were then ground up and it was in this form that the 
ibuprofen tablet was used in the reaction. The direct formation of amides from 
carboxylic acid moieties of drugs in solution could be used to aid the analytical 
detection of drugs such as ibuprofen via techniques such as mass spectroscopy and 









The reaction proved to be highly efficient and high yielding. Interestingly, there was 
little interference in the reaction from any of the other compounds that make up the 
ibuprofen tablet such as sugars. The lack of interference on the reaction from the 
other components of the ibuprofen tablet, it is an important result in the analysis of 
this reaction as a conjugation tool of carboxylic acids for analytical detection. 
Functionalised 2-oxaxolines were then used in the reaction, the ferroceneoxazoline 
and the 3,5-bis(trifluoromethyl)phenyloxazoline were chosen as two possible 
analytical reporters for this reaction (Scheme 5.31).  
 
 
Scheme 5.31: Ring-opening reaction with Ibuprofen and sensing 2-oxazolines 
 
Both the functionalised 2-oxazolines work to a good yield in the ring-opening 
conjugation reaction with ibuprofen. 212 allows the use of electrochemical detection 
methods in the analytical detection of ibuprofen. As stated previously the oxidation 
potential of 212 is 360 mV vs. Ag/AgCl, therefore using the shift in oxidation 
potential from the oxazoline 212 to the ring-opened form 242 allows for the 
analytical detection of the presence of ibuprofen in the solution. 242 was analysed 

















Figure: 5.3: DVP voltammogram of 242 
 
 The same principle would apply for 232 as an analytical reporter for the detection of 
carboxylic acids via 
19
F NMR or mass spec.  
 




This chapter has shown the synthesis of a range of 2-oxazolines with various 
functionality aimed towards conjugation with the goal of analytical detection of 
carboxylic acids, such as electrochemical, fluorescent and a fluoride marker. The 
ring-opening reaction was found to tolerate a wide range of carboxylic acid 
derivatives. The electrochemical analytical detection capability was analysed 
through the difference in the oxidation potential between ferrocene-2-oxazoline and 
the ring-opened form, which was found to have a 70 mV shift in oxidation potential. 
This reaction was analysed under more challenging conditions for the detection of 




6 Future Work  
 
The future work related to this project will be to further investigate the effects of 
substituting the ferrocene core of the redox-active labels with a wider range of 
functional groups as well as the use of different elements present in the functional 
groups such as sulfur and phosphorus. This will lead to the expansion of the range of 
labels that are currently available for the DNA detection assay as well as looking to 
increase the range of oxidation potentials available. This will allow for the 
development of a DNA detection assay capable of involving a larger number of 
labels than the triplex assay that was shown to be viable through the work carried out 
within this thesis. The ability to develop a DNA detection assay with a larger number 
of probes opens up the ability of the point of care device being developed by Atlas 
genetics to detect for a wider range of bacterial pathogens through one DNA 
detection assay.  
 
However, in the immediate future the development of the mono-ferrocenyl labels 
currently being used in the triplex assay discussed in chapter 4, 127 and 135, into di-
ferrocenyl labels to match the third label 98 being used in the triplex assay. The 
importance of developing the current mono-ferrocenyl labels into di-ferrocenyl 
labels is to overcome the sensitivity issues that have been shown throughout the 
work presented in this thesis. This would lead to a triplex assay with a greater 
sensitivity than the current triplex being carried out in the DNA detection assay.  
 
The future of DNA sensing could be seen to be developing into two different 
pathways; the first being the detection of infectious diseases and the second being in 
the sequencing for the detection of mutations as well as inherited genetic diseases 
such as Huntington’s disease through technologies such as nanopores. The first 
pathway could be said to be caused by the rise in the requirement for the rapid, 
accurate and highly sensitive detection of infectious diseases such as sexually 
transmitted diseases. The rise has been driven by the attempt to cut down patient 
waiting times between being tested and receiving the results for the test with the aim 
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to increase the rapid treating and therefore reduce the infection rate of the disease.  
This is needed in both the developed and the developing world, which could see a 
rise in the development of smaller self-contained point of care devices for use at the 
patient interface. For example, the point of care device being developed by Atlas 
genetics which is currently designed to be used in GP’s offices could be transformed 







7.1 General Considerations 
 
Commercially available solvent and reagents were obtained from Sigma-Aldrich and 
Fisher Scientific Ltd and were used without any further purification. Deoxygenation 
of solvents and reagents when necessary were carried out by purging with nitrogen. 
The term Petrol refers to the fraction of petroleum ether that boils in the range of 40-
60ᵒC. Reactions carried out using anhydrous conditions used HPLC – grade solvent 
that was passed through an Innovative Technology Pure – Solv Solvent purification 
system (SPS).  
Thin layer chromatography (TLC) was performed using commercially available 
aluminium backed plates coated with Merck kieselgel 60 0.20mm (ALUGRAM® sl 
G/UV254) and visualised under UV or by staining. Melting points were calculated 
using a Büchi 535 melting point apparatus and are uncorrected. Mass spectra were 
obtained using the mass spectrometry service at the University of Bath, on a Bruker 
MicroTOF machine. Voltagrams were run on µAUTOLAB, type II using GPES 
manager. 
Chemical shifts (δ) are expressed in parts per million (ppm) and referenced to the 
internal SiMe4 for 
1
H-NMR and refenced to the relative solvent for 
13
C-NMR. NMR 
spectra were recoreded on Brucker AV 250, AV 300, AV 400 or AV 500 
spectrometers at 298K unless otherwise stated. Multiplicities of spectroscopic data 
are presented in the following manner: singlet (s), broad singlet (br.s), doublet (d), 
doublet of doublets (dd), triplet (t), quartet (q) and multiplet (m). The coupling 





7.2 General electrochemical procedure 
 
Preparation of buffer solution 
The buffer solution used for the electrochemical analysis of the ferrocene derivatives 
synthesised in this thesis was the same buffer solution as was used for the Atlas 
DNA detection assay, which is the Atlas 10x PCR buffer solution developed by 
Atlas genetics.  
Preparation: 
Tris(hydroxymethyl)aminomethane base (3.70 g) was dissolved in deionised water 
(500 mL) and Tris(hydroxymethyl)aminomethane HCl (3.07 g) was added and once 
dissolved the pH was checked to be 8.3. Potassium chloride (18.38 g) was then 
added and the solution was stirred until fully dissolved the final pH was checked to 
be 8.55. 
Standard solutions and dilutions 
General electrochemical solution: 
Ferrocene (free alcohol) derivatives (5 mg) are dissolved in DMSO (1 mL), of which 
25 µL is diluted with Atlas 10x PCR buffer (600 µL).   
General electrochemical procedure and conditions: 
General electrochemical solution (10-20 µL) was applied to a screen printed 
electrode and a scan is taken. Procedure repeated three times on separate electrodes.   
 




Purge time (s): 0 Modulation time (s): 0.05 Initial potential (V): -0.1 
Conditioning Potential 
(V): 0 
Interval time (s): 0.1 End potential (V): 0.7 
Duration (s): 0  Step potential (V): 0.003 
Depostion potential (V): 0  Modulation amplitude 
(V): 0.04995 
Duration (s): 0  Standby potential (V): 
0.05 
Equilibration time (s): 0   
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7.3 Synthesis of mono-ferrocenyl redox active labels 
 
Ethyl-3-ferrocenyl acrylate 101 
 
 
Triethylphosphonoacetate (0.86 mL, 4.22 mmol) was dissolved in dry THF (25 mL), 
to this solution n-butyl lithium (1.6M in THF, 1.69 mL, 4.22 mmol) was added 
dropwise via a pressure equalising dropping funnel and the reaction mixture was 
stirred at 0˚C under nitrogen for two minutes. The reaction is then warmed up to 
room temperature and stirred for 30 mins. Ferrocenecarboxaldehyde (0.78 g, 3.52 
mmol) in dry THF (10 mL) was added via a dropping funnel to the solution. The 
reaction was then stirred for another 15mins. The solvent was then removed in 
vacuo. The residue was taken up in diethyl ether (30 mL) and water (30 mL). The 
organic layer was separated and the aqueous fraction was then extracted with diethyl 
ether (30 mL). The organic fractions were combined dried over MgSO4, the solvent 
was removed and the crude product was purified via column chromatography (9:1, 
hexanes:ethyl acetate) to yield the product as a waxy red solid (1.4 g, 75%). 
1
H 
NMR (300 MHz; CDCl3) δ 7.49 (1H, d, J =  15.5, CH), 6.31 (1H, d, J =  15.5, CH), 
4.21 (2H, q, J =  6.25, CH2) 4.13 (2H, s, FcH) 4.02 (7H, s, FcH) 1.38 (3H, t, J =  
5.0, CH3) 
13
C NMR (75.5 MHz; CDCl3) δ 167.2, 145.6, 114.9, 77.5, 77.0, 76.6, 










Ethyl-3-ferrocenyl acrylate (0.5 g, 1.76 mmol) was dissolved in absolute ethanol (20 
mL) and 10% of palladium on activated carbon (0.19 g, 0.18 mmol) was added to the 
solution. Hydrogen gas is bubbled through the solution for 5 minutes, then the 
reaction is left to stir under a hydrogen (1 atm) for 2.5hrs. The reaction is then 
filtered through Celite 521. The solvent was then removed in vacuo to yield the 




H NMR (300 
MHz; CDCl3) δ 4.20 (2H, q, J =  7.0, CH2) 4.09 (2H, s, FcH) 4.02 (7H, s, FcH) 2.93-
2.87 (2H, m, CH2) 2.54-2.49 (2H, m, CH2) 1.37 (3H, t, J =  7.0, CH3). 
13
C NMR 










Ethyl-3-ferrocenyl propanoate (0.2 g, 0.69 mmol) was dissolved in ethanol (25 mL) 
and sodium hydroxide (0.16 g, 4.0 mmol). The solution was then heated to 50 ˚C and 
stirred for 18 hours. Acetic acid was then added until the solution reached a pH of 
6.5. The product was extracted in CH2Cl2 (2 × 25 mL). The organic fraction was 
washed with brine (3 × 20 mL) and water (3 × 20 mL). The organic layer was dried 
over MgSO4 and the solvent evaporated to afford the crude product, which was 
purified via column chromatography (7:3, hexanes : ethyl acetate) to yield the 
product as a dark yellow solid (1.36 g, 65%). 
1
H NMR (300 MHz; CDCl3) δ 4.09 
(2H, s, FcH) 4.02 (7H, s, FcH) 2.70 (2H, s, CH2) 2.51 (2H, s, CH2). 
13
C NMR (75.5 
MHz; CDCl3) δ 170.2, 77.5, 77.0, 76.6, 70.9, 69.8, 24.1, HRMS (ESI) calcd for 










Oxalyl chloride (0.87 mL, 10.36 mmol) in dry CH2Cl2 (2 mL) was added dropwise 
via a pressure equalising dropping funnel to a stirred solution of 3-
ferrocenylpropanoic acid (1.2 g, 4.78 mmol) in dry CH2Cl2 (100 mL) at 0 ˚C under 
N2. The reaction was warmed to room temperature and stirred for 2 hrs. Then the 
solvent was removed en vacuo and the acid chloride product was taken up in dry 
CH2Cl2 (75 mL) and cooled to 0 ˚C. 6 – amino hexan – 1 – ol (0.56 g, 4.78 mmol) in 
dry CH2Cl2 (75 mL) was added dropwise via a dropping funnel under N2. The 
reaction was then stirred for 2 hrs while warming to room temperature. The solution 
was then washed with NaHCO3 (sat.) (100 mL) and 1M HCl (aq.) (100 mL). The 
organic fractions were dried over MgSO4 and the solvent was removed to yield the 
crude product, which was purified via column chromatography (7:3, hexanes : ethyl 
acetate) to yield the product as a yellow solid (1.68 g, 80%). IR (cm
-1
): 3259, 3101, 
2972, 2934, 2204, 2049, 1729, 1654, 1576, 1425 
1
H NMR (300 MHz; CDCl3) δ 4.12 
(2H, s, FcH), 4.09 (7H, s, FcH), 3.60 (1H, s, OH), 3.52 (2H, t, J =  4.0, CH2), 3.00 
(2H, s, CH2), 2.85 (2H, s, CH2), 2.30 (2H, s, CH2), 1.56–1.25 (8H, m, CH2). 
13
C 
NMR (75.5 MHz; CDCl3) δ 173.3, 77.8, 77.4, 76.9, 62.0, 38.85, 35.4, 32.0, 30.6, 
26.7, 26.3, 25.4, 25.4. HRMS (ESI) calcd for C19H27N1O2Fe1 m/z: 357.1321 found 









Lithium aluminium hydride (0.15 g, 0.15 mL, 3.87 mmol) was dissolved in ether (40 
mL) in a two necked round bottomed flask. 3-ferrocenylpropanoic acid (0.5 g, 1.94 
mmol) in ether (10 mL) was added dropwise and the solution was stirred at 0˚C for 
10mins. The solution was then refluxed for 2 hours, the reaction mixture was then 
quenched with water (10 mL) then NaOH 20% solution (15 mL). Water (12 mL) was 
then added and the ether layer was decanted and the solvent was removed to afford 
the product as an orange oil (0.44 g, 88%).  
1
HNMR (300 MHz; CDCl3)  4.19 (9H, 
s, FcH), 4.65 (2H, t, J =  6.0, CH2), 2.55 (2H, d, J =  5.0, CH2), 1.70 (2H, t, J =  5.5, 
CH2). 
13
C NMR (75.5 MHz; CDCl3) δ 77.8, 77.6, 77.4, 76.9, 63.4, 38.5, 29.4. 










A solution of ferrocenecarboxaldehyde (0.5 g, 2.31 mmol) in EtOH : dioxane (50 
mL, 4:1) was added NaBH4 (0.25 g, 6.76 mmol) in a round bottomed flask. The 
solution was stirred for 1 hour. Water was then added and the product extracted with 
ether (30 mL). The organics were washed with water (2 × 25 mL) and the organic 
layer was dried over MgSO4. The solvent was removed in vacuo to afford the 
product as a yellow solid without any further purification (0.5 g, 99%). 
1
H NMR 
(300 MHz; CDCl3) δ 4.34 (2H, s, CH2), 4.28 (2H, s, FcH), 4.13 (7H, s, FcH), 3.60 
(1H, s, OH). 
13














Ferrocene methanol (0.4 g, 1.85 mmol) was dissolved in ether (30 mL) and cooled to 
0˚C in an ice bath, phosphorous tribromide (0.74 g, 0.3 mL, 2.77 mmol) was then 
added dropwise to the reaction mixture once addition was complete the solution was 
allowed to warm up to room temperature and stirred for 14 hrs. The reaction mixture 
was then re-cooled to 0˚C in an ice bath and the reaction was quenched with water 
(20 mL). The product was then extracted into ether (20 mL) and dried over MgSO4 
and the solvent evaporated to afford the product as a dark red oil (0.39 g, 99%). IR 
(cm
-1
): 3009, 2204, 2049, 1729, 1634, 1576, 1435 
1
H NMR (300 MHz; CDCl3) δ 
4.59 (2H, s, CH2) 4.34 (2H, s, FcH), 4.28 (2H, s, FcH), 4.13 (5H, s, FcH). 
13
C NMR 
(75.5 MHz; CDCl3) δ 77.8, 77.4, 76.9, 69.7, 40.3. HRMS (ESI) calcd for 









Sodium hydride (0.11 g, 4.62 mmol) was added to a solution of ferrocene methanol 
(0.5 g, 2.31 mmol) in THF (20 mL) and allowed to stir for 2hrs in an ice bath. To 
this suspension was added 3-bromopropanoic acid (0.4 g, 2.31 mmol), the reaction 
was stirred at room temperature for 2 hrs. Water (20 mL) was then added and the 
product was extracted with ether (20 mL). The organic fraction was dried over 
MgSO4 and the solvent was removed to yield the crude product as a yellow solid. 
The product was purified via column chromatography (6:4, hexanes : ethyl acetate) 
to afford the title compound as a yellow oil (0.4 g, 50%). IR (cm
-1
): 3101, 2972, 
2934, 2204, 2049, 1729, 1634, 1566, 1435. 
1
H NMR (300 MHz; CDCl3) δ 4.86 (2H, 
s, CH2) 4.82 (2H, s, FcH), 4.57 (2H, s, FcH), 4.28 (5H, s, FcH), 3.76 (2H, t, J =  6.5, 
CH2), 3.33 (2H, t, J =  6.5, CH2). 
13
C NMR (75.5 MHz; CDCl3) δ 173.6, 77.6, 77.1, 










Lithium aluminium hydride (0.5 g, 1.38 mmol) was dissolved in dry ether (20 mL) in 
a two necked round bottomed flask. 3-(ferrocenylmethoxy)propanoic acid (0.2 g, 
0.69 mmol) in ether (5 mL) was added dropwise and the solution was stirred at 0 ˚C 
for 30 mins. The solution was then refluxed for 2 hrs. The solution was then 
quenched by the addition of water (5 mL) then NaOH (aq.) (10 mL). Water (12 mL) 
was then added and the ether layer was separated and the solvent was removed. The 
product was purified via column chromatography (8:2, hexanes : ethyl acetate) and 
the product was afforded as a yellow oil (0.12 g, 59%). IR (cm
-1
): 3254, 3101. 2204, 
2049, 17001, 1622, 1476. 
1
H NMR (300 MHz; CDCl3) δ 4.82 (2H, s, FcH), 4.57 
(2H, s, FcH), 4.28 (5H, s, FcH), 3.66 (2H, t, J =  6.75Hz, CH2), 3.45 (2H, t, J =  
6.5Hz, CH2), 3.32 (2H, t, J =  6.5, CH2) 1.75 (2H, t, J =  6.75, CH2). 
13
C NMR (75.5 
MHz, CDCl3) δ 72.6, 70.1, 69.9, 69.2, 67.2, 66.1, 58.2, 32.4. HRMS (ESI) calcd for 










Ferroceneacetic acid (0.5 g, 4.35 mmol) was dissolved in dry CH2Cl2 (15 mL) and 
was treated with oxalyl chloride (0.7 mL, 8.69 mmol) under an inert atmosphere and 
was stirred at room temperature for 30mins to obtain a red solution. Excess oxalyl 
chloride was removed under vacuum. The residue was re-dissolved in dry CH2Cl2 
(15 mL) and cooled to 0 ˚C. 6-Aminohexan-1-ol (0.4 g, 4.35 mmol) in dry CH2Cl2 
(20 mL) was added dropwise followed by triethylamine (0.6 mL, 4.35 mmol) and the 
reaction was left to stir overnight. The reaction mixture was then treated with NH4Cl 
(sat) (30 mL) and extracted with CH2Cl2 (30 mL). The organic layer was washed 
with water (30 mL) and dried over MgSO4 and solvent was removed to yield the 
crude product, which was purified via column chromatography (7:3, hexanes : ethyl 
acetate) to yield the product as an orange solid (0.65g, 72%). IR (cm
-1
): 3101, 2972, 
2934, 1729, 1634, 1566, 1428  
1
H NMR (300 MHz; CDCl3) δ 4.12 (2H, s, FcH), 
4.09 (7H, s, FcH), 3.60 (1H, s, OH), 3.52 (2H, t, J =  4, CH2), 3.00 (2H, s, CH2), 
2.85 (2H, s, CH2), 2.30 (2H, s, CH2), 1.56–1.25 (8H, m, CH2). 
13
C NMR (75.5 MHz; 
CDCl3) δ 173.3, 77.8, 77.4, 76.9, 62.0, 38.8, 35.4, 32.0, 30.6, 26.7, 25.4, 25.4. 










Ferrocene (1 g, 5.3 mmol) was dissolved in dry CH2Cl2 (25 mL) in a two-necked 
flask equipped with a condenser. The solution is cooled to 0
˚
C in an ice bath then 
acetyl chloride (0.5 mL, 6 mmol) was added to the reaction mixture. Aluminum 
chloride (1.1 g, 8.2 mmol) is then added portionwise and the reaction mixture was 
then stirred at room temperature for 30mins. The solution was then poured into an 
ice water bath and extracted with CH2Cl2 (25 mL) and the organic layer was washed 
with water (25 mL). The organic fraction was then dried over MgSO4 and the solvent 
removed to yield the product as an orange crystalline solid (0.78g, 75% yield). 
1
H 
NMR (300 MHz; CDCl3) δ 4.72 (2H, s, FcH), 4.53 (2H, s, FcH), 4.13 (5H, s, FcH), 
2.31 (3H, s, CH3). 
13
C NMR (75.5 MHz; CDCl3) δ 201.0, 80.7, 77.8, 77.3, 76.9, 
73.6, 70.9, 27.6. HRMS (ESI) calcd for C12H12O1Fe1 m/z: 229.0314 found 229.0315 










Acetylferrocene (0.18 g, 0.78 mmol) was dissolved in THF (5 mL) and treated with 
BMS (0.78 mL, 0.78 mmol). The reaction mixture was stirred at room temperature 
for 3hrs. The reaction mixture was then quenched with aqueous NH4Cl (sat, 20 mL) 
and the aqueous layer was then extracted with EtOAc (15 mL). The combined 
organic layers were dried over MgSO4 and the solvent was removed to yield the 
crude product as a yellow solid, that was purified by column chromatography (9:1, 
hexanes:EtOAc) to afford the crude product as a yellow amorphous solid (0.55, 
50%). 
1
H NMR (300 MHz; CDCl3) δ 4.23 (2H, s, FcH), 4.19 (2H, s, FcH), 4.13 (5H, 
s, FcH), 2.75 (2H, s, CH2) 1.26 (3H, s, CH3). 
13
C NMR (75.5 MHz; CDCl3) δ 80.6, 
76.9, 73.6, 70.8, 28.9, 11.8 HRMS (ESI) calcd for C12H14Fe1 m/z: 214.0367 found 











Ferrocene carboxaldehyde (0.6 g, 1.75 mmol) and piperidine-4-methanol (0.2 g, 1.75 
mmol) were dissolved in dry THF (20 mL) to which sodium triacetoxyborohydride 
(1 g, 3.52 mmol) was added portionwise the suspension was then stirred at room 
temperature under an inert atmosphere for 12hrs. The reaction mixture is then 
partitioned between EtOAc (20 mL) and 1M NaOH (20 mL). The organic fraction 
was then dried over MgSO4 and the solvent was evaporated to yield the crude 
product as a pale orange oil. The crude prduct was purified via column 
chromatography (7:3, hexanes : EtOAc) to afford the desired product as a yellow 
solid (0.45g, 75%). IR (cm
-1
): 3256, 3121. 2214, 2050, 17001, 1622, 1476 
1
H NMR 
(300 MHz; CDCl3) δ 4.18 (2H, s, FcH), 4.17 (2H, s, FcH), 4.13 (5H, s, FcH), 3.66 
(4H, t, J =  6.25, CH2), 3.48 (2H, s, CH2), 1.48-1.17 (5H, m, CH3, CH). 
13
C NMR 
(75.5 MHz; CDCl3) δ 88.2, 77.8, 77.4, 77.1, 76.6, 69.6, 68.5, 67.5, 60.6, 58.5, 52.7, 










DBU (0.16 mL, 1.07 mmol) and DPPA (0.16 mL, 0.74 mmol) were added to a 
stirred solution of ferrocene methanol (0.1 g, 0.5 mmol) in dry toluene (6 mL). The 
reaction mixture was stirred at room temperature for 12hrs. The product was not 
isolated as was used sequentially. Propargyl alcohol (0.05 g, 0.05 mL, 0.86 mmol) 
was added to then added to the reaction mixture followed by copper acetate (50 mg, 
5 mol%) and sodium ascorbate (80 mg, 10 mol%). The reaction was then left to stir 
at room temperature overnight. The product was extracted using CH2Cl2 (20 mL) 
and washed with NaHCO3 (sat, 20 mL). The organic fractions were dried over 
MgSO4 and the solvent was removed to yield the crude product as a dark yellow 
solid. The crude product was purified via column chromatography (7:3, hexanes : 
EtOAC) to afford the product as a dark yellow solid (0.11 g, 73%). 
1
H NMR (300 
MHz; CDCl3) δ: 7.48 (1H, s, CHC=C), 5. 39 (2H, t, J =  1.75, CH2), 4.82 (2H, t, J =  
2.65, CH2), 4.21 (2H, s, FcH), 4.17 (2H, s, FcH) 4.16 (5H, s, FcH). 
13
C NMR (75.5 












6-Bromohexan-1-ol (0.1 g. 0.1 mL, 0.6 mmol) was dissoloved in Butanol : water 
(1:1, 1.5 mL) solvent mixture. Sodium azide (0.04 g, 0.6 mmol) was added and the 
reaction mixture was stirred at room temperature for 12hrs. The product was not 
isolated as it was used sequentially. Ethynylferrocene (0.09 g, 0.428 mmol) was 
added to the reaction mixture followed by copper acetate (40 mg, 5 mol%) and 
sodium ascorbate (80 mg, 10 mol%). The reaction was then left to stir at room 
temperature overnight. The product was extracted using CH2Cl2 (20 mL) and washed 
with NaHCO3 (sat) (20 mL).  The organic fractions were dried over MgSO4 and the 
solvent was removed to yield the crude product as a dark yellow solid. The crude 
product was purified via column chromatography (7:3, hexanes:EtOAC) to afford 
the product as a dark yellow solid (0.21 g, 83%). IR (cm
-1
): 3256, 3121. 2214, 2050, 
17001, 1622, 1476. 
1
H NMR (300 MHz; CDCl3) δ 7.59 (1H, s, CHC=C) 4.16 (2H, s, 
FcH), 4.14 (2H, s, FcH), 4.12 (5H, s, FcH), 3.66 (2H, t, J =  6.25, CH2), 3.53 (2H, t, 
J =  6, CH2), 1.74–1.28 (8H, m, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 148.5, 130.2, 
73.5, 72.4, 72.3, 70.5, 68.8, 52.5, 32.2, 28.2, 27.5, 25.3. HRMS (ESI) calcd for 





General procedure A: Synthesis of 4-(5-(ferrocenyl)-5-oxopentyl)tetrahydro-1H-
thieno[3,4-d]inidazol-2(3H)-ones 
 
To a solution of biotin (1mmol) in dry dichloromethane (5 mL) was added 
trifluoroacetic anhydride (TFA, 1 mmol) and the reaction mixture was stirred at 
room temperature for 30 mins or until the biotin has fully dissolved. Ferrocene 
derivative (1 mmol) and trimethylsilyl trifluoromethane sulfonate (TMSTf, 1 mmol) 
were added and the reaction mixture was stirred at room temperature for two hours. 
Water (25 mL) was then added to quench the reaction and extracted with 
dichloromethane (3 x 25 mL). The combined organic fractions were dried over 
MgSO4 and the solvent was removed. The crude product was purified using column 







Biotin (0.244 g, 1 mmol), TFAA (0.21 g, 150 µL, 1 mmol), ferrocene (0.186 g, 1 
mmol) and TMStf (0.22 g, 180 µL, 1 mmol) reacted under general condition. (98% 
yield). 
1
H NMR (300 MHz;  CDCl3) δ 6.53 (1H, br s, NH), 6.43 (1H, brs, NH), 4.85 
(2H, t, J = 1.8, FcH), 4.62 (2H, t, J = 1.8, FcH), 4.37 (1H, dd, J = 7.6, 5.3, CH), 
4.28 (5H, s, FcH), 4.23-4.21 (1H, m, CH), 2.91 (2H, t, J = 7.3, CH2), 2.78 (2H, t, J = 
7.3, CH2), 1.73-1.42 (6H, m, CH2). 
13
C NMR (75.5 MHz; CDCl3) δ 203.4, 162.7, 
79.1, 72.0, 69.5, 69.0, 61.1, 59.2, 55.5, 39.8, 38.7, 28.4, 24.2, 24.1. HRMS (ESI) 
189 
 







Biotin (0.244 g, 1 mmol), TFAA (0.21 g, 150 µL, 1 mmol), ethylferrocene (0.228 g, 
1 mmol) and TMStf (0.22 g, 180 µL, 1 mmol). Reacted under the general reaction 
conditions. (0.35 g, 92%). IR (cm
-1
): 3121. 2214, 2050, 1729, 1713, 1622, 1476.  
1
H 
NMR (300 MHz; CDCl3) δ 6.51 (1H, br s, NH), 6.42 (1H, brs, NH), 4.83 (1H, s, 
FcH), 4.63 (2H, t, J = 1.8, FcH), 4.34 (1H, dd, J = 7.6, 5.3, CH), 4.29 (5H, s, FcH), 
4.24-4.22 (1H, m, CH), 2.92 (2H, t, J = 7.25, CH2), 2.78 (2H, t, J = 7.25, CH2), 2.69 
(2H, t, J = 5.5, CH2), 1.73-1.45(6H, m, CH2), 1.28 (3H, s, CH3). 
13
C NMR (75.5 
MHz; CDCl3) δ 203.4, 162.7, 79.1, 72.0, 69.5, 69.0, 61.1, 59.2, 55.5, 39.8, 38.7, 







Biotin (0.244 g, 1 mmol), TFAA (0.21 g, 150 µL, 1 mmol), acetylferrocene (0.228 g, 
1 mmol) and TMStf (0.22 g, 180 µL, 1 mmol). Reacted under the general reaction 
conditions. (0.37 g, 92%). IR (cm
-1





NMR (300 MHz; CDCl3) δ 6.51 (1H, br s, NH), 6.42 (1H, brs, NH), 4.83 (1H, s, 
FcH), 4.62 (2H, t, J = 1.8, FcH), 4.34 (1H, dd, J = 7.6, 5.3, CH), 4.28 (5H, s, FcH), 
4.24-4.22 (1H, m, CH), 2.92 (2H, t, J = 7.25, CH2), 2.78 (2H, t, J = 7.25, CH2), 2.69 
(2H, t, J = 5.5, CH2), 1.73-1.45(6H, m, CH2), 1.28 (3H, s, CH3). 
13
C NMR (75.5 
MHz; CDCl3) δ 203.4, 201.4. 162.7, 79.1, 72.0, 69.5, 69.0, 61.1, 59.2, 55.5, 39.8, 
38.7, 28.4, 24.2, 24.1, 14.3 HRMS (ESI) calcd for C22H28N2O2Fe1S1 m/z 454.1014 







Biotin (0.244 g, 1 mmol), TFAA (0.21 g, 150 µL, 1 mmol), bromoferrocene (0.264 
g, 1 mmol) and TMStf (0.22 g, 180 µL, 1 mmol). Reacted under the general reaction 
conditions. (0.45 g, 90%). IR (cm
-1
): 3122. 2214, 2050, 1727, 1713, 1622, 1476. 
1
H 
NMR (300MHz, CDCl3) δ 6.55 (1H, br s, NH), 6.47 (1H, brs, NH), 4.76 (2H, t, J=4, 
FcH), 4.54 (2H, t, J=4, FcH), 4.46 (2H, t, J=4, FcH), 4.36 (1H, dd, J = 7.6, 5.3, 
CH), 4.22-4.19 (1H, m, CH), 4.15 (2H, t, J=4, FcH), 2.94 (2H, t, J = 7.3, CH2), 2.73 
(2H, t, J = 7.2, CH2), 1.73-1.42 (6H, m, CH2). 
13
C NMR (75.5 Hz, CDCl3) δ 203.4, 
162.7, 79.1, 72.0, 69.5, 69.0, 61.1, 59.2, 55.5, 39.8, 38.7, 28.4, 24.2, 24.1. HRMS 










3-bromopropionic acid (0.152 g, 1 mmol) was dissolved in dry CH2Cl2 (5 mL), to 
which trifluoroacetic anhydride (150 μL, 1 mmol) was added and the reaction 
mixture was stirred at room temperature for 30mins. An appropriate Ferrocene 
derivative (1 mmol) was then added along with trimethylsilyl 
trifluoromethanesulfonate (180 μL, 1 mmol) and the reaction mixture was stirred for 
two hours at room temperature. The reaction was then quenched with water (20 mL), 
the organic layer was then separated and the aqueous layer was then extracted with 
CH2Cl2 (20 mL). The combined organic layers were dried over MgSO4 and then the 
solvent was removed to yield the crude product. The crude product was purified via 





3-bromopropionic acid (0.76 g, 5 mmol), TFAA (1.05 g, 0.69 mL, 5 mmol), 
ferrocene (0.93 g, 5 mmol) and TMStf (1.11 g, 0.9 mL, 5 mmol) were reacted under 
general procedure B. Product afforded as a red crystalline solid (1.6 g, 95%).   
1
H 
NMR (250 MHz, CDCl3) δ 4.82 (2H, s, FcH), 4.57 (2H, s, FcH), 4.28 (5H, s, FcH), 
3.76 (2H, t, J =  6.5, CH2), 3.33 (2H, t, J =  6.5, CH2). 
13
C NMR (75.5 MHz, 
CDCl3) δ 200.6, 72.6, 70.1, 69.9, 69.2, 42.3, 26.0. HRMS (ESI) calcd for 
C13H13O1Fe1Br1 m/z: 319.9421 found 319.9422. 
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3-bromopropionic acid (0.152 g, 1 mmol), TFAA (0.15 mL, 1 mmol), 
Bromoferrocene (0.264 g, 1 mmol) and TMStf (0.18 mL, 1 mmol) were reacted 
under the general procedure B. Product yield  (0.06g, 65%). 
1
H NMR (300 MHz, 
CDCl3) δ: 4.74 (2H, t, J=3.75, FcH), 4.50 (2H, t, J=3.75, FcH), 4.41 (2H, t, J=3.75, 
FcH), 4.14 (2H, t, J=1.75, FcH), 3.66 (2H, t, J=6.75, CH2), 3.27 (2H, t, J=6.75, 
CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 200.0, 79.9, 74.7, 72.5, 72.4, 69.0, 42.6, 25.8. 
HRMS (ESI) calcd for C13H12O1Fe1Br2 m/z: 397.8526 found 397.8527. 
 




3-bromopropionic acid (0.152 g, 1 mmol), TFAA (0.15 mL, 1 mmol), Ethylferrocene 
(0.214 g, 1 mmol) and TMStf (0.18 mL, 1 mmol) were reacted under general 
procedure B. Product yield (0.18 g, 65%). 
1
H NMR (500 MHz; CDCl3) δ 4.22 (2H, 
s, FcH), 4.16 (1H, s, FcH), 4.09 (5H, s, FcH), 3.69 (2H, t, J =  1.75, CH2), 3.66–3.62 
(4H, m, CH2), 2.75 (2H, t, J =  1.75 CH2), 1.26 (3H, s, CH3). 
13
C NMR (75.5 MHz; 
CDCl3) δ 198.3, 72.7, 72.6, 70.1,  69.9, 69.7, 65.6, 61.7, 26.7, 22.4, 14.2. HRMS 









Ethylene glycol (0.9 mL, 16.13 mmol) was dissolved in dry THF (20 mL) under an 
inert atmosphere and the solution was cooled down to 0˚C in an ice bath. To this 
sodium hydride (0.38 g, 16.13 mmol) was added and the reaction mixture was stirred 
at 0 ˚C for 2 hours. The reaction mixture was then re-cooled using an ice bath and 3-
bromopropionic acid (2.45 g, 16.13 mmol) was added to the reaction mixture in a 
solution of THF (2 mL). The reaction mixture was then stirred at room temperature 
for 6 hours. Water (25 mL) was then added and the reaction mixture was extracted 
using ether (2 × 25 mL). The combined organic layers were then dried over MgSO4 
and the solvent was removed to yield the crude product as an off white solid. The 
crude product was then purified via column chromatography (8:2, hexanes:EtOAc) 
to afford the compound as an amorphous off white solid (2.24 g, 65%). IR (cm
-1
): 
3258, 3121. 2214, 2050, 1728, 1712, 1612, 1476.  
1
H NMR (250 MHz, CDCl3) δ 
3.72 (2H, t, J = 6.6, CH2), 3.51 (2H, t, J =  6.6, CH2), 2.92 (2H, t, J =  6.6, CH2).
13
C 
NMR (75.5 MHz, CDCl3) δ 175.8, 67.5, 63.5, 37.4, 25.5, 25.2. HRMS (ESI) calcd for 









3-(2-hydroxyethoxy)propanoic acid (0.130 g, 1 mmol) was dissolved in dry CH2Cl2 
(5 mL), to which trifluoroacetic anhydride (150 μL, 1 mmol) was added and the 
reaction mixture was stirred at room temperature for 30mins. Ferrocene (0.186 g, 1 
mmol) was then added along with trimethylsilyl trifluoromethanesulfonate (180 μL, 
1 mmol) and the reaction mixture was stirred for two hours at room temperature. The 
reaction was then quenched with water (20 mL), the organic layer was then separated 
and the aqueous layer was then re-washed with CH2Cl2 (20 mL). The combined 
organic layers were dried over MgSO4 and then the solvent was removed to yield the 
crude product as a brown oil. The crude compound was then purified silca column 
chromatography (8:2, hexanes:EtOAc) to afford the compound as a red oil 
(0.27g,85%). IR (cm
-1
): 3258, 3121. 2214, 2050, 1728, 1712, 1612, 1476. 
1
H NMR 
(300 MHz, CDCl3) δ: 4.73 (2H, t, J=3.75, FcH), 4.45 (2H, t, J=3.75, FcH), 4.16 
(5H, s, FcH), 3.83 (2H, t, J=6.25, CH2), 3.68 (2H, s, CH2), 3.58 (2H, t, J=5.75, 
CH2), 2.93 (2H, t, J=6.25, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 202.5, 72.9, 72.5, 
70.1, 69.9, 69.7, 69.3, 65.6, 61.7, 38.6. HRMS (ESI) calcd for C15H18O3Fe1  m/z: 








3-(2-hydroxyethoxy)propanoic acid (0.130 g, 1 mmol) was dissolved in dry CH2Cl2 
(5 mL), to which trifluoroacetic anhydride (150 μL, 1 mmol) was added and the 
reaction mixture was stirred at room temperature for 30 mins. Bromoferrocene 
(0.264 g, 1 mmol) was then added along with trimethylsilyl 
trifluoromethanesulfonate (180 μL, 1 mmol) and the reaction mixture was stirred for 
two hours at room temperature. The reaction was then quenched with water (20 mL), 
the organic layer was then separated and the aqueous layer was then extracted with 
CH2Cl2 (20 mL). The combined organic layers were dried over MgSO4 and then the 
solvent was removed to yield a brown oil. The compound was then purified via 
column chromatography (8:2, hexanes : EtOAc) to afford the product as a deep red 
oil (0.25g, 65%). IR (cm
-1
): 3256, 3121. 2214, 2050, 1728, 1622, 1476. 
1
H NMR 
(250 MHz, CDCl3) δ: 4.86 (2H, t, J=2.5, FcH), 4.62 (2H, t, J=2.5, FcH), 4.52 (2H, t, 
J=2.5, FcH), 4.26 (2H, t, J=2.5, CH2), 3.97 (2H, t, J=7.25, CH2), 3.81 (2H, s, CH2), 
3.68 (2H, t, J=5.75, CH2) 3.08 (2H, t, J=7.25, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 
203.58, 72.94, 72.57, 70.11 69.89, 69.73, 69.35, 65.66, 61.73, 38.69 HRMS (ESI) 








3-(2-hydroxyethoxy)propanoic acid (0.130 g, 1 mmol) was dissolved in dry CH2Cl2 
(5 mL), to which trifluoroacetic anhydride (150 μL, 1 mmol) was added and the 
reaction mixture was stirred at room temperature for 30mins. Ethylferrocene (0.264 
g, 1 mmol) was then added along with trimethylsilyl trifluoromethanesulfonate (180 
μL, 1 mmol) and the reaction mixture was stirred for two hours at room temperature. 
The reaction was then quenched with water (20 mL), the organic layer was then 
separated and the aqueous layer was then extracted with CH2Cl2 (20 mL). The 
combined organic layers were dried over MgSO4 and then the solvent was removed 
to yield a brown oil. The compound was then purified via column chromatography 
(99:1, hexanes : EtOAc) to afford the compound as a red oil (0.05g, 65%). IR (cm
-1
): 
3256, 3121. 2214, 2050, 1729, 1622, 1476. 
1
H NMR (500 MHz, CDCl3) δ 4.21 (2H, 
s, FcH), 4.15 (1H, s, FcH), 4.13 (5H, s, FcH), 3.67 (2H, t, J =  1.75, CH2), 3.64 – 
3.60 (4H, m, CH2), 2.69–2.62 (4H, m, CH2), 1.26 (3H, t, J =  6.5, CH3). 
13
C NMR 
(75.5 MHz, CDCl3) δ 198.1, 72.8, 72.6, 70.1, 69.9, 69.7, 65.6, 61.7, 38.6, 22.5, 14.3. 








1-ferrocenyl-3-(2-hydroxyethoxy)propan-1-one (0.2 g, 0.66 mmol) was dissolved in 
dry CH2Cl2 (20 mL) to which BMS (0.3 mL, 1.5 mL) the reaction mixture was then 
stirred at room temperature until completion. The reaction was monitored by TLC 
(9:1, petrol:ethylacetate). When the reaction was complete, NH4Cl (sat, 30 mL) was 
used to quench the reaction. The aqueous layer was then extracted with ethyl acetate 
(25 mL) and then the combined organic layers are dried using MgSO4 and the 
solvent was removed to yield the product as an orange/yellow oil (0.19 g, 96%). IR 
(cm
-1
): 3256, 3131. 2221, 2065, 1932 1712, 1622, 1476 
1
H NMR (300 MHz; CDCl3) 
δ: 4.63 (2H, t, J=3.75, FcH), 4.34 (2H, t, J=3.75, FcH), 4.25 (5H, s, FcH), 3.95 (2H, 
t, J=6, CH2), 3.83 (2H, t, J=6.25, CH2), 3.68 (2H, s, CH2), 3.58 (2H, t, J=6, CH2), 
2.93 (2H, t, J=6, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 72.9, 72.5, 70.1, 69.9, 69.7, 
69.3, 65.6, 61.7, 38.6, 36.3. HRMS (ESI) calcd for C15H19O2Fe1  m/z: 287.1553 





General synthetic procedure for phosphoramidite synthesis 
 
N, N – diisopropylethylamine (0.4 mL, 8.4 mmol) was added to a stirred solution of 
the ferrocene derivative (2.1 mmol) in dry THF (25 mL) under a nitrogen 
atmosphere. 2 – cyanoethyldiisopropylchlorophosphoramidite (0.2 ml, 3.15 mmol) 
was added dropwise and the resulting mixture was stirred for 15 mins. MilliQ 
filtered water (200 mL) was added and the solution was stirred for a further 30 mins. 
Ethyl Acetate – Triethylamine (1:1, 25 mL) was added, a precipitate formed. The 
mixture was washed with saturated NaCHCO3 (25 mL) and MilliQ filtered water (25 
mL). The organic fraction was dried over MgSO4 and the solvent was removed under 
vacuo. The crude product was then purified via column chromatography (9:1, 
hexanes : EtOAc). 
 





H NMR (500 MHz, CDCl3) δ 4.23 (2H, s, FcH), 4.18 (2H, s, FcH), 4.13 (5H, s, 
FcH), 3.61 (2H, t, J =  1.75, CH2), 3.58 (4H, m, CH2), 3.41 (2H, t, J=6.5, CH2), 3.33 
(2H, t, J =  6.5, CH), 2.65 (2H, t, J =  6.5, CH2), 0.86 (12H, t, J =  7, CH3). 
13
C 
NMR (75.5 MHz, CDCl3) δ 198.6, 117.3, 79.3, 79.2, 78.7, 76.9, 71.2, 65.3, 64.7, 
58.4, 51.3, 51.1, 40.8, 24.8, 20.3. 
31








H NMR (500 MHz, CDCl3) δ 4.32 (2H, s, FcH), 4.22 (2H, s, FcH), 4.15 (5H, s, 
FcH), 3.75 (2H, t, J =  1.75, CH2), 3.64 (4H, m, CH2), 3.52 (2H, t, J=6, CH2), 3.34 
(2H, t, J =  6.5, CH), 2.75 (2H, t, J =  6.5, CH2), 2.59 (2H, q, J =  6.5, CH2)0.98 
(12H, t, J =  7, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 116.8, 79.5, 79.3, 78.9, 76.3, 
71.6, 71.4, 64.3, 58.0, 51.9, 51.8, 35.6, 27.6, 24.4, 24.3. 
31
P NMR (DEC) (202.5 








H NMR (500 MHz, CDCl3) δ 4.26 (2H, s, FcH), 4.16 (2H, s, FcH), 4.12 (5H, s, 
FcH), 3.65 (2H, t, J =  1.75, CH2), 3.60 (4H, m, CH2), 3.57 (2H, t, J=6, CH2), 3.35 
(2H, t, J =  6.5, CH), 2.69 (2H, t, J =  6.5, CH2), 1.26 (3H, t, J =  6, CH3), 0.86 
(12H, t, J =  7, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 197.4, 114.6, 79.8,79.6, 78.4, 
76.9, 71.3, 65.3, 64.1, 58.3, 51.7, 51.6, 40.4, 32.7, 24.5, 20.6, 11.8. 
31
P NMR (DEC) 









H NMR (500 MHz, CDCl3) δ 4.78 (2H, t, J=3.5, FcH), 4.56 (2H, t, J=3.75, FcH), 
4.44 (2H, t, J=3.5, FcH), 4.18 (2H, t, J=1.75, FcH), 3.65 (2H, t, J =  1.75, CH2), 
3.60 (4H, m, CH2), 3.57 (2H, t, J=6, CH2), 3.35 (2H, t, J =  6, CH), 2.69 (2H, t, J =  
6, CH2), 0.86 (12H, t, J =  7, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 197.6, 115.3, 
81.4, 79.8, 79.6, 78.5, 76.4, 71.3, 65.6, 64.3, 59.1, 51.7, 42.7, 24.7, 21.0. 
31
P NMR 







H NMR (500 MHz, CDCl3) δ 7.48 (1H, s, CHC=C), 5. 39 (2H, t, J =  1.75Hz, 
CH2), 4.26 (2H, s, FcH), 4.16 (2H, s, FcH), 4.12 (5H, s, FcH), 3.65 (2H, t, J =  1.75, 
CH2), 3.60 (4H, m, CH2), 3.57 (2H, t, J=6, CH2), 3.35 (2H, t, J =  6.5, CH), 2.69 
(2H, t, J =  6.5, CH2), 1.26 (3H, t, J =  6, CH3), 0.86 (12H, t, J =  7, CH3). 
13
C NMR 
(75.5 MHz, CDCl3) δ 142.4, 122.4, 111.9, 61.2, 58.3, 51.9, 51.7, 24.6, 22.4. 
31
P 












H NMR (500 MHz, CDCl3) δ 4.06 (2H, s, CH2), 3.69-3.46 (7H, m, CH2, CH), 3.36-
3.29 (3H, q, J = 7.2, CH2), 2.52 (2H, t, J = 6.0, CH2), 1.62 (6H, s, CH3Fc), 1.59 (6H, 
s, CH3Fc), 1.56 (15H, s, CH3Fc). 
13
C NMR (75.5 MHz, CDCl3) δ 79.5, 79.1, 78.3, 
76.9, 65.4, 65.3, 64.9, 60.2, 59.9, 58.0, 57.8, 42.5, 42.3, 31.3, 31.1, 23.7, 23.6, 23.5, 
19.7, 19.6, 14.3, 8.5, 8.4, 8.2.  
31








Decamethylferrocene (2.5 g, 7.66 mmol) was added to a solution of ground barium 
manganate (9.81 g, 38.30 mmol) in benzene : ether (1:1, 40 mL) and placed in an 
ultrasound bath for 10-15 mins. The reaction mixture was then heated at 45˚C for 
18hrs before being cooled to room temperature and the barium manganate residues 
being removed by suction filtration. The solvent was evaporated under reduced 
pressure and the crude product as a deep red solid. The crude product was purified 
via coloumn chromatography (9:1, hexanes:EtOAc) to afford the product as a red 
solid (1.4 g, 63%). 
1
H NMR (300 MHz, CDCl3) δ 9.91 (1H, s, CHO), 1.94 (6H, s, 
c(CHO)C(CMe)2), 1.70 (6H, s, c(CHO)C(CMe2)), 1.59 (15H,s, C(CMe)5). 
13
C NMR 
(75.5 MHz, CDCl3) δ 196.2, 86.4, 83.3, 81.1, 73.4, 9.6, 9.2. HRMS (ESI) calcd for 









A solution of nonamethylferrocenecarboxaldehyde (0.5 g, 1.47 mmol)in EtOH : 
dioxane (4:1, 50 mL) was added sodium borohydride (0.05 g, 1.47 mmol) in a round 
bottomed flask. The solution was stirred for 1 hour. Water (30 mL) was then added 
and then extracted with ether (30 mL). Re – extracted with water and the organic 
solution was dried with MgSO4. The solvent was removed in vacuo to afford the 
product as a yellow solid (0.5 g, 99%). IR (cm
-1
): 3256, 3121. 2214, 1654, 1622, 
1476 
1
H NMR (300 MHz, CDCl3) δ, 3.49 (2H, t, J =  6.4, CH2) 1.91 (6H, s, 
c(CHO)C(CMe)2), 1.63 (6H, s, c(CHO)C(CMe2)), 1.56 (15H,sm, C(CMe)5). 
13
C 
NMR (75.5 MHz, CDCl3) δ 87.5, 84.6, 82.3, 73.4, 63.2 9.4, 9.1. HRMS (ESI) calcd 









Sodium hydride (0.042 g, 1.75 mmol) was added to a solution of 
nonamethylferrocene methanol (0.3 g, 0.88 mmol) in THF (20 mL) and allowed to 
stir for 2 hours in an ice bath. To the formed suspension 3-bromopropanoic acid 
(0.11 g, 0.88 mmol) was added and the reaction was stirred at room temperature for 
2 hours. Water (20 mL) was then added and the product was extracted with ether (20 
mL). The organic fraction was dried over MgSO4 and the solvent was evaporated to 
yield the crude product as a yellow solid. The crude product was purified via column 
chromatography (7:3, hexanes : EtOAc) to afford the product as a yellow powder 
(0.14g, 40%). IR (cm
-1
): 3256, 3121. 2214, 2050, 1728, 1652, 1621, 1476 
1
H NMR 
(300 MHz, CDCl3) δ 3.76 (2H, t, J =  6.5Hz, CH2), 3.59 (2H, t, J =  6.75, CH2), 3.33 
(2H, t, J =  6.5Hz, CH2), 1.94 (6H, s, C(CMe)2), 1.70 (6H, s, c(CHO)C(CMe2)), 1.59 
(15H,sm, C(CMe)5). 
13
C NMR (75.5 MHz, CDCl3) δ 176.2, 86.4, 83.3, 81.1, 73.4, 








Lithium aluminium hydride (0.06 g, 1.74 mmol) was dissolved in ether (20 mL) in a 
two necked round bottomed flask. 6-(nonamethylferrocenylmethoxy)propanoic acid 
(0.36 g, 0.87 mmol) in ether (5 mL) was added dropwise and the solution was stirred 
at 0 ˚C for 30 mins. The solution was then refluxed for 2 hours. The solution was 
then quenched with water (3 mL) then NaOH 20% solution. Water (12 mL) was then 
added and the ether layer was decanted and the solvent was evaporated. (0.219 g, 
60%). IR (cm
-1
): 3258, 3021. 2214, 2150, 1701, 1622, 1476 
1
H NMR (300 MHz, 
CDCl3) δ 3.56 (2H, t, J =  6.5, CH2), 3.41 (2H, t, J =  6.75, CH2), 3.23 (2H, t, J =  
6.75, CH2), 1.94 (6H, s, C(CMe)2), 1.75 (2H, t, J =  7, CH2).  1.70 (6H, s, 
c(CHO)C(CMe2)), 1.59 (15H, s, C(CMe)5). 
13
C NMR (75.5 MHz, CDCl3) δ 86.4, 
84.5, 83.3, 81.1, 73.4, 58.4, 32.2, 9.7, 9.4. HRMS (ESI) calcd for C23H35O2Fe1 m/z 
399.1986 found 399.1986. Anal. Calcd. C23H35O2Fe1: C, 69.17% H, 8.83% found C, 




(nonamethylferrocenyl-1-methyl-piperidin-4-yl) methanol 132 
 
 
Nonaferrocene  carboxaldehyde (0.6 g, 1.75 mmol) and piperidine-4-methanol (0.2 
g, 1.75 mmol) were dissolved in dry THF (20 mL) to which sodium 
triacetoxyborohydride (1 g, 3.52 mmol) was added portionwise and stir at room 
temperature under an inert atmosphere for 12hrs. The reaction mixture is then 
extracted between EtOAc and 1N NaOH. The organic fraction was then dried over 
MgSO4 and the solvent was removed to yield the crude product as a orange/brown 
soild. The crude product was purified via column chromatography (7:3, 
hexanes:EtOAc) to afford the product as a yellow solid (0.45 g, 55%). IR (cm
-1
): 
3256, 3121. 2214, 2050, 17001, 1622, 1476, 1465. 
1
H NMR (300 MHz, CDCl3) δ 
3.66 (4H, t, J =  6.25, CH2), 2.21(6H, s, CH3), 2.11 (6H, s, CH3), 1.92 (15H, s, CH2) 
1.84-1.17 (5H, m, CH2, OH). ). 
13
C NMR (75.5 MHz, CDCl3) δ 86.4, 84.5, 83.3, 











Ferrocene carboxaldehyde (2.1 g, 9.81 mmol) and 6 – aminohexan - 1 – ol (0.5 g, 
4.27 mmol) in dry THF (25 mL) were added to an oven dried flask. Sodium 
triacetoxyborohydride (2.3 g, 10.90 mmol) was added portionwise to the solution. 
The reaction was left overnight. The reaction was taken up in ethyl acetate (40 mL), 
the organic layer was washed with NaCO3 (20 mL), Brine (20 mL) and MilliQ water 
(20 mL). The organic fraction was then dried over MgSO4 and the solvent removed 
en vacuo. The crude product was then purified via column chromatography (9:1-7:3, 
hexanes:EtOAc) to afford the product as a dark orange solid (2.21 g, 85%). IR (cm
-
1
): 3101, 2972, 2934, 2204, 2049, 1700, 1632, 1466, 1395. 
1
H NMR (300 MHz, 
CDCl3) δ 4.18 (4H, s, FcH), 4.17 (4H, s, FcH), 4.13 (10H, s, FcH), 3.66 (4H, t, J =  
6.25, CH2), 3.48 (2H, s, CH2), 2.20 (2H, t, J =  6.25, CH2), 1.59 – 1.31 (8H, m, 
CH2). 
13
C NMR (75.5 Hz, CDCl3) δ 77.8, 77.4, 76.9, 70.5, 68.8, 63.3, 53.0, 52.1, 
33.1, 27.4, 25.8. HRMS (ESI) calcd for C28H33N1O1Fe2 m/z 519.1430 found 
519.1430. Anal. Calcd. C28H33N1O1Fe2: C, 65.52% H, 6.87% N, 2.73% found C, 












Ferrocene carboxaldehyde (2.1 g, 9.81 mmol) and (aminoethoxy) ethanol (0.5 g, 
4.27 mmol) in dry THF (25 mL) were added to an oven dried flask. Sodium 
triacetoxyborohydride (2.3 g,10.90 mmol) was added portionwise to the solution. 
The reaction was left overnight. The reaction was taken up in ethyl acetate (40 mL), 
the organic layer was washed with NaCO3 (20 mL), Brine (20 mL) and MilliQ water 
(20 mL). The organic fraction was then dried over MgSO4 and the solvent was 
removed. The crude product was then purified via column chromatography (9:1-7:3, 
hexanes:EtOAc) to afford the product as an orange amorphous solid (2.0 g, 78%). IR 
(cm
-1
):  3241, 2972, 2934, 2204, 2049, 1700, 1632, 1466, 1395, 1364. 
1
H NMR (300 
MHz, CDCl3) δ 4.18 (4H, s, FcH), 4.17 (4H, s, FcH), 4.13 (10H, s, FcH), 3.66 (4H, t, 
J = 6.25, CH2), 3.60–3.52 (4H, m, CH2), 3.48 (2H, s, CH2), 2.20 (2H, t, J = 6.25, 
CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 77.8, 77.4, 76.9, 70.5, 68.8, 63.3, 53.0, 52.1, 









n-Butyl lithium (3.1 mL, 32.63 mmol) was added to a stirring solution of 
((Dimethylamino)methyl) ferrocene (1 g, 4.11 mmol) in dry ether (40 mL). The 
reaction mixture was stirred at room temperature for 16 hours. DMF (0.41 mL, 5.36 
mmol) was then added and the reaction mixture was stirred for four hours, water (30 
mL) was then added and the product was extracted with ether (30 mL). The organic 
fraction was dried over MgSO4 and the solvent was removed to afford the crude 
product as a dark orange solid. The crude product was purified via column 
chromatography (ethyl acetate:hexane 1:9) to afford the product as an orange solid 
(1.25 g, 75%).
1
H NMR (300 MHz, CDCl3) δ 9.98 (1H, s, CHO), 4.81 (1H, s, FcH), 
4.62 (1H, s, FcH), 4.56 (1H, s, FcH) 4.21 (5H, s, FcH), 3.85 (2H, s, CH2), 2.16 (6H, 
s, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 190.8, 72.8, 72.4, 70.9, 69.5, 66.3, 58.8, 
46.1. HRMS (ESI) calcd for C28H33N1O1Fe2 m/z 271.1634 found C28H34N1O1Fe1: 
272.1701 (with H
+










(dimethylamino)methyl ferrocenecarboxaldehyde (1.1 g, 4.04 mmol) was dissolved 
in dry THF (30 mL). 6 – aminohexan – 1 –ol (0.25 g, 2.13 mmol) was added. Then 
Sodium triacetoxyborohydride (1.3 g, 6.16 mmol) was added to the reaction mixture. 
The solution was stirred under nitrogen at room temperature overnight. Ethyl acetate 
(20 mL) and 1N NaOH (20 mL) were then added and the organic layer was then 
extracted with NaCO3 (25mL), Brine (25 mL) and Milli Q filtered water (25 mL) 
then dried over MgSO4 and the solvent removed to afford the crude product as an 
orange oil, which was purified via column chromatography (9:1-6:4, 
Hexanes:EtOAc) to afford the product as an orange oil (0.95 g, 75%). IR (cm
-1
): 
3252, 3201, 3164, 3101, 2972, 2204, 2049, 1700, 1632, 1446. 
1
H NMR (300 MHz, 
CDCl3) δ 4.24 (2H, s, FcH), 4.21 (2H, s, FcH), 4.19 (2H, s, FcH), 4.15 (10H, s, 
FcH), 3.86 (4H, s, CH2), 3.66 (4H, t, J =  6.25Hz, CH2), 3.48 (2H, s, CH2), 2.20 (2H, 
t, J =  6, CH2), 2.17 (12H, s, CH3) 1.59 – 1.31 (6H, m, CH2). 
13
C NMR (75.5 MHz, 
CDCl3) δ 77.4, 77.2, 76.8, 70.5, 64.6, 62.7, 62.6, 58.1, 47.3, 32.2, 28.6, 26.4, 25.2, 








Ferrocenecarboxylic acid (1 g, 4.35 mmol) was dissolved in dry CH2Cl2 (15 mL) and 
was treated with oxalyl chloride (1.1 g, 0.7 mL, 8.69 mmol) under an inert 
atmosphere and was stirred at room temperature for 30 mins to obtain a red solution. 
Excess oxalyl chloride was removed under vacuum. The residue was re-dissolved in 
CH2Cl2 (15 mL) and cooled to 0˚C. Diisopropylamine (0.4 g, 0.6 mL, 4.35 mmol) in 
dry CH2Cl2 was added dropwise followed by triethylamine (0.44 g, 0.6 mL, 4.35 
mmol) and the reaction was left to continue over night. The reaction mixture was 
treated with NH4Cl (30 mL) and extracted with CH2Cl2 (30 mL). The organic layer 
was washed with water (30 mL) and dried over MgSO4 and solvent was removed to 
yield an off yellow solid (0.92 g, 66%). 
1
H NMR (300 MHz, CDCl3) δ 4.53 (2H, s, 
FcH), 4.25 (2H, s, FcH), 4.21 (5H, s, FcH), 3.89 (2H, m, CH), 1.50 (12H, s, CH3). 
13











n-Butyl lithium (1.69 mL, 17.33 mmol) was added to a stirring solution of N,N-
diisopropferrocenecarboxamide (1 g, 4.11 mmol) in dry ether (40 mL). The reaction 
mixture was stirred at room temperature for 16 hours. DMF (0.41 mL, 5.36 mmol) 
was then added and the reaction mixture was stirred for four hours, water (30 mL) 
was then added and the product was extracted with ether (30 mL). The organic 
fraction was dried over MgSO4 and the solvent was removed to yield the crude 
product as a dark orange solid.  The crude product was purified by column 
chromatography (ethyl acetate:hexane 1:9) to afford the product as an orange solid 
(1.18g, 56%). IR (cm
-1
): 3212, 3201, 3164, 3101, 2972, 2934, 2204, 2049, 1729, 
1727, 1700, 1634, 1458.  
1
H NMR (300 MHz, CDCl3) δ 9.88 (1H, s, CHO), 4.47 
(1H, s, FcH), 4.24 (1H, s, FcH), 4.20 (1H, s, FcH), 4.18 (5H, s, FcH), 3.92 (2H, m, 
CH2), 1.53 (12H, s, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 194.7, 171.7, 72.3, 72.0, 
70.8, 68.8, 54.6, 21.1. HRMS (ESI) calcd for C18H23N1O2Fe1 m/z 341.1078 found 










2-formyl-N,N-dissopropylferrocenecarboxamide (1 g, 4.04 mmol) was dissolved in 
dry THF (30 mL). 6 – aminohexan – 1 –ol (0.25 g, 2.13 mmol) was added. Then 
Sodium triacetoxyborohydride (1.3 g, 6.16 mmol) was added to the reaction mixture. 
The solution was stirred under nitrogen at room temperature overnight. Ethyl acetate 
(20 mL) and 1N NaOH (20 mL) were then added and the organic layer was then 
extracted with NaCO3 (25 mL), Brine (25 mL) and Milli Q filtered water (25 mL) 
then dried over MgSO4 and the solvent removed unvacuo to afford the crude 
product, the crude product was then purified via column chromatography (9:1-7:3, 
hexanes:EtOAc) to afford the product as an orange oil (0.96 g, 75%). IR (cm
-1
): 
3215, 3207, 3164, 3111, 2970, 2930, 2214, 2047, 1753 1700, 1632. 
1
H NMR (300 
MHz, CDCl3) δ 4.34 (2H, s, FcH), 4.29 (2H, s, FcH), 4.25 (2H, s, FcH), 4.19 (10H, 
s, FcH), 3.91 (2H, m, CH) 3.63 (4H, t, J = 6, CH2), 3.46 (2H, s, CH2), 2.23 (2H, t, J 
=  6, CH2), 2.17 (12H, s, CH3) 1.56 – 1.30 (6H, m, CH2).
 13
C NMR (75.5 MHz, 
CDCl3) δ 172.4, 77.6, 77.5, 76.7, 70.5, 63.3, 62.6, 59.2, 58.4, 33.1, 28.7, 25.5, 22.9, 








n-Butyl litium (1.69 mL, 17.33 mmol) was added dropwise to a stirring solution of 
ferrocene (0.5 g, 2.68 mmol) in dry ether (30 mL). The reaction mixture was stirred 
at room temperature for 16hrs, then iodomethane (0.17 mL, 2.68 mmol) was added 
and the reaction was left for a further 4hrs. Water (30 mL) was then added and the 
product was extracted with ether (30 mL). The organic fraction was dried over 
MgSO4 and the solvent was removed to yield the crude product, which was then 
purified via column chromatography (9:1,  hexanes:EtOAc) to afford the product as 
an orange powder (0.59 g, 68%). 
1
H NMR (300 MHz, CDCl3) δ 4.15 (2H, s, FcH), 
4.12 (2H, s, FcH), 4.09 (5H, s, FcH), 2.32 (3H, s, CH3). 
13
C NMR (75.5 MHz, 
CDCl3) δ 72.8, 72.4, 70.9, 68.8, 14.2. HRMS (ESI) calcd for C11H12Fe1 m/z 









n-Butyl litium (1.69 mL, 17.33 mmol) was added dropwise to a stirring solution of 
methylferrocene (0.5 g, 2.68 mmol) in dry ether (30 mL). The reaction mixture was 
stirred at room temperature for 16hrs, then DMF (0.17 mL, 2.68 mmol) was added 
and the reaction was left for a further 4hrs. Water (30 mL) was then added and the 
product was extracted with ether (30 mL). The organic fraction was dried over 
MgSO4 and the solvent was removed to yield the crude product (0.6 g, 73%).  
1
H 
NMR (300 MHz, CDCl3) δ 9.91(1H, s, CHO) 4.15 (2H, s, FcH), 4.12 (2H, s, FcH), 
4.09 (5H, s, FcH), 2.36 (3H, s, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 192.0 72.8, 









Methylferrocenecarboxaldehyde (1 g, 5 mmol) was dissolved in dry THF (30 mL). 6 
– aminohexan – 1 –ol (0.25 g, 2.13 mmol) was added. Then Sodium 
triacetoxyborohydride (1.3 g, 6.16 mmol) was added to the reaction mixture. The 
solution was stirred under nitrogen at room temperature overnight. Ethyl acetate (20 
mL) and 1N NaOH (20 mL) were then added and the organic layer was then 
extracted with NaCO3 (25 mL), Brine (25 mL) and Milli Q filtered water (25 mL) 
then dried over MgSO4 and the solvent removed to afford the crude product as an 
orange oil, which was purified via column chromatography (6:4, hexanes, EtOAc) to 
afford the product as a dark orange oil (0.95 g, 65%). IR (cm
-1
): 3226, 3207, 3167, 
3099, 2976, 2964, 2204, 2049, 1632, 1466. 
1
H NMR (300 MHz, CDCl3) δ 4.21 (2H, 
s, CH2), 4.18 (2H, s, FcH), 4.17 (2H, s, FcH), 4.13 (10H, s, FcH), 3.63 (4H, t, J =  
6.25, CH2), 3.42 (2H, s, CH2), 2.41 (6H, s, CH3), 2.28 (2H, t, J =  6.25, CH2), 1.47 – 
1.28 (8H, m, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 76.7, 76.4, 74.6 72.8, 72.4, 65.2, 
63.1, 58.6, 33.1, 28.7, 25.6, 23.2, 18.6. HRMS (ESI) calcd for C30H47N1O1Fe2 m/z 









Ferrocene carboboxaldehyde (2.1 g, 9.81 mmol) was added to a round bottomed 
flask containg dry THF (20 mL). Glycine (0.5 g, 6.66 mmol) was added to the 
solution and the reaction was stirred under N2. Sodium triacetoxyborohydride (2.3 g, 
10.90 mmol) was added portionwise to the stirring solution. The reaction was stirred 
overnight. The solution was then partitioned between ethyl acetate (40 mL) and 1M 
aqueous sodium hydroxide (40 mL). The organic fraction was washed with saturated 
aqueous NaHCO3 (20 mL), brine (40 mL) and water (40 mL). The organic fraction 
was dried using MgSO4 and the solvent was removed to afford the crude product as 
an dark orange solid. The crude product was purified via column chromatography 
(7:3, hexanes:EtOAc) to afford the product as an orange soild (1.66 g 64%). IR (cm
-
1
): 3212, 3201, 3164, 3101, 2972, 2934, 2204, 2049, 1729, 1632, 1466 
1
H NMR 
(250 MHz, CDCl3) δ 4.09 (2H, s, FcH), 4.05 (2H, s, FcH), 4.02 (12H, s, FcH), 3.55 
(4H, t, J =  6.75, CH2), 3.35 (2H, s, CH2), 1.979 (1H, s, OH). 
13
C NMR (75.5 MHz, 
CDCl3) δ 171.5, 78.0, 77.5, 77.1, 68.9, 67.4, 61.1.  HRMS (ESI) calcd for 








To a stirred solution of ferrocenecarboxaldehyde (1 g, 4.67 mmol) in dry THF (40 
mL) was added glycine ethyl ester (0.32 g, 2.34 mmol) and TEA ( 1.6 mL, 11.50 
mmol) the reaction mixture was stirred at room temperature for 5 minutes. Sodium 
triacetoxyborohydride (1.055 g, 5 mmol) was then added and the reaction mixture 
was stirred at room temperature for 12 hours. The reaction mixture was quenched 
with water (40 mL) and extracted with EtOAc (2 x 30 mL). The combined organic 
fractions were then washed with saturated aquesous NaHCO3 (30 mL) and brine (30 
mL). The organic fraction was dried over MgSO4 and the solvent was removed to 
yield the crude product as deep orange oil. The crude product was purified via 
column chromatography (9:1, hexanes:EtOAc – 7:3, hexanes:EtOAc) to afford the 
product as an orange solid (1.28 g, 97%). 
1
H NMR (300 MHz, CDCl3) δ 4.21 (4H, s, 
FcH), 4.11 (6H, m, CH2), 4.07 (10H, s, FcH), 3.63 (4H, s, CH2), 3.16 (2H, s, CH2), 
1.24 (3H, t, J = 6.5, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 171.5, 83.10, 70.17, 
68.55, 68.06, 60.22, 52.97, 14.35.  HRMS (ESI) calcd for C26H29N1O2Fe2 m/z: 










Ethyl 2-(bis(ferrocenylmethyl)amino)acetate (1 g, 2 mmol) was dissolved in ethanol 
(40 mL) and sodium hydroxide (0.24 g, 6.0 mmol). The solution was then heated to 
50˚C and stirred for 18 hours. Acetic acid was then added until the solution reached a 
pH of 6.5. The product was extracted in DCM (2x25 mL). The organic fraction was 
washed with brine (3x20 mL) and MilliQ filtered water (3x20 mL). The organic 
layer was dried over MgSO4 and the solvent removed to afford the crude product, 
which was purified via column chromatography (7:3, hexanes:ethylacetate) to yield 
the product as a dark yellow solid (0.87 g, 85%). 
1
H NMR (250 MHz, CDCl3) δ 4.09 
(2H, s, FcH), 4.05 (2H, s, FcH), 4.02 (10H, s, FcH), 3.54 (4H, t, J =  6.75, CH2), 
3.34 (2H, s, CH2), 1.99 (1H, s, OH). 
13
C NMR (75.5Hz, CDCl3) δ 171.5, 78.0, 77.5, 










Oxalyl chloride (0.87 mL, 8.69 mmols) in dry CH2Cl2 (2 mL) was added dropwise 
via a pressure equalising dropping funnel to a stirred solution of 2-
(bis(ferrocenylmethyl)amino)acetic acid (1 g, 4.35 mmol) in dry CH2Cl2 (100 mL) at 
0˚C under N2. The reaction warmed to room temperature and stirred for 2hrs. Then 
the solvent was removed and the acid chloride product was taken up in dry CH2Cl2 
(75 mL). 6 – amino hexan – 1 – ol (0.56 g, 4.78 mmols) in dry CH2Cl2 (75 mL) was 
added dropwise via a dropping funnel at 0˚C under N2. The reaction was then stirred 
for 2hrs while warming to room temperature. The solution was then washed with 
NaHCO3 (100 mL) and 1.0M HCL (100 mL). The organic fraction was dried over 
MgSO4 then the solvent was removed to afford the crude product as an dark orange 
solid, which was purified by column chromatography (7:3-hexanes:EtOAc) to afford 
the product as a dark yellow solid (1.23 g, 79%). IR (cm
-1
): 3222, 3205, 3174, 3111, 
2972, 2934, 2204, 2049, 1700, 1632, 1466. 
1
H NMR (250MHz, CDCl3) δ 4.16 (4H, 
t, J = 6, FcH), 4.13 (4H, t, J = 6, FcH), 4.11 (10H, s, Fc), 3.55 (4H, t, J = 6.25, CH2), 
3.31 (2H, s, CH2), 1.48 – 1.18 (8H, m, CH2). 
13
C NMR (75.5Hz, CDCl3) δ 173.3, 
77.8, 77.3, 76.9, 62.1, 38.8, 35.4, 32.0, 30.6, 26.7, 25.5, 25.4. HRMS (ESI) calcd for 







Oxalyl chloride (0.87 mL, 8.69 mmols) in dry CH2Cl2 (2 mL) was added dropwise 
via a pressure equalising dropping funnel to a stirred solution of 2-
(bis(ferrocenylmethyl)amino)acetic acid (1 g, 4.35 mmol) in dry CH2Cl2 (100 mL) at 
0˚C under N2. The reaction warmed to room temperature and stirred for 2hrs. Then 
the solvent was removed and the acid chloride product was taken up in dry CH2Cl2 
(75 mL). 4-piperidene methanol (0.56 g, 4.78 mmols) in dry CH2Cl2 (75mL) was 
added dropwise via a dropping funnel at 0˚C under N2. The reaction was then stirred 
for 2hrs while warming to room temperature. The solution was then washed with 
NaHCO3 (100 mL) and 1.0M HCL (100 mL). The organic fraction was dried over 
MgSO4 then the solvent was removed to afford the crude product as an orange solid. 
The crude product was purified via column chromatography (8:2-6:4, 
hexanes:EtOAc) to afford the product as a light orange oil (1.31 g, 85%). IR (cm
-1
): 
3212, 3201, 3164, 3101, 2972, 2934, 2204, 2049, 1700, 1495. 
1
H NMR (250MHz, 
CDCl3) δ 4.19 (2H, s, FcH), 4.15 (2H, s, FcH),  4.11 (10H, s, FcH), 3.65 (4H, t, J =  
6.0, CH2), 3.55 (2H, s, CH2), 1.48 – 1.18 (5h, m, CH2). 
13
C NMR (75.5 MHz, 
CDCl3) δ 173.3, 77.8, 77.9, 76.9, 62.1, 38.8, 35.4, 32.0, 30.7, 26.5, 25.5, 25.4. 








To a stirred solution of ((dimethylamino)methyl)ferrocene (3 g, 12.09 mmol) in 
MeOH (20 mL) was added methyl iodide (2.55 g, 18.02 mmol) and the reaction 
mixture was stirred at room temperature for 1 hour. The reaction mixture was then 
evaporated to dryness, the residue was taken up in MeOH and Et2O was added and 
the producted was filtered off. The filtrate was washed with cooled Et2O (2 x 25 
mL). The product was dried under reduced pressure to afford a pale orange 
crystalline solid (5.68 g, 99%). 
1
H NMR (300 MHz, CDCl3) δ 4.86 (2H, m, CH2), 
4.59 (2H, s, FcH), 4.34 (2H, s, FcH), 4.31 (5H, s, FcH), 3.31 (9H, s, CH3) 
13
C NMR 












Trimethyl(ferrocenylmethyl) ammonium iodide (3.2 g, 8 mmol), 1,1 – 
tris(hydroxymethyl) – ethane (0.5 g, 4 mmol) and potassium carbonate (1g, 8 mmol) 
were dissolved in dry acetonitrile (100 mL) and refluxed for 6hrs. The solvent was 
then removed in vacuo and the residue was portioned between water (30 mL) and 
dichloromethane (30 mL). The aqueous layer was re-washed with dichloromethane. 
The combined organic fractions were dried over MgSO4, filtered and the solvent was 
removed to afford the product as a yellow powder (2.5 g, 84%). 
1
H NMR (300 MHz, 
CDCl3) δ 4.17 (4H, s, FcH), 4.16 (4H, s, FcH), 4.11 (10H, s, FcH), 3.79 (4H, s, 
CH2), 3.45 (2H, s, CH2), 1.05 (4H, m, CH2), 0.93 (3H, s, CH3). 
13
C NMR (75.5 
MHz, CDCl3) δ 77.8, 77.4, 76.9, 75.9, 70.5, 67.7, 64.1, 39.6, 15.8. HRMS (ESI) 




General synthetic procedure for phosphoramidite synthesis 
 
N, N – diisopropylethylamine (0.4 mL, 8.4 mmol) was added to a stirred solution of 
the ferrocene derivative (2.1 mmol) in dry THF (25 mL) under a nitrogen 
atmosphere. 2 – cyanoethyldiisopropylchlorophosphoramidite (0.2 ml, 3.15 mmol) 
was added dropwise and the resulting mixture was stirred for 15mins. MilliQ filtered 
water (200 mL) was added and the solution was stirred for a further 30mins. Ethyl 
Acetate – Triethylamine (1:1, 25 mL) was added, a precipitate formed. The mixture 
was washed with saturated NaCHCO3 (25 mL) and MilliQ filtered water (25 mL). 
The organic fraction was dried over MgSO4 and the solvent was removed under 
vacuo. The crude product was then purified by silica gel chromatography (petroleum 








H NMR (500 MHz, CDCl3) δ 4.23 (4H, s, FcH), 4.18 (4H, s, FcH), 4.13 (10H, s, 
FcH), 3.61 (4H, t, J =  1.75, CH2), 3.58 (2H, s, CH2), 3.41 (2H, s, CH2), 3.35 (2H, s, 
CH2), 3.33 (2H, t, J =  6.5, CH), 2.65 (2H, t, J =  6.5, CH2), 1.26 – 1.18 (8H, m, 
CH2), 0.86 (12H, t, J =  7, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 111.6, 77.2, 77.0, 
225 
 
76.7, 68.5, 67.8, 52.5, 42.9, 25.7, 23.6, 22.5, 21.4, 14.1. 
31
P NMR (DEC) (202.5Hz, 






H NMR (500 MHz, CDCl3) δ 4.20 (4H, s, FcH), 4.18 (4H, s, FcH), 4.15 (10H, s, 
FcH), 3.66 (4H, t, J = 6.5, CH2), 3.60–3.52 (4H, m, CH2), 3.48 (2H, s, CH2), 2.71 
(2H, t, J =  6.5, CH2), 2.20 (2H, t, J = 6.5, CH2), 0.86 (12H, t, J =  7, CH3). 
13
C 
NMR (75.5 MHz, CDCl3) δ 171.1, 112.6, 77.2, 77.0, 76.7, 68.5, 67.8, 52.5, 42.9, 
21.0, 14.3. 
31
P NMR (DEC) (202.5Hz, CDCl3) δ 148.28. HRMS (ESI) calcd for 







H NMR (500MHZ, CDCl3) δ 4.16 (4H, t, J = 6, FcH), 4.13 (4H, t, J = 6, FcH), 
4.11 (10H, s, Fc), 3.61 (2H, t, J =  1.75, CH2), 3.55 (4H, t, J = 6, CH2), 3.41 (2H, s, 
CH2), 3.31 (2H, s, CH2), 3.28 (2H, t, J =  6, CH), 2.65 (2H, t, J =  6.5, CH2), 1.48 – 
1.18 (8H, m, CH2),  0.86 (12H, t, J =  7, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 
226 
 
171.1, 111.6, 77.2, 77.0, 76.5, 68.0, 67.8, 52.5, 42.9, 21.4, 14.9. 
31
P NMR (DEC) 
(202.5 MHz, CDCl3) δ 147.24. HRMS (ESI) calcd for C33H43N3O3Fe2P1 m/z: 







H NMR (500 MHz, CDCl3) δ 4.23 (2H, s, Cp), 4.18 (2H, s, Cp), 4.13 (15H, s, Cp), 
3.90-3.82 (2H, m, CH2), 3.71-3.54 (4H, m, CH2), 3.44 (4H, s, CH2), 2.64 (2H, t, J =  
6, CH2), 2.35 (2H, t, J =  6.5, CH2), 1.69 – 1.35 (5H, m, CH2, CH), 1.23 (12H, t, J =  
7, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 171.1, 111.7, 7.26, 77.0, 76.7, 68.5, 67.8, 
52.5, 42.9, 21.0, 14.2. 
31
P NMR (DEC) (202.5 MHz, CDCl3) δ 148.43. HRMS (ESI) 










A solution of ferrocene carboxylic acid (1 g, 4.347 mmol) in dry dichloromethane 
(20 mL) was called to 0
ᵒ
C in an ice bath, to this solution oxalyl chloride (1.09 g, 0.72 
mL, 8.694 mmol) was added and the reaction mixture was warmed to room 
temperature and stirred for 2 hrs. Excess oxalyl chloride was then removed en vacuo, 
the residue was then taken up in dry dichloromethane (20 mL). To which TEA (1.2 
mL, 8.694 mmol) and ethanol amine (0.3 mL, 4.918 mmol) were added and the 
reaction mixture was stirred at room temperature overnight. The reaction mixture 
was diluted with dichloromethane (100 mL) and was with water (2 x 25 mL). The 
organic fractions were combined and dried over MgSO4 and the solvent was 
removed to yield a dark brown solid. The crude product was purified via column 
chromatography (7:3, dichloromethane:MeOH) to afford the product as an orange 
powder (1.08 g,  84%). 
1
H NMR (300 MHz, CDCl3) δ 6.17 (1H, s, NH), 4.62 (2H, s, 
FcH), 4.29 (2H, s, FcH), 4.15 (5H, s, FcH), 3.74 (2H, q, J =  4.5, CH2), 3.49 (2H, q, 
J =  4.5, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 171.9, 71.5 70.6, 69.8, 68.2, 62.9, 












To an ice cold solution of N-(2-hydroxyethyl)ferrocenecarboxamide (0.5 g, 1.937 
mmol) in dry dichloromethane (10 mL) was added TEA (0.39 g, 0.53 mL, 3.875 
mmol) followed by methane sulfonyl chloride (0.22g, 0.149 mL, 1.937 mmol). The 
reaction mixture was stirred at 0
ᵒ
C for 1 hr, the reaction mixture was then diluted 
with dichloromethane (100 mL) and washed with water (2 x 50 mL). The organic 
fractions were combined and dried over MgSO4 and the solvent was removed to 
afford deep red oil that was used without further purification. The oil residue was 
taken up in a 0.5M sodium hydroxide solution in water/MeOH (1:1, 50 mL) and the 
reaction mixture was refluxed for 3 hrs. The reaction mixture was then allowed to 
cool to room temperature, diluted with water (50 mL) and extracted with 
dichloromethane (3 x 25 mL). The combined organic fractions were dried over 
MgSO4 and the solvent was removed to yield the crude product as a brown solid. 
The crude product was purified via coloumn chromatography (8:2, hexanes:EtOAc) 
to afford the product as a dark orange solid (0.37, 75%). 
1
H NMR (300 MHz, 
CDCl3) δ 4.67 (2H, s, FcH), 4.27 (4H, at, J =  9.6, FcH, CH2), 4.13 (5H, s, FcH) 3.83 
(2H, t, J =  9.3, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 167.2, 70.5, 70.2, 70.1, 69.8, 











To a solution of p-bromobenzaldehyde (1.5 g, 8.1 mmol) in tert-butyl alcohol (80 
mL) was added ethanol amine (0.49 g, 0.49 mL, 8.1 mmol). The reaction mixture 
was stirred at room temperature for 30 mins under an inert atmosphere, then K2CO3 
(3.35 g, 24.3 mmol) and iodine (4.09 g, 16.2 mmol) were added to the reaction 
mixture and the solution was heated at 70
ᵒ
C for 18 hrs. After the reaction mixture 
had been cooled to room temperature the reaction mixture was quenched with 
saturated Na2SO3 until the iodine colour had almost disappeared and was extracted 
with ether (3 x 25 mL). the combined organic fractions were washed with  brine (2 x 
20 mL) and dried over Na2SO4. The solvent was then removed to yield the cride 
product as an off white solid. The crude product was purified via column 
chromatography (8:2, hexanes:EtOAc) to afford the product as a white powder (1.43 




H NMR (300 MHz, CDCl3) δ 7.74 (2H, d, J = 8.7, ArCH), 
7.47 (2H, d, J =  8.7, ArCH), 4.36 (2H, t, J =  9.6, CH2), 3.98 (2H, t, J =   9.6, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 163.9, 131.6, 129.7, 126.6, 125.9, 61.8, 54.9. Data 
















To a solution of 3,5-bistrifluorobenzoic acid (3 g, 11.63 mmol) in dry 
dichloromethane (50 mL) was added amino ethanol (0.7 mL, 11.63mmol), EDCI 
(1.9 g, 12.78 mmol), HOBT (1.7 g, 12.78 mmol) and triethylamine ( 3.2 mL, 22.77 
mmol) and the reaction mixture was stirred at room temperature for 12 hours. The 
reaction mixture was then filtered and washed with water (30 mL), the organic 
fraction was dried over MgSO4 and the solvent was removed to afford the crude 
product as an off white solid, which was purified via column chromatography (95:5, 
CH2Cl2:MeOH) to afford the product as a white solid (2.55 g, 69%). 
1
H NMR (300 
MHz, CDCl3) δ 8.34 (2H, s, ArCH), 7.90 (1H, s, ArCH), 4.44 (2H, t, J =  10.2, 
CH2), 4.05 (2H, t, J =  10.2, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 162.2, 132.6, 
132.1, 131.7, 131.2, 129.9, 128.3, 128.3, 124.7, 124.6, 124.6, 124.5, 121.1, 117.5, 
68.3, 55.1. 
19












N-(2-hydroxyethyl)-3,5-bis(trifluoromethyl)benzamide (1.2 g, 3.99 mmol) was 
dissolved in dry dichloromethane (20 mL) and cooled to 0
˚
C. To which methane 
sulfonyl chloride (0.3 mL, 3.99 mmol) and triethylamine were added and the 
reaction mixture was stirred at 0
 ˚
C for 1 hours. The solution was then diluted with 
dichloromethane (100 mL) and washed with water (2 x 5o mL). The organic fraction 
was dried over MgSO4 and the solvent was removed. The crude colourless oil 
residue was then dissolved in 0.5M sodium hydroxide (50 mL, 1:1 H2O:MeOH) and 
the reaction mixture was refluxed for 3 hours. The reaction mixture was allowed to 
cool to room temperature and diluted with water (50 mL) and extracted with 
dichloromethane (3 x 25 mL), the combined organic fractions were dried over 
MgSO4 and the solvent was removed to afford the crude product as a white product. 
The crude product was purified via column chromatography (7:3, hexanes:EtOAc) to 
afford the product as a white product (0.98 g, 82%). IR (cm
-1
): 2968, 2924, 2234, 
2167, 1701, 1632, 1466. 
1
H NMR (300 MHz; CDCl3) δ 8.34 (2H, s, ArCH), 7.90 
(1H, s, ArCH), 4.44 (2H, t, J =  10.2, CH2), 4.05 (2H, t, J =  9.3, CH2). 
13
C NMR 
(75.5 MHz; CDCl3) δ 162.21, 132.64, 132.19, 131.74, 129.92, 128.32, 124.78, 68.30, 
55.11. 
19








To a solution of 9 – anthracenecarboxaldehyde (0.406 g, 2 mmol) in tert-butyl 
alcohol (20 mL) was added aminoethanol (0.12 mL, 2 mmol). The mixture was 
stirred at room temperature under an inert atmosphere for 30 mins. Potassium 
carbonate (0.828 g, 6 mmol) and iodine (1.012 g, 4 mmol) were then added and the 
reaction mixture was heated at 70˚C for 18 hours. The reaction mixture was then 
allowed to cool to room temperature and was quenched with satd aq Na2SO3, until 
the iodine colour was lost and was extracted with Et2O (25 mL). The organic layer 
was washed with brine (20 mL) and dried over Na2SO4. The solvent was removed 
and the product was purified via column chromatography (8:2, hexanes:EtOAc) to 
afford the product as an dark orange oil (0.34, 65%). 
1
H NMR (300 MHz; CDCl3) δ 
8.53 (1H, m, ArH), 7.90 (4H,d, J = 7.5, ArH), 7.43 (4H, d, J = 7.5, ArH), 3.96 (2H, t, 
J = 6.2, CH2), 3.46 (2H, t, J = 6.2, CH2). 
13
C NMR (75.5 MHz; CDCl3) δ 164.2, 









To a solution of 1-naphthalenecarboxaldehyde (0.2 g, 1.2 mmol) in tert-butyl alcohol 
(10 mL) was added aminoethanol (0.07 mL, 1.2 mmol) and the solution was stirred 
at room temperature for 30 mins under an inert atmosphere. Potassium carbonate 
(0.49 g, 3.6 mmol) and iodine (0.6 g, 2.4 mmol) were added and the reaction mixture 
was heated at 70˚C for 18 hours. After cooling to room temperature the reaction was 
quenched with Na2SO3 and extracted with Et2O. The organic fraction was washed 
brine (20 mL) and dried over Na2SO4 and the solvent was removed to afford the 
crude product as an oil, which was purified by column chromatography (8:2, 
hexanes:EtOAc) to afford the product as a colourless oil (0.14 g, 69%). %). 
1
H NMR 
(300 MHz, CDCl3) δ 9.13 (1H, d, J = 8.5, ArH), 8.08 (1H,dd, J = 7.2, 0.3, ArH), 
7.92 (1H, d, J = 8.2, ArH), 7.84 (1H, d, J = 8.2, ArH), 7.60-7.55 (1H, m, ArH), 7.50-
7.43 (2H, m, ArH) 4.39 (2H, t, J = 9.2, CH2), 4.17 (2H, t, J = 9.2, CH2). 
13
C NMR 
(75.5 MHz, CDCl3) δ 164.2, 133.5, 131.4, 131.2, 128.5, 128.1, 127.3, 126.4, 126.0, 













To an oven dried carousel tube was added 2-(4-bromophenyl)oxazoline (0.2 g, 0.88 
mmol) and the flask was purged with argon for 30 mins. 3,5-
bis(trifluoromethyl)benzeneboronic acid (0.25 g, 1.32 mmol), Pd(PPh3)4 (0.101 g, 
0.088 mmol), K2CO3 (0.24 g, 1.76 mmol) and ethanol (4 mL) were added under an 
atmosphere of argon. The reaction mixture was then heated at 80˚C for 12 hours. 
Upon cooling to room temperature the reaction mixture was passed through a pad of 
celite and the celite pad was washed with EtOAc (30 mL). the organics were then 
washed with water (15 mL) and dried over MgSO4. The solvent was removed to 
yield the crude compound as an off white solid. The crude product was purified via 
column chromatography (8:2, hexanes:EtOAc) to afford the compound as a white 
powder (0.45 g, 74%). IR (cm
-1
): 3101, 2972, 2954, 2199, 2053, 1701, 1648, 1421. 
1
H NMR (400 MHz, CDCl3) δ 8.09 (1H, d, J =  5.25, ArH), 7.91-7.82 (1H, m, 
ArH), 7.74-7.49 (5H, m, ArH), 4.52 (2H, t, J =  9.2, CH2), 4.15 (2H, t, J =  9.2, 
CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 164. 3, 142.4, 141.0, 133.0, 132.1, 131.9, 
131.5, 130.4, 129.5, 128.6, 128.4, 127.4, 127.1, 124.5, 124.5, 124.0, 123.9, 67.7, 
55.0. 
19
F NMR (376 MHz, CDCl3) δ -62.71. HRMS (ESI) calcd for C17H11F6N1O1 










To a solution of oxazoline (3.0 mmol) is dry acetonitrile (3 mL) was added 
carboxylic acid (1.5 mmol) and heated at 80˚C for 18 hours. The reaction mixture 
was then allowed to cool to room temperature and diluted with water (25 mL) and 
extracted with dichloromethane (3 x 25 mL), the combined organic fractions were 
dried over MgSO4 and solvent removed.  
 
2-((tert-Butoxycarbonyl)amino)-3-phenylpropanamido)ethyl benzoate 206  
 
 
Phenyloxazoline (0.39 mL, 3.0 mmol), boc-phenylalanine (0.4 g, 1.5 mmol). 
Purified via column chromatography (7:3, hexanes:EtOAc) to yield the compound as 
a colourless oil (0.72 g, 92%). IR (cm
-1
): 3167, 3111, 3025, 2949, 2901, 2211, 2023, 
1729, 1648, 1436 
1
H NMR (300 MHz, CDCl3) δ 7.78 (2H, d, J =  7.2, ArCH), 7.45-
7.33 (3H, m, ArH), 7.22-7.07 (5H, m, ArH), 4.95 (1H, d, J =  6.6, CH), 4.26-4.23 
(2H, m, CH2), 3.67-3.52 (2H, m, CH2), 2.99 (2H, d, J =  6.9, CH2), 1.32 (9H, s, CH3) 
13
C NMR (75.5 MHz, CDCl3) δ 172.3, 162.4, 155.4, 135.8, 134.1, 131.5, 129.1, 
128.7, 125.5, 127.2, 127.1, 80.3, 64.3, 55.0, 39.0, 38.0, 28.2. HRMS (ESI) calcd for 






2-(2-((tert-butoxycarbonyl)amino)propanamido)ethyl benzoate 207 
 
 
Phenyloxazoline (0.39 mL, 3.0 mmol), boc-alanine (0.28 g, 1.5 mmol). Purified via 
column chromatography (7:3, hexanes:EtOAc), to yield the title compound as a 
colourless oil (0.64 g, 93%). IR (cm
-1
): 3168, 3107, 2967, 2938, 2209, 2053, 1728, 
1727, 1723, 1636, 1459. 
1
H NMR (300 MHz, CDCl3) δ 8.02 (2H, d, J = 7.3, ArH), 
7.67-7.59 (3H, m, ArH), 4.37-4.32 (2H, m, CH2), 4.29 (1H, d, J = 6.5, CH), 3.85-
3.82 (2H, m, CH2), 2.21-2.18 (1H, m, CH), 1.45 (3H, s, CH3), 1.30 (9H, s, CH3). 
13
C 
NMR (75.5 MHz, CDCl3) δ 173.8, 167.5, 155.3, 134.3, 132.7, 128.5, 127.31 79.6, 
62.6, 61.3, 38.3, 30.3, 28.9, 17.3. HRMS (ESI) calcd for C17H24N2O5 m/z 336.1685 
found 336.1685. 
 
2-(2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)ethyl benzoate 208 
 
 
Phenyloxazoline (0.39 mL, 3.0 mmol), boc-valine (0.33 g, 1.5 mmol). Purified via 
column chromatography (7:3, hexanes:ethyl acetate) to afford the title compound as 
a colourless oil (0.064 g, 89%). IR (cm
-1
): 3164, 3101, 2972, 2934, 2204, 2049, 
1731, 1726, 1724, 1632, 1466. 
1
H NMR (300 MHz, CDCl3) δ 8.03 (2H, d, J = 7.1, 
ArH), 7.65-7.58 (3H, m, ArH), 4.35-4.30 (2H, m, CH2), 4.27 (1H, d, J = 6.0, CH), 
3.81 (2H, m, CH2), 2.21 (1H, m, CH), 1.31 (9H, s, CH3), 0.89 (6H, dd, J = 5.5). 
13
C 
NMR (75.5 MHz, CDCl3) δ 172.8, 167.3, 155.7, 134.2, 132.5, 128.0, 127.3, 79.7, 




Tert-butyl 2-((2-(benzoyloxy)ethyl)carbamoyl)pyrrolidine-1-carboxylate 209 
 
 
Phenyloxazoline (0.39 mL, 3.0 mmol), boc-proline (0.32 g, 1.5 mmol). Purified via 
column chromatograpy (7:3, hexanes:EtOAc), to yield the title compound as a 
colourless oil (0.53 g, 74%). IR (cm
-1
): 3163, 3101, 2974, 2934, 2204, 2048, 1733, 
1727, 1724, 1632, 1467. 
1
H NMR (300 MHz, CDCl3) δ 8.03 (2H, d, J = 7.1, ArH), 
7.65-7.58 (3H, m, ArH), 4.31 (2H, t, J = 6.25 CH2), 4.27 (1H, s, CH), 3.82 (2H, t, J 
= 6.25, CH2), 3.41-3.32 (2H, t, J = 7.0, CH2) 1.73-1.46 (4H, m, CH2), 1.38 (9H, s, 
CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 172.6, 167.5, 155.3, 134.5, 132.2, 128.3, 
127.1, 79.4, 66.5, 62.3, 49.3, 38.6, 30.4, 28.2, 24.5. HRMS (ESI) calcd for 
C19H26N2O5 m/z 362.1842 found 362.1842. 
 
2-(2-(Methylamino)acetamido)ethyl benzoate 210 
 
 
Phenyloxazoline (0.39 mL, 3.0 mmol), sarcosine (0.13 g, 1.5 mmol). Purified via 
column chromatography (7:3, hexanes:EtOAc), to yield the compound as a 
colourless oil (0.5 g, 95%). IR (cm
-1
): 3031, 2972, 2934, 2204, 2049, 1731, 1727, 
1724, 1632, 1495.
 1
H NMR (300 MHz, CDCl3) δ 8.04 (2H, d, J = 7.1, ArH), 7.63-
7.56 (3H, m, ArH), 4.34 (2H, t, J = 6.0 CH2), 3.96 (3H, s, CH3), 3.43 (2H, t, J = 7, 
CH2), 3.23 (2H, s, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 173.3, 166.2, 134.6, 133.2, 
129.4, 128.3, 78.1, 63.5, 57.3, 38.2. HRMS (ESI) calcd for C12H16N2O3 m/z 





2-(3-bromopropanamido)ethyl benzoate 211 
 
 
Phenyloxazoline (0.39 mL, 3.0 mmol), 3-bromopropionic acid (0.23 g, 1.5 mmol). 
Purified via column chromatography (7:3, hexanes:EtOAc), to yield the compound 
as a colourless oil (0.57 g, 92%). IR (cm
-1
): 3164, 3087, 2972, 2934, 2206, 2049, 
1727, 1724, 1720, 1632, 1466.
 1
H NMR (300 MHz, CDCl3) δ 8.04 (2H, d, J = 7.1, 
ArH), 7.63-7.56 (3H, m, ArH), 4.34 (2H, t, J = 7.5 CH2), 3.59 (2H, t, J = 6.0 CH2), 
3.48 (2H, t, J = 7.5, CH2), 2.66 (2H, t, J = 6.0, CH2). 
13
C NMR (75.5 MHz, CDCl3) 
δ 176.6, 166.4, 133.6, 132.2, 128.4, 127.3, 63.6, 38.5, 38.2, 28.3. HRMS (ESI) calcd 






Ferroceneoxazoline (0.76 g, 3.0 mmol), boc-Val-OH (0.33 g, 1.5 mmol). Purified via 
column chromatography (7:3, hexanes: EtOAc), to yield the compound as an orange 
oil (0.83 g, 76%). IR (cm
-1
): 3231, 3164, 3101, 2972, 2934, 2204, 2049, 1731, 1724, 
1722, 1632, 1459.
 1
H NMR (300 MHz, CDCl3) δ 4.55-4.43 (2H, m, CH2), 4.27 (1H, 
d, J = 6.0, CH), 4.19 (2H, s, FcH), 4.15 (2H, s, FcH), 4.09 (5H, s, FcH), 3.83-3.76 
(2H, m, CH2), 2.23-2.12 (1H, m, CH), 1.33 (9H, s, CH3), 0.86 (6H, dd, J = 5.6, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 172.8, 167.3, 155.7, 79.7, 78.4, 77.3, 77.2, 76.3 
62.3, 61.3, 38.4, 30.2, 28.9, 18.7. HRMS (ESI) calcd for C23H31N2O5Fe1 m/z 








Ferroceneoxazoline (0.76 g, 3.0 mmol), boc-Phe-OH (0.4 g, 1.5 mmol). Purified via 
column chromatography (7:3, hexanes: EtOAc), to yield the compound as an orange 
oil (0.91 g, 79%). IR (cm
-1
): 3164, 3101, 3012, 2972, 2934, 2204, 2049, 1731, 1726, 
1724, 1632, 1466.
 1
H NMR (300 MHz, CDCl3) δ 7.21-7.13 (5H, m, ArH), 4.97 (1H, 
d, J =  6.6, CH), 4.26-4.23 (2H, m, CH2), 4.18 (2H, s, FcH), 4.16 (2H, s, FcH), 4.03 
(5H, s, FcH), 3.67-3.52 (2H, m, CH2), 2.94 (2H, d, J =  6.6, CH2), 1.32 (9H, s, CH3) 
13
C NMR (75.5 MHz, CDCl3) δ 172.3, 166.9, 155.4, 135.8, 134.6, 131.5, 129.1, 
128.7, 80.3, 77.8, 77.4, 76.7, 76.2, 64.3, 55.0, 39.0, 38.0, 28.2. HRMS (ESI) calcd 













2-(2-((tert-butoxycarbonyl)amino)propanamido)ethyl ferrocenecarboxylate 216 
 
 
Ferroceneoxazoline (0.76 g, 3.0 mmol), boc-Ala-OH (0.28 g, 1.5 mmol). Purified via 
column chromatography (7:3, hexanes: ethyl acetate), to yield the compound as an 
orange oil (0.64 g, 76%). IR (cm
-1
): 3173, 3121, 2982, 2912, 2200, 2050, 1728, 
1724, 1722, 1633, 1462. 
1
H NMR (300 MHz, CDCl3) δ 4.37-4.34 (2H, m, CH2), 
4.27 (1H, d, J = 6.5, CH), 4.17 (2H, s, FcH), 4.14 (2H, s, FcH), 4.10 (5H, s, FcH), 
3.87-3.83 (2H, m, CH2), 2.23-2.16 (1H, m, CH), 1.47 (3H, s, CH3), 1.33 (9H, s, 
CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 173.8, 167.5, 155.3, 79.6, 77.5, 77.1, 76.8, 
76.4, 62.6, 61.3, 38.3, 30.3, 28.9, 17.3. HRMS (ESI) calcd for C21H27N2O5Fe1 m/z 
443.1270 found C21H28N2O5Fe1 m/z 444.1341. 
 
2-(3,5-bis(trifluoromethyl)benzamido)ethyl ferrocenecarboxylate 217 
 
 
Ferroceneoxazoline (0.76 g, 3.0 mmol), 3,5-bis(trifluoromethyl)benzoic acid (0.38 g, 
1.5 mmol). Purified via column chromatography (7:3, hexanes: EtOAc), to yield the 
compound as an orange oil (1.0 g, 88%). IR (cm
-1
): 3172, 3102, 2973, 2939, 2214, 
2044, 1730, 1727, 1724, 1632, 1476.
 1
H NMR (300 MHz, CDCl3) δ 8.52 (2H, s, 
ArH), 8.02 (1H, s, ArH), 4.75 (2H, s, FcH), 4.35 (2H, s, FcH), 4.21 (2H, t, J = 6.25, 
CH2), 4.09 (5H, s, FcH), 3.89 (2H, t, J = 6.25, CH2). 
13
C NMR (75.5 MHz; CDCl3) δ 
172.3, 164.3, 132.5, 132.2, 132.0, 129.9, 126.7, 124.2, 70.9, 70.0, 68.4, 65.2, 39.8. 




2-(2-methylamino)acetamido)ethyl ferrocenecarboxylate 218 
 
 
Ferroceneoxazoline (0.76 g, 3.0 mmol), sarcosine (0.13 g, 1.5 mmol). Purified via 
column chromatography (7:3, hexanes: EtOAc), to yield the compound as an orange 
oil (0.68 g, 76%). IR (cm
-1
): 3167, 3103, 2976, 2929, 2208, 2052, 1735, 1728, 1723, 
1629, 1476.
 1
H NMR (300 MHz, CDCl3) δ 4.36 (2H, t, J = 6.25 CH2), 4.18 (2H, s, 
FcH), 4.12 (2H, s, FcH), 4.08 (5H, s, FcH), 3.96 (3H, s, CH3), 3.42 (2H, t, J = 7, 
CH2), 3.25 (2H, s, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 173.3, 166.2, 78.1, 77.7, 
77.3, 76.8, 76.2, 63.5, 57.3, 38.2. HRMS (ESI) calcd for C16H19N2O3Fe1 m/z 
343.0745 found C16H20N2O3Fe1 m/z 344.1432. 
 
 
2-(3-bromopropanamido)ethyl ferrocenecarboxylate 219 
 
 
Ferroceneoxazoline (0.76 g, 3.0 mmol), 3-bromopropionic acid (0.23 g, 1.5 mmol). 
Purified via column chromatography (7:3, hexanes: ethyl acetate), to yield the 
compound as an orange oil (0.74 g, 93%). IR (cm
-1
): 3101, 2972, 2934, 2204, 2049, 
1737, 1725, 1722, 1635, 1469.
 1
H NMR (300 MHz, CDCl3) δ 4.32 (2H, t, J = 7.25 
CH2), 4.16 (2H, s, FcH), 4.12 (2H, s, FcH), 4.09 (5H, s, FcH), 3.60 (2H, t, J = 6.25 
CH2), 3.52 (2H, t, J = 7.25, CH2), 2.63 (2H, t, J = 6.25, CH2). 
13
C NMR (75.5 MHz, 
CDCl3) δ 176.6, 166.4, 77.6, 77.1, 76.7, 76.2, 63.6, 38.5, 38.2, 28.3. HRMS (ESI) 









2-(-3,5-Bis(trifluoromethyl)phenyl)-2-oxazoline (0.84 g, 3.0 mmol), boc-Val-OH 
(0.33 g, 1.5 mmol). Purified via column chromatography (7:3, hexanes: ethyl 
acetate), to yield the compound as a colourless oil (0.84 g, 88%). IR (cm
-1
): 3162, 
3110, 2970, 2935, 2201, 2053, 1733, 1724, 1632, 1462.
 1
H NMR (300 MHz, CDCl3) 
δ 8.34 (2H, s, ArH), 7.91 (1H, s, ArH), 4.36-4.32 (2H, m, CH2), 4.29 (1H, d, J = 7.0, 
CH), 3.79-3.72 (2H, m, CH2), 2.19-2.05 (1H, m, CH), 1.34 (9H, s, CH3), 0.91 (6H, 
dd, J = 6.5, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 172.8, 167.3, 155.7, 131.2, 130.8, 
128.4, 127.2, 79.4, 62.7, 61.3, 38.6, 30.6, 28.7, 18.2. 
19
F NMR (376 MHz, CDCl3) δ 







2-(-3,5-Bis(trifluoromethyl)phenyl)-2-oxazoline (0.84 g, 3.0 mmol), boc-Phe-OH 
(0.4 g, 1.5 mmol). Purified via column chromatography (7:3, hexanes: EtOAc), to 
yield the compound as a colourless oil (0.93 g, 91%). IR (cm
-1
): 2982, 2924, 2209, 
2009, 1731, 1726, 1724, 1629, 1501.
 1
H NMR (300 MHz, CDCl3) δ 8.34 (2H, s, 
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ArH), 7.93 (1H, s, ArH), 7.24-7.13 (5H, m, ArH), 4.96 (1H, d, J =  6.6, CH), 4.27-
4.23 (2H, m, CH2), 3.67-3.52 (2H, m, CH2), 2.83 (2H, d, J =  6.6, CH2), 1.32 (9H, s, 
CH3) 
13
C NMR (75.5 MHz, CDCl3) δ 172.3, 167.4, 155.4, 135.8, 134.1, 131.5, 
129.1, 128.7, 125.5, 127.2, 127.1, 80.3, 64.3, 55.0, 39.0, 38.0, 28.2. 
19
F NMR (376 
MHz, CDCl3) δ -63.41 HRMS (ESI) calcd for C25H26N2O5F6 m/z 548.1746 found 
C25H27N2O5F6 m/z 549.1824. 
 
2-(2-(methylamino)acetamido)ethyl 3,5-bis(trifluoromethyl)benzoate 237 
 
 
2-(-3,5-Bis(trifluoromethyl)phenyl)-2-oxazoline (0.84 g, 3.0 mmol), sarcosine (0.13 
g, 1.5 mmol). Purified via column chromatography (7:3, hexanes: ethyl acetate), to 
yield the compound as a colourless oil (0.67 g, 89%). IR (cm
-1
): 3101, 2972, 2934, 
2204, 2049, 1731, 1726, 1724, 1632, 1466.
 1
H NMR (300 MHz, CDCl3) δ 8.36 (2H, 
s, ArH), 7.93 (1H, s, ArH), 4.41 (2H, t, J = 6.25, CH2), 3.99 (3H, s, CH3), 3.46 (2H, 
t, J = 6.25, CH2), 3.25 (2H, s, CH2). 
13
C NMR (75.5 MHz, CDCl3) δ 173.3, 166.2, 
131.2, 130.4, 128.6, 127.6, 78.3, 63.1, 57.5, 38.1. 
19
F NMR (376 MHz, CDCl3) δ -
63.36. HRMS (ESI) calcd for C14H14N2O3F6 m/z 372.0909 found C14H15N2O3F6 m/z 
373.1233. 
 





2-(-3,5-Bis(trifluoromethyl)phenyl)-2-oxazoline (0.84 g, 3.0 mmol), 3-
bromopropionic acid (0.23 g, 1.5 mmol). Purified via column chromatography (7:3, 
hexanes: EtOAc), to yield the compound as a colourless oil (0.68 g, 79%). IR (cm
-1
): 
3101, 2972, 2934, 2204, 2049, 1731, 1726, 1724, 1632, 1466.
 1
H NMR (300 MHz, 
CDCl3) δ 8.35 (2H, s, ArH), 7.94 (1H, s, ArH), 4.36 (2H, t, J = 7.25 CH2), 3.61 (2H, 
t, J = 5.5 CH2), 3.46 (2H, t, J = 7.25, CH2), 2.64 (2H, t, J = 5.5, CH2). 
13
C NMR 
(75.5 MHz, CDCl3) δ 176.6, 166.4, 131.7, 130.4, 128.6, 127.4, 63.6, 38.5, 38.2, 28.3. 
19
F NMR (376 MHz, CDCl3) δ -63.32. HRMS (ESI) calcd for C14H12N1O3Br1F6 m/z 
434.9905 found 434.9905. 
 
  
2-(4-bromobenzamido)ethyl 3,5-bis(trifluoromethyl)benzoate 239 
 
 
2-(-3,5-Bis(trifluoromethyl)phenyl)-2-oxazoline (0.84 g, 3.0 mmol), p-nitrobenzoic 
aicd (0.25 g, 1.5 mmol). Purified via column chromatography (7:3, hexanes: EtOAc), 
to yield the compound as a colourless oil (0.73 g, 83%).
 1
H NMR (300 MHz, 
CDCl3) δ 8.45 (2H, s, ArH), 7.91 (1H, s, ArH), 7.74 (2H, d, J =  8.7, ArCH), 7.47 
(2H, d, J =  8.7, ArCH),  4.26 (2H, t, J = 7.0, CH2), 3.67 (2H, t, J = 7.0, CH2). 
13
C 
NMR (75.5 MHz, CDCl3) δ 172.3, 164.3 135.8, 134.1, 131.5, 129.1, 128.7, 125.5, 
127.2, 127.1, 80.3, 55.0, 39.0. 
19
F NMR (376 MHz, CDCl3) δ -63.64. HRMS (ESI) 












2-(-3,5-Bis(trifluoromethyl)phenyl)-2-oxazoline (0.84 g, 3.0 mmol), boc-Ala-OH 
(0.28 g, 1.5 mmol). Purified via column chromatography (7:3, hexanes: EtOAc), to 
yield the compound as a colourless oil (0.78 g, 86%). IR (cm
-1
): 3106, 2976, 2934, 
2211, 20496, 1731, 1728, 1718, 1632, 1459.
 1
H NMR (300 MHz, CDCl3) δ 8.36 
(2H, s, ArH), 7.89 (1H, s, ArH), 4.41-4.37 (2H, m, CH2), 4.30 (1H, d, J = 6.25, CH), 
3.87-3.83 (2H, m, CH2), 2.19-2.13 (1H, m, CH), 1.47 (3H, s, CH3), 1.35 (9H, s, 
CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 173.8, 167.5, 155.3, 131.6, 130.4, 128.6, 
127.4, 78.9, 62.3, 61.6, 38.2, 30.4, 28.6, 18.2. 
19
F NMR (376 MHz, CDCl3) δ -64.21 




2-(2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)ethyl 4-bromobenzoate 223 
 
 
P-bromophenyl oxazoline (0.67 g, 3.0 mmol), boc-Val-OH (0.33 g, 1.5 mmol). 
Purified via column chromatography (7:3, hexanes: EtOAc), to yield the compound 
as a colourless oil (0.78 g, 79%). IR (cm
-1
): 3111, 2952, 2844, 2214, 2029, 1731, 
1726, 1724, 1632, 1466.
 1
H NMR (300 MHz, CDCl3) δ 7.74 (2H, d, J =  8.7, 
ArCH), 7.47 (2H, d, J =  7.1, ArCH), 4.37-4.33 (2H, m, CH2), 4.29 (1H, d, J = 6.25, 
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CH), 3.81-3.75 (2H, m, CH2), 2.28-2.21 (1H, m, CH), 1.37 (9H, s, CH3), 0.91 (6H, 
dd, J = 6.5). 
13
C NMR (75.5 MHz, CDCl3) δ 172.8, 167.3, 155.7, 131.6, 129.7, 
126.6, 125.9, 79.7, 62.3, 61.3, 38.4, 30.2, 28.9, 18.7. HRMS (ESI) calcd for 
C19H27N2O5Br1 m/z 442.1103 found C19H28N2O5Br1 m/z 443.1232. 
  
2-(2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)ethyl 1-naphthoate 224 
 
 
2-(Naphthalene-1-yl)oxazoline (0.59 g, 3.0 mmol), boc-Val-OH (0.33 g, 1.5 mmol). 
Purified via column chromatography (7:3, hexanes: EtOAc), to yield the compound 
as a colourless oil (0.67 g, 73%). IR (cm
-1
): 3101, 2972, 2936, 2209, 2055, 1731, 
1723, 1644, 1446. 
 1
H NMR (300 MHz, CDCl3) δ 9.12 (1H, d, J = 8.3, ArH), 8.11 
(1H,dd, J = 7.5, 0.4, ArH), 7.94 (1H, d, J = 8.3, ArH), 7.86 (1H, d, J = 8.3, ArH), 
7.75 (2H, d, J =  7.5, ArCH), 7.63-7.57 (1H, m, ArH), 4.95 (1H, d, J =  6.6, CH), 
4.26-4.23 (2H, m, CH2), 3.67-3.52 (2H, m, CH2), 2.75 (2H, d, J =  6.6, CH2), 1.34 
(9H, s, CH3), 0.87 (6H, dd, J = 7.25). 
13
C NMR (75.5 MHz, CDCl3) δ 172.3, 164.3, 
155.4, 135.8, 134.1, 133.5, 131.5, 131.4, 131.2, 129.2, 128.7 128.5, 128.1, 127.3, 
127.1, 126.4, 126.0, 124.2, 124.0, 80.3, 64.3, 55.0, 39.0, 38.0, 28.2. HRMS (ESI) 
calcd for C23H30N2O5 m/z 414.2155 found C23H30N2O5Na1 m/z 437.1934. 
 
2-(2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)ethyl 1-naphthoate 225 
 
 
2-(Naphthalene-1-yl)oxazoline (0.59 g, 3.0 mmol), boc-phenylalanine (0.4 g, 1.5 
mmol). Purified via column chromatography (7:3, hexanes: EtOAc) to yield the 
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compound as a colourless oil (0.77 ,78%). IR (cm
-1
): 3107, 2969, 2954, 2210, 2055, 
1736, 1723, 1724, 1632, 1436. 
1
H NMR (300 MHz, CDCl3) δ 9.13 (1H, d, J = 8.5, 
ArH), 8.08 (1H,dd, J = 7.2, 0.3, ArH), 7.92 (1H, d, J = 8.2, ArH), 7.84 (1H, d, J = 
8.2, ArH), 7.78 (2H, d, J =  7.2, ArCH), 7.60-7.55 (1H, m, ArH), 7.49-7.41 (5H, m, 
ArH), 4.91 (1H, d, J =  6.5, CH), 4.26-4.22 (2H, m, CH2), 3.68-3.54 (2H, m, CH2), 
2.88 (2H, d, J =  6.5, CH2), 1.32 (9H, s, CH3).  
13
C NMR (75.5 MHz, CDCl3) δ 
172.3, 167.5, 155.4, 135.8, 134.1, 131.5, 129.1, 128.7, 127.4, 125.5, 80.3, 64.2, 55.2, 






2-(anthrancen-9-yl)-2-oxazoline (0.74 g, 2.25 mmol), Boc-Val-OH (0.33 g, 1.5 
mmol). Purified via column chromatography (7:3, hexanes: ethyl acetate), to yield 
the compound as a colourless oil (0.75 g, 70%). IR (cm
-1
): 3104, 2971, 2941, 2208, 
2046, 1731, 1726, 1722, 1632, 1446.
 1
H NMR (300 MHz, CDCl3) δ 8.42 (3H, d, J =  
6.25, ArH), 7.63-7.56 (2H, m, ArH), 7.31-7.24 (4H, m, ArH), 4.93 (1H, d, J =  6, 
CH), 4.26-4.23 (2H, m, CH2), 3.67-3.52 (2H, m, CH2), 2.99 (2H, d, J =  6, CH2), 
1.32 (9H, s, CH3), 0.86 (6H, dd, J = 7.5, CH3). 
13
C NMR (75.5 MHz, CDCl3) δ 
172.3, 155.4, 135.8, 134.1, 131.5, 129.1, 128.7, 125.5, 127.5, 127.1, 80.6, 64.2, 55.2, 












2-(3’,5’-nistrifluoromethyl)-[1,1’-biphenyl]-4-yl)-oxazoline (1.07 g, 3.0 mmol), boc-
Val-OH (0.33 g, 1.5 mmol). Purified via column chromatography (7:3, hexanes: 
ethyl acetate), to yield the compound as a colourless oil (0.91 g, 65%). IR (cm
-1
): 
2972, 2934, 2204, 2049, 1731, 1726, 1724, 1632, 1466
 1
H NMR (300 MHz; CDCl3) 
δ 8.09 (1H, d, J =  5.25, ArH), 7.91-7.82 (1H, m, ArH), 7.74-7.49 (5H, m, ArH), 
4.35-4.30 (2H, m, CH2), 4.27 (1H, d, J = 6.0, CH), 3.81 (2H, m, CH2), 2.21 (1H, m, 
CH), 1.31 (9H, s, CH3), 0.89 (6H, dd, J = 5.5, CH3). 
13
C NMR (75.5 MHz; CDCl3) δ 
172.3, 164.5, 155.4, 135.8, 134.1, 131.5, 129.1, 128.7, 127.1, 124.5, 124.2, 80.3, 
64.3, 55.0, 39.0, 38.0, 28.2. 
19
F NMR (376 MHz, CDCl3) δ -62.81. HRMS (ESI) 
calcd for C27H30N2O5F6 m/z 576.2059 found C27H31N2O5F6 m/z 577.1934. 
 
2-(2-(4-isobutylphenyl)propanamido)ethyl benzoate 241 
 
 
Phenyloxazoline (0.39 mL, 3.0 mmol), ibuprofen tablet (0.25 g, 1.5 mmol). Purified 
via column chromatography (7:3, hexanes: ethyl acetate), to yield the compound as a 
colourless oil (0.51 g, 93%).
 1
H NMR (300MHz, CDCl3) δ 8.12 (2H, d, J =  7.2, 
ArCH), 7.65-7.59 (3H, m, ArH), 7.21 (2H, d, J = 7.5, ArH), 7.06 (2H, d, J = 7.5, 
ArH), 4.38 (2H, t, J = 6.5, CH2), 3.78-3.69 (1H, m, CH), 3.39 (2H, t, J = 6.5, CH2), 
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2.43 (2H, s, CH2), 1.82-1.78 (1H, m, CH), 1.51 (3H, s, CH3), 0.89 (6H, s, CH3). 
13
C 
NMR (75.5 MHz, CDCl3) δ 173.2, 167.5, 140.2, 134.6, 132.1, 132.0, 128.9, 127.5, 
64.1, 44.5, 40.1, 38.7, 29.0, 22.1, 14.2. HRMS (ESI) calcd for C22H27N1O3 m/z 
353.1991 found 354.1834. 
 
2-(2-(4-isobutylphenyl)propanamido)ethyl ferrocenecarboxylate 242 
 
 
Ferroceneoxazoline (0.76 g, 3.0 mmol), ibuprofen tablet (0.25 g, 1.5 mmol). Purified 
via column chromatography (7:3, hexanes: ethyl acetate), to yield the compound as 
an orange oil (0.68 g, 89%).
 1
H NMR (300MHz, CDCl3) δ 7.22 (2H, d, J = 6.25, 
ArH), 7.08 (2H, d, J = 6.25, ArH), 4.36 (2H, t,  J = 6.0, CH2), 4.18 (2H, s, FcH), 
4.14 (2H, s, FcH), 4.09 (5H, s, FcH) 3.77-3.70 (1H, m, CH), 3.42 (2H, t, J = 6.0, 
CH2), 2.29 (2H, s, CH2), 1.85-1.81 (1H, m, CH), 1.53 (3H, s, CH3), 0.90 (6H, s, 
CH3) 
13
C NMR (75.5 Hz, CDCl3) δ 172.36, 167.5, 140.2, 134.6, 132.1, 132.0, 128.9, 
127.5, 72.7, 72.3, 71.6, 70.8, 64.5, 450, 41.3, 39.1, 29.6, 22.3, 14.5. HRMS (ESI) 
calcd for C26H31N1O3Fe1 m/z 461.1653 found 461.1655. 
 
2-(2-(4-isobutylphenyl)propanamido)ethyl 3,5-bis(trifluoromethyl)benzoate 243 
 
 
2-(-3,5-Bis(trifluoromethyl)phenyl)-2-oxazoline (0.84 mL, 3.0 mmol), ibuprofen 
tablet (0.25 g, 1.5 mmol). Purified via column chromatography (7:3, hexanes: ethyl 
acetate), to yield the compound as a colourless oil (0.80 g, 91%).
 1
H NMR 
(300MHz, CDCl3) δ 8.37 (2H, s, ArCH), 7.86 (1H, s, ArH), 7.24 (2H, d, J = 7.5, 
250 
 
ArH), 7.16 (2H, d, J = 7.5, ArH), 4.34 (2H, t, J = 5.5, CH2), 3.74-3.66 (1H, m, CH), 
3.42 (2H, t, J = 5.5, CH2), 2.45 (2H, s, CH2), 1.84-1.79 (1H, m, CH), 1.54 (3H, s, 
CH3), 0.88 (6H, s, CH3).
13
C NMR (75.5 Hz, CDCl3) δ 172.5, 167.8, 140.4, 134.3, 
132.6, 132.3, 132.0 128.7, 127.3, 124.2, 64.3, 44.1, 40.3, 38.9, 29.3, 22.5, 14.6. 
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9  Appendix  
Table 1. Assay volumes for probe 177 
 
Reagent 1 x rxn 
(µL) 
Positive 4 x rxn (µL) Negative 4 x rxn 
(µL) 
177 0.6 2.4 2.4 
Synth target 
DNA 
1 4 / 
MgCl2 4 16 16 
10x Atlas PCR 
buffer 
2 8 8 
T7 0.2 0.8 0.8 
H2O 12.2 46.4 52 
 
Table 2. Assay volumes for probe 179  
 
Reagent +ve rxn (µL) -ve 4x rxn (µL)  
179 2.4 2.4 
Synth. Target DNA 4 0 
MgCl2 16 16 
10x Atlas PCR buffer 8 8 
T7 0.8 0.8 
H2O 48.8 52 





Reagent Positive 4 x rxn (µL) Negative 4 x rxn (µL) 
172  2.4 2.4 
179  2.4 2.4 
Synth target DNA 4 / 
MgCl2 16 16 
10x Atlas PCR buffer 8 8 
T7 0.8 0.8 
H2O 46.4 52 
 
Table 4. Assay reaction volumes for the triplex between probes 172, 179 and 182 
 
 
Reagent Positive 4 x rxn (µL) Negative 4 x rxn (µL) 
172 1.5 1.5 
179 4.5 4.5 
182 4.5 4.5 
Synth target DNA 7.45 / 
MgCl2 16 16 
10x Atlas PCR buffer 8 8 
T7 0.8 0.8 




5. Assay reaction volumes for the triplex between probes 172, 179 and 182 
 
 
Reagent Positive 4 x rxn (µL) Negative 4 x rxn (µL) 
172 0.5 0.5 
179 4.5 4.5 
182 4.5 4.5 
Synth target DNA 7.45 / 
MgCl2 16 16 
10x Atlas PCR buffer 8 8 
T7 0.8 0.8 
H2O 45.9 51.5 
 
  
